

# INDIA TB REPORT 2018

# **Revised National TB Control Programme**

# **Annual Status Report**





Directorate General of Health Services Ministry of Health and Family Welfare, Nirman Bhawan, New Delhi - 110108 www.tbcindia.gov.in





This Publication can be obtained from:

# Central TB Division,

Directorate General of Health Services, Ministry of Health and Family Welfare, Nirman Bhawan, New Delhi 110108 http://www.tbcindia.gov.in March 2018

© Central TB Division, Directorate General of Health Services

Printed By: India Offset Press, New Delhi







## स्वास्थ्य एवं परिवार कल्याण मंत्री भारत सरकार Minister of Health & Family Welfare Government of India



#### FOREWORD

It is with great pleasure I present the Annual India TB Report for the year 2017. I hope you will find this report both informative and interesting and that it will give you a greater understanding of the work under taken by Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare.

Government of India has set the goal of ending TB in India by 2025. Yes, the targets are very ambitious. However, to pursue it, we have prepared the National Strategic Plan 2017-25, focusing on universal health coverage along with social protection, implementation of which will help us achieve our goal.

Ministry of Health & Family Welfare is moving ahead with scaling up of novel diagnostics tools like CBNAAT to more than 1100 labs in 2018. We have made changes in our treatment protocols with introduction of fixed drug combination of daily regimen, newer and shorter regimens. The newer anti TB drug Bedaquiline has already been introduced for DR-TB patients in the country and soon we will be rolling out Delamanid as well.

Reaching to TB patients in private sector has been identified as one of the key priority to help us achieve our goal. Mixture of collaborative and regulatory approaches have been adopted to increase participation of private providers to improve surveillance and universal access to free diagnosis, drugs and high quality of care.

Patient support system has been an integral part of RNTCP. The Programme has established an efficient system of targeted delivery of patient support benefits. Linkages of AADHAR, NIKSHAY and PFMS have been established to provide Direct Benefit Transfer. We have also decided to provide support of Rs. 500 per month to each TB patient for the duration of his/her treatment.

We are committed to address the challenge of TB and are open to innovate and implement bold strategies. I personally urge all stakeholders—the State Government, the developmental partners, the community, the civil society, to come forward and join us in our fight against TB.

Jai Hind !!

(Jagat Prakash Nadda)

Union Minister of Health & Family Welfare

March 2018

348, ए-स्कंध, निर्माण भवन, नई दिल्ली-110011 348, A-Wing, Nirman Bhawan, New Delhi - 110011

Tele.: (O): +91-11-23061661, 23063513, Telefax: 23062358, 23061648

E-mail: hfwminister@gov.in







भारत सरकार स्वास्थ्य एवं परिवार कल्याण विभाग स्वास्थ्य एवं परिवार कल्याण मंत्रालय Government of India Department of Health and Family Welfare Ministry of Health & Family Welfare

#### MESSAGE

I congratulate Central TB Division for bringing out an Annual Report exclusively on TB programme every year. I am happy to see the Annual Report this year also. The Revised National Tuberculosis Control Programme (RNTCP) has been able to bring down the mortality and morbidity due to TB continuously. Annual Report has covered the different aspect of programme Implementation especially during the last one year in a detailed manner.

In order to put a stop to this human tragedy which wreaks havoc in lives of lakhs of families every year, we have committed to eliminate TB by 2025, 5 years ahead of Sustainable Development Goals' target and 10 years before WHO End-TB target. We have improvised several ongoing programmes to reduce and reverse mortality and morbidity rate and also have added several new initiatives to achieve this target. All these action plans have been brought out clearly in the National Strategic Plan, 2017-2025 to eliminate TB (NSP) in line with our National Health Policy, 2017.

NSP has strengthened the RNTCP with a number of newly introduced features. We have launched a campaign for Active TB Case Finding wherein door to door visits are made by health personnel in an effort to find patients with the varied symptoms of tuberculosis and then they are brought to the public health facilities. For rapid diagnosis of TB at these facilities, we have introduced more than 1135 CB-NAAT/GeneXpert test machines covering all the districts of the country. To enhance treatment adherence, Fixed Dose Course (FDC) in Daily Regimen. It has also been observed that TB affects poor disproportionately. Further, TB is a cause as well as the consequence of malnourishment. We are, therefore, starting financial incentives for all TB patients to address their out of pocket expenditure and nutrition through Direct Benefit Transfer (DBT) @ Rs.500/patient/month.

As nearly half the patients seek treatment from the private health sector, we are striving to integrate the efforts of the public as well as the private sector through mandatory notification of TB by all health care personnel. Notifying TB patients will enable the programme to offer all necessary public health support to such patients. It is expected that notification will get a boost and by Active Case Findings and DBT.

In our continuous endeavor to enhance the supervision, monitoring, surveillance and programme operations, we are now linking NIKSHAY, the case based system of surveillance with Drugs Logistics Management Information System, Public Financial Management System (PFMS) etc.

With these value added initiatives, which are described in detail in this report, I look forward to achieving impressive gains in the reduction of morbidity and mortality due to TB in India.

New Delhi 8 March 2018 (Preeti Sudan)

# डॉ. बी.डी. अथणी Dr. B.D. Athani

M.S.(Ortho.), DNB
Director General Health Services





भारत सरकार स्वास्थ्य सेवा महानिदेशालय 439–ए, ए–विंग, निर्माण भवन, नई दिल्ली -110 108

Government of India
Directorate General of Health Services
439-A, A-Wing, Nirman Bhawan,
New Delhi- 110108

1st March, 2018

दिनांक/Dated.....

#### MESSAGE

Revised National TB Control Programme (RNTCP) provides quality assured free diagnostic and treatment services to all the TB patients in our country. The programme has developed Standards for TB Care in India (STCI) to facilitate uniform care of TB patients in India including the private sector. In the recent past, the programme has successfully implemented a few pilot interventions for involving the private sector in the country using free drugs/diagnostics and Information Communication Technology. Expansion of such interventions across country would facilitate Government in ensuring standards of care outside public sector and increasing notification in the public health system.

However, late diagnosis of the disease, non-adherence or non-completion of treatment, co-morbidities, drug resistant TB and inter and intra-state difference in health system response are some of the challenges we are facing today. Elimination of TB is not possible unless there is a major jump in notification, diagnosis and treatment of all TB cases.

Currently TB incidence is declining by about 1-2% per year and to achieve the TB elimination goal by 2025, we need to have a decline in TB incidence by about 15-20% annually. For this we need to optimize utilization of CBNAAT lab, engage private sector by providing free diagnostic and drugs using ICT and ensure social protection for all TB patients through available social schemes in different line Ministries.

Mass public campaign about preventive and curative aspects of TB, counseling of patients and their family members on all aspects of Tuberculosis will go long way in achieving the goal of TB elimination in India.

Total notification of TB patient is gradually improving year by year due to improvement in TB notification from private sector as well. As per the NSP estimates, early diagnosis of TB & active case finding increases further in upcoming years with the help of many newer interventions to detect TB as early as possible.

(Dr. B.D. Athani)

#### Dr. N.S. DHARMSHAKTU

Principal Advisor (PH)

MD (AllMS), Cert. Sr. H. Plg. (JH), GEIS (CDC)





## स्वास्थ्य एवं परिवार कल्याण मंत्रालय निर्माण भवन, नई दिल्ली-110 108

Ministry of Health & Family Welfare Nirman Bhawan, New Delhi-110 108 Tel: 011-2306 2401 Fax: 011-2306 1963 E-mail: ns.dharmshaktu@nic.in

#### MESSAGE

Tuberculosis has remained a disease of public health importance since ages and is known to inflict large quantum of socioeconomic cost on the society. The Revised National Tuberculosis Control program is being implemented under the umbrella of the National Health Mission(NHM).

The Revised National TB Control Program has taken many new initiatives and policy changes in the last year. The National Strategic Plan (NSP) sets out the strategic direction and key initiatives that the Ministry of Health and Family Welfare will undertake from 2017 to 2025 for working towards achieving the goals of eliminating TB by 2025.

Reaching TB patients in private sector has been identified as one of the key to universal health coverage for TB care services under the programme. The expansion of free diagnosis and treatment services with newer tools and strategies to private sector will be the key to achieve our success of reaching every one.

RNTCP and National program for Prevention and Control of Cancer, Diabetes, Cardio vascular diseases and Stroke (NPCDCS) have jointly developed a frame work for collaboration which aims to reduce mortality and morbidity by promoting bidirectional screening, early detection and prompt management Diabetes and TB. In another initiative, National Tobacco Control Program is working in synergy with RNTCP for implementation of a joint collaborative frame work

TB has been curable for several decades now. Great strides have been made in innovations for newer diagnostics and drugs. All we need now is a surge in our actions to reduce the TB burden dramatically. To achieve our goals, all health care providers need to work in synergy and all available resources including those in private sector are utilized for TB control.

On the occasion of this publication of TB INDIA 2018 report I am humbled by the progress that we have made in the last one year. Ending TB will need a quantum leap in our efforts, and yet we're hopeful of a new beginning. I take this opportunity to express the commitment of Ministry of Health and Family Welfare, Government of India to achieve TB elimination by 2025 as envisaged by our Honorable Prime Minister.

> Dr. N.S. Dharmshaktu (Principal Advisor MoHFW)

March 2018



Dy. Director General
Head, Central TB Division
Project Director RNTCP





Tel : 011-2306 3226 011-2306 2980

E-mail: ddgtb@rntcp.org

भारत सरकार
Government of India
स्वास्थ्य सेवा महानिदेशालय
Directorate General of Health Services
स्वास्थ्य एवं परिवार कल्याण मंत्रालय
Ministry of Health & Family Welfare
निर्माण भवन, नई दिल्ली -110108
Nirman Bhayan, New Delhi- 110 108

Dated 1st March, 2018

#### MESSAGE

TB India 2017 is an annual publication from Central TB Division wherein a comprehensive status of TB control activities in the country has been compiled. The TB India report is released every year on 24<sup>th</sup> March, on the occasion of World TB Day.

The programme has seen many new initiatives and policy changes in the last one year. These include revised guidelines for PMDT, Universal Drug Susceptibility Testing for all diagnosed TB Patients including notified patients from the private Sector, roll out of daily regimen for drug sensitive TB across all the State/UTs, expansion of Bedaquiline services, Active Case Finding in vulnerable groups, and expansion of molecular diagnostic services. All these initiatives lead to early case detection, treatment, adherence and better outcome. The programme is also collaborating with the Pharmacovigilance programme of India to systematically identify, detect and manage adverse effect of anti TB drugs. The programme is continuously working to engage with the private sector to further increase access to patients for a public health impact.

I am delighted to share that our Hon'able Prime Minister Shri. Narendra Modi has written a letter to the Hon'ble Chief Ministers / Lieutenant Governers of all States/UTs in the country, to address the challenge of TB in a mission mode. Our goal is to achieve the vision of universal access to quality diagnosis and treatment for all TB. We will continue our endeavour to overcome challenges and undertake newer initiatives to ensure we achieve this goal. For this, we need support from all of you-civil society, patients, private sector and professional bodies/associations related to medical and pharmaceutical sector. We also need participation from other health and development programmes such as diabetes, nutrition, and urban planning. Unless we receive this multi-sectoral support it is unlikely that we will be able to address these challenges in a comprehensive manner.

I'm thankful to officers and staff of Directorate General Health Services, Ministry of Health and Family Welfare and State Governments for their continued support and endeavours for betterment for the programme. I also acknowledge the support of partners who have pledged to come together for a common cause. RNTCP fraternity will strive further to do the good work as the years continue with renewed enthusiasm and dedication.

(Dr. Sunil D. Khaparde)

# **ABBREVIATIONS**

ACF	Active Case Finding
ACSM	Advocacy, Communication and Social Mobilization
AIDS	Acquired Immune Deficiency Syndrome
AIIMS	All India Institute of Medical Sciences
ANSV	Annual Negative Slide Volume
ART	Anti-Retroviral Therapy
ARTI	Annual Risk of Tuberculosis Infection
ASHA	Accredited Social Health Activist
CGHS	Central Government Health Scheme
CHAI	Clinton Health Access Initiative
CHAI	Catholic Health Association of India
СНС	Community Health Centre
CTD	Central TB Division
DALYs	Disability Adjusted Life Years
DBS	Domestic Budgeting Source
DBT	Direct Benefit Transfer
DDG	Deputy Director General
DGHS	Director General of Health Services
DMC	Designated Microscopy Centre
DOTS	Directly Observed Treatment Short Course
DRS	Drug Resistance Surveillance
DRTB	Drug Resistant Tuberculosis

DST	Drug Susceptibility Testing
DTC	District Tuberculosis Centre
DTO	District Tuberculosis Officer
E	Ethambutol
EPTB	Extra-pulmonary Tuberculosis
EQA	External Quality Assurance
FIND	Foundation for Innovative New Diagnostics
GFATM	The Global Fund to Fight against AIDS, Tuberculosis and Malaria
GMSD	Government Medical Store Depot
GoI	Government of India
Н	Isoniazid
HBCs	High Burden Countries
HIV	Human Immuno Deficiency Virus
HRD	Human Resource Development
ICMR	Indian Council of Medical Research
ICT	Information and Communication Technology
ICTC	Integrated Counselling and Testing Centre
IDSP	Integrated Disease Surveillance Project
IEC	Information, Education and Communication
IMA	Indian Medical Association
IPT	Isoniazid Preventive Therapy

IRL	Intermediate Reference Laboratory
JMM	Joint Monitoring Mission
KAP	Knowledge, Attitude and Practices
LT	Laboratory Technician
MDGs	Millennium Development Goals
MDRTB	Multi Drug Resistant
MIS	Management Information System
MO	Medical Officer
MoHFW	Ministry of Health and Family Welfare
MOTC	Medical Officer-Tuberculosis Control
MoU	Memorandum of Understanding
NACO	National AIDS Control Organisation
NACP	National AIDS Control Programme
NCDC	National Centre for Disease Control
NEP	New Extra Pulmonary
NGO	Non-Governmental Organisation
NIRT	National Institute of Research in Tuberculosis
NJIMOD	National Jalma Institute of Mycobacterial and Other Diseases
NRHM	National Rural Health Mission

NRL	National Reference Laboratory
NSN	New Smear Negative
NSP	New Smear Positive
NSP	National Strategic Plan
NTF	National Task Force
NTI	National Tuberculosis Institute
NTP	National Tuberculosis Programme
NUHM	National Urban Health Mission
OR	Operational Research
OSE	On-Site Evaluation
PATH	Program for Appropriate Technology in Health
PHC	Primary Health Centre
PHI	Peripheral Health Institution
PLHIV	People Living with HIV and AIDS
PP	Private Practitioner
PPM	Public-Private Mix
PSU	Public Sector Unit
PTB	Pulmonary Tuberculosis
PWB	Patient-Wise Box
QA	Quality Assurance
R	Rifampicin
RBRC	Random Blinded Re-Checking
RCH	Reproductive and Child Health
RNTCP	Revised National Tuberculosis Control Programme
S	Streptomycin

SDGs	Sustainable Development Goals
SDS	State Drug Store
SHGs	Self Help Groups
SOP	Standard Operating Procedure
SPR	Slide Positivity Rate
STC	State TB Cell
STDC	State Tuberculosis Training & Demonstration Centre
STF	State Task Force
STLS	Senior TB Laboratory Supervisor
STO	State TB Officer
STS	Senior Treatment Supervisor
ТВ	Tuberculosis

The Union	International Union Against Tuberculosis and Lung Disease
TU	Tuberculosis Unit
UDST	Universal Drug Susceptibility Test
UHC	Urban Health Coverage
UNOPS	United Nations Office for Project Services
USAID	United States Agency for International Development
WHO	World Health Organization
WVI	World Vision India
XDR-TB	Extensively Drug Resistant TB
Z	Pyrazinamide
ZTF	Zonal Task Force

# **CONTENT**

Chapter No.	Content	Page No.
	Forewords and Executive Summary	
1	Activities Undertaken in 2017	1
2	TB Disease Burden and Surveillance in India	7
3	National Strategic Plan (NSP) 2017–2025 for TB Elimination	11
4	RNTCP Implementation Status	
4	4.1 Case Finding & Diagnosis of Tuberculosis	23
	4.2 Treatment of TB Services	31
	4.3 TB-HIV	37
5	Partnership	41
6	Budgeting and Finance	59
7	Procurement & Logistics Management	65
8	Advocacy, Communication and Social Mobilization	71
9	Research	79
10	Monitoring and Evaluation	87
11	Human Resources	93
12	Success Stories	97
	Annexures	105

# **EXECUTIVE SUMMARY**

his Annual TB Report provides an update on progress of TB control activities, information on newer initiatives, policies and guidelines developed in 2017. Revised National TB Control Programme (RNTCP) is an on-going Centrally Sponsored Scheme, being implemented under the umbrella of National Health Mission. The programme was initiated from 1997, covered entire country in 2006. The programme, since then, has achieved global benchmark of case detection and treatment success and achieved millennium development goals in 2015 of halting and reversing the incidence of TB.

The major initiatives taken in 2017 are expansion of Daily Regimen for treatment of TB across the country; scale up of Bedaquiline; conditional approval of Delamanid; release of guidelines on PMDT in India; National ToT guidelines on PMDT and introduction of MERM boxes.

One of the landmark achievement of 2017 is approval of bold and ambitious National Strategic Plan (NSP) 2017-25 for TB Elimination is a framework to provide guidance for the activities of stakeholders including the National and State Governments, Development Partners, Society Organizations, International Agencies, Research Institutions, Private Sector, and many others whose work is relevant to TB elimination in India. It provides goals and strategies for the country's response to the disease during the period 2017-2025 and aims to direct the attention of all stakeholders to the most important interventions or activities that the RNTCP believes will bring about significant changes in the incidence, prevalence and mortality of TB. These strategies and interventions are in addition to the processes and activities already ongoing in the country.

As per the Global TB report 2017 the estimated incidence of TB in India was approximately 28,00,000 accounting for about a quarter of the world's TB cases. In 2017 India re-estimated its national figures of the burden of Tuberculosis incorporating information from a wider range of sources.

The program has put in a number of patient centric systems such as ICT based adherence monitoring, increasing the breadth of treatment and social support options available to people affected with TB, expanded laboratory capacity and policy for detecting drug resistance. The program is currently scaling up its policy of Universal DST whereby all cases diagnosed with TB will receive a minimum of Rifampicin and Isoniazid resistance testing.

The programme adopted a Direct Benefit Transfer (DBT) mechanism for transfer of monetary support and incentives to patients. This will ensure the funds reach rightful recipients in a timely manner.

The programme is making special efforts for reaching the unreached through Active Case Finding (ACF) campaign, focusing on clinically, socially and occupationally vulnerable populations and shifting from passive to active case finding along with passive case finding in selected populations. For achieving the ambitious targets, the programme has modified its diagnostic approach to drug sensitive and drug resistance TB cases.

TB C&DST laboratories under RNTCP Lab Network are equipped with different diagnostic technologies for DR TB diagnosis, which include Solid/Liquid Culture DST or Line Probe assay. Currently, there are 74 TB C&DST laboratories which are certified by RNTCP for one or more diagnostic technologies. Out of the 74 TB C&DST laboratories, 45 laboratories are certified for all the three diagnostic technologies. Cumulatively, 48 laboratories are certified for solid culture DST; 45 laboratories for first-line liquid culture DST and 38 laboratories for second-line liquid culture DST; 56 laboratories for first-line LPA technology and 50 laboratories for second-line LPA technology.

For decentralized diagnosis of TB and Rifampicin resistance CBNAAT machines have been provided at district levels. In the year 2017, more than one million CBNAAT tests have been conducted.

In addition to the existing 628 Machines, 507 machines have been procured and deployed to

cover all districts of the entire country. Genome sequencing facilities are being established at six Reference Laboratories, for surveillance of drug resistance, for providing information on transmission dynamics and molecular epidemiology.

First National Drug Resistance Survey results showed the rates of MDR among new TB patients to be 2.84% and that in previously treated to be 11.60%.

CTD has developed a web based application "Nikshay Aushadhi" for the management of Anti TB Drugs and other commodities under RNTCP.

The subsequent chapters in this report bring out details of implementation status, various initiatives and activities undertaken during the year 2017.







मुझे खुशी है कि भारत की Health और Family Welfare Ministry, WHO South East Asia Region और Stop TB Partnership मिलकर एशिया, अफ्रीका और दुनिया के अनेक देशों के प्रतिनिधियों को आज एक मंच पर लाए हैं: PM

11:36 AM - Mar 13, 2018

 $\bigcirc$  1,438  $\bigcirc$  417 people are talking about this

θ

www.tbcindia.gov.in www.nikshay.gov.in www.nikshayaushadhi.in

## **January**

- 1. Zonal Task Force Meeting for North East held on 19<sup>th</sup> -20<sup>th</sup> January 2017.
- Active case finding for TB implemented in 50 districts across 18 States from 16<sup>th</sup> January - 30<sup>th</sup> January 2017.
- 3. Tribal TB project launched in Mandla district of Madhya Pradesh on 19<sup>th</sup>-20<sup>th</sup> January by Hon'ble MoS Shri Faggan Singh Khulaste.

## **February**

- 1. ZTF South zone 1 was held in Bangalore on 2nd and 3<sup>rd</sup> Feb 2017.
- 2. ZTF North zone was held on 25<sup>th</sup> and 26<sup>th</sup> Feb 2017 at Shimla.
- 3. Stakeholders Consultative Meeting for development of concept note for Global Fund Grant 2018-2020 took place on 9<sup>th</sup> Feb 2017.
- 4. 68<sup>th</sup> CCM Meeting took place on 14<sup>th</sup> Feb 2017.

#### March

- 1. Consultative Workshop for NSP 2017-25 took place on 28<sup>th</sup> Feb and 1<sup>st</sup> March 2017.
- 2. ZTF east zone took place at Ranchi on 4<sup>th</sup> and 5<sup>th</sup> March 2017.
- 3. World TB Day was observed on 24<sup>th</sup> March 2017.
- 4. WHO Ministerial Meeting by SEARO, WHO took place on 15<sup>th</sup> and 16<sup>th</sup> March 2017 at New Delhi.
- 5. Nutritional Support Guideline and National

- Framework for TB-Diabetes Collaborative activities was released on 24th March 2017
- 6. Initiated SMS services to support treatment adherence under RNTCP

### April

- 1. Implementation of Daily Regimen for Drug sensitive TB was launched in five States in a phased manner
- 2. National Task Force Meeting took place at Guwahati on 11<sup>th</sup> and 12<sup>th</sup> April 2017.
- 3. National Training of Trainers (ToT) for expansion of Bedaquiline in the country took place in New Delhi from 18<sup>th</sup> -20<sup>th</sup> April 2017.
- 4. Finalization of National Strategic Plan for TB (2017-25)

#### May

- 1. Approval of National Strategic Plan 2017-25 for TB elimination in India by the Hon'ble HFM
- 2. Proposal for Global Fund Grants for 2017-20 submitted after approval of CCM
- Supportive supervision visits by Central team to the 5 States implementing Daily Regimen
- Preliminary discussion on introduction of Delaminid in India under chairmanship of Secy. DHR and DG ICMR at New Delhi on 11th May 2017.

#### June

1. Monitoring visits by Central teams to Bihar, Himachal Pradesh, Kerala, Maharashtra and

- Sikkim to review and assess implementation status of daily regimen.
- 2. 2<sup>nd</sup> phase of Active Case Finding started across 26 States/UTs covering 100 priority districts.
- 3. Feasibility Study for Indigenous Rapid Molecular Diagnostic tool (TrueNat) for TB initiated in 100 designated microscopy centres across 50 districts in the country.

## July

- 1. Central team visits to 11 States to assess the preparedness for the implementation of Daily Regimen.
- 2. "Centre State Summit for TB Elimination through Effective Partnerships" was organized in Nagpur, Maharashtra. This was attended by policy makers, national and international experts on TB, Program managers, development partners and representatives from private sector, media and community.

# August

- 1. 99 DOTS was rolled out in five States for all patients on daily regimen.
- 2. 2nd round of Active Case Finding ended on 31st July, over 20 crore population was screened with over 9000 patients diagnosed with TB.
- 3. Dr Eric Goosby, UN Special Envoy on TB, concluded his five day visit to India commending the Government of India for its bold vision and leadership in combating TB.
- 4. DO letter regarding implementation of Universal DST in phased manner was

- issued to 19 States/UTs identified for the first phase.
- 5. Pre Drug safety and Monitoring committee meeting for Bedaquiline implementation was held on 17th of August 2017 at Mumbai

### September

- 1. STO Consultant review meeting of RNTCP was held from 12<sup>th</sup>-14<sup>th</sup> September at Chandigarh.
- Global Fund grant making (2018-2021) meeting held from 11<sup>th</sup>-22<sup>nd</sup> September. Debriefing meeting was held on 22<sup>nd</sup> September 2017.
- 3. Meeting of National Expert Committee on "Regulation of newer anti-TB drugs in India held under chairmanship of Secretary DHR and DG ICMR on 21st September 2017 for introduction of Delamanid, new anti TB drug in India.

#### October

- Video Conference with all Principal Secretaries and Mission Directors under NHM was held on 30<sup>th</sup> October 2017 by Secretary H&FW to review TB control activities by the State/UTs.
- 2. Daily regimen for all TB patients has been initiated across the country in October 2017.
- 3. Hon'ble HFM reviewed the RNTCP programme on 10th October 2017.

#### November

1. Bedaquiline drug introduced in 21 sites in 5 States. Drugs for 1000 more patients received. Trainings of all States completed.

- Joint Assessment of Laboratory Network under RNTCP was conducted during 30th Oct – 10th November 2017
- Hon'ble HFM participated in the 1<sup>st</sup> WHO Global Ministerial Conference at Moscow, Russian Federation during 16-17<sup>th</sup> November 2017
- Review on PMDT for North Zone (8 States) held at Shimla during 21<sup>st</sup> – 23<sup>rd</sup> November, 2017

#### December

- 1. Central Internal Evaluation was conducted for the States of Madhya Pradesh by a team of experts.
- 2. 3<sup>rd</sup> phase of ACF organized in 221 districts throughout the country. More than 3000 cases have been diagnosed by the end of 3rd Phase.
- 3. The Additional 507 CBNAAT Machines were dispatched to the States for installation.



Hon'ble Prime Minister Shri Narendra Modi with Dr Tedros Adhanom Ghebreyesus, Director-General, WHO





मुझे उम्मीद है कि 'Delhi End TB Summit' TB को धरती से हमेशा के लिए खत्म करने की दिशा में एक landmark event के तौर पर

जाना जाएगा: PM @narendramodi

Watch Live: facebook.com/PMOIndia/video...

11:37 AM - Mar 13, 2018

 $\bigcirc$  1,639  $\bigcirc$  408 people are talking about this

.

www.tbcindia.gov.in www.nikshay.gov.in www.nikshayaushadhi.in

# Strengthening Disease surveillance for better measurement of Burden

isease surveillance in TB is particularly challenging as there is no single reliable method. To be most effective, a multi-pronged approach, combining a number of measures adapted contextually, is required. The government of India has been giving increased emphasis to establishing a strong multi-pronged surveillance system.

Currently the program is attempting to bring all cases of TB disease under its service delivery umbrella, from the point of diagnosis. A number of existing measures were and are being further strengthened. Over the counter sales of Anti-TB drugs, included in the Schedule H1, have been increasingly monitored to facilitate notification. Notification is incentivised with extension of free quality drugs and diagnostics to the patients accessing care from the private sector. A number of additional incentives are also planned in the NSP 2017-25 to improve notification from the private sector.

Surveillance in TB is not only about detecting TB Cases; for being effective surveillance should also include adherence monitoring, surveillance of Drug resistance and surveillance using genomics. This will prevent emergence and spread of resistance, and be able to detect epidemic patterns within localities. The program has put in a number of patient centric systems such as ICT based adherence monitoring, increasing the breadth of treatment and social support options available to people affected with TB, expanded laboratory capacity and policy for detecting drug resistance. The program is currently scaling up

its policy of Universal DST whereby all cases diagnosed with TB will receive a minimum of Rifampicin and Isoniazid resistance testing.

#### TB Disease Burden

As per the Global TB report 2017 the estimated incidence of TB in India was approximately 28,00,000 accounting for about a quarter of the world's TB cases.

In 2017 India re-estimated its national figures of the burden of Tuberculosis; incorporating information from a wider range of sources and thus is more accurate than previous estimates. The major additional information source is the private sector notification seen throughout the country and in certain project locations with interventions targeted at private sector notification. The following table shows the current statistics of TB and MDR/RR TB incidence, HIV TB Co-morbidity and TB related mortality.

Table: 2.1. Estimates of TB Burden in India and Global, 2016

Indicator	No.	No/ Lakhs	Global statistics
Incidence of TB (including HIV)	27,90,000	211	1,04,00,000
Mortality due to TB (Excluding HIV)	4,23,000	32	13,00,000
Incidence of MDRTB/RR	1,47,000	11	6,01,000
Incidence of HIV-TB	87,000	6.6	10,30,000
Mortality due to HIV-TB co-morbidity	12,000	0.92	3,74,000

Source: Global Tuberculosis Report 2017



Hon'ble Prime Minister Shri Narendra Modi with Dr. Soumya Swaminathan, Deputy Director General, WHO





भारत में तो वैसे भी किसी भी communicable disease से TB का प्रभाव सबसे ज्यादा है और इसका सबसे ज्यादा शिकार भी गरीब होते हैं। इसलिए TB खत्म करने के लिए उठाया गया हर कदम, सीधे-सीधे गरीबों के जीवन से जुड़ा हुआ है: PM @narendramodi 11:39 AM - Mar 13, 2018

♥ 4,113 ♥ 1,019 people are talking about this

6

www.tbcindia.gov.in www.nikshay.gov.in www.nikshayaushadhi.in he NSP 2017-2025 builds on the success and learning's of the last NSP and encapsulates the bold and innovative steps required to eliminate TB in India by the year 2025. It is crafted in line with other health sector strategies and global efforts, such as the draft National Health Policy 2015, World Health Organization's (WHO) End TB Strategy and the Sustainable Development Goals (SDGs) of the United Nations (UN).

This NSP is a framework to provide guidance for the activities of stakeholders including the National and State Governments, Development Partners, Civil Society Organizations, International Agencies, Research Institutions, Private Sector, and many others whose work is relevant to TB elimination in India. The NSP 2017-2025 is a three year costed plan and an eight year strategy document. It provides goals and strategies for the country's response to the disease during the period 2017-2025 and aims to direct the attention of all stakeholders to the most important interventions or activities that the RNTCP believes will bring about significant changes in the incidence, prevalence and mortality of TB. These strategies and interventions are in addition to the processes and activities already ongoing in the country.

As a strategic document, the subsequent operational plans will necessarily follow. The NSP will guide the development of the national project implementation plan (PIP) and state PIPs, as well as district health action plans (DHAP) under the National Health Mission (NHM). This NSP replaces previous strategies, and will inform and guide the updating of technical and operational guidelines and associated programme tools.

The development of this NSP has been a collaborative effort between all the stakeholders including national and state governments, development partners, civil society organizations, and the private sector in India which was and has been led by the Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare. Knowledge and insights generated from a series of workshops and consultations with the stakeholders, learnings from the implementation of the past NSP and experiences from the pilots, models and approaches tested during the last NSP period informed the strategies proposed in the current NSP.

# Vision, Goals and Targets of NSP

The NSP proposes bold strategies with commensurate resources to rapidly decline TB incidence and mortality in India by 2025, five years ahead of the global End TB targets under Sustainable Development Goals to attain the vision of a TB-free India.

**VISION:** TB-Free India with zero deaths, disease and poverty due to TB

**GOAL:** To achieve a rapid decline in burden of TB, morbidity and mortality while working towards elimination of TB in India by 2025.

# **Objectives:**

1. Find all Drug Sensitive TB and Drug Resistant TB cases with an emphasis on reaching TB patients seeking care from private providers and undiagnosed TB in high-risk populations.

- Initiate and sustain all patients on appropriate anti-TB treatment wherever they seek care, with patient friendly systems and social support.
- 3. Prevent the emergence of TB in susceptible populations.
- 4. Build and strengthen enabling policies, empowered institutions, additional human resources with enhanced capacities, and provide adequate financial resources.

### **Key Strategies:**

- 1. Private sector engagement
- 2. Active Case finding
- 3. Drug resistant TB case management
- 4. Addressing social determinants including nutrition
- 5. Robust Surveillance system
- 6. Community engagement & Multi-sectoral approach

## **Expected Outcome:**

The National Strategic Plan is aiming to achieve elimination of TB, by 2025. During plan period, targets for TB are

- 1. 80% reduction in TB incidence (i.e. reduction from 211 per lakh to 43 per lakh)
- 2. 90% reduction in TB mortality (i.e. reduction from 32 per lakh to 3 per lakh)
- 3. 0% patient having catastrophic expenditure due to TB

Below table highlights the core impact, outcome indicators and targets of the NSP that highlights the four priority areas that include private sector engagement, ensuring a seamless, efficient TB care cascade, active TB case-finding among key population (socially vulnerable and clinically high risk) and preventing progression from latent TB infection (LTBI) to active TB in high risk groups.

Table: 3.1 NSP 2017-25 Results Framework

	Baseline	Target		
IMPACT INDICATORS	2015	2020	2023	2025
To reduce estimated TB Incidence rate (per 100,000 population)	217	142	77	44
	(112-355)	(76-255)	(49-185)	(36-158)
To reduce estimated TB prevalence (per 100,000 population)	320	170	90	65
	(280-380)	(159-217)	(81-125)	(56-93)
To reduce estimated mortality due to TB (per 100,000 population)	32	15	6	3
	(29-35)	(13-16)	(5-7)	(3-4)
To ensure no family should suffer catastrophic cost due to TB	35%	0%	0%	0%

	Baseline	Target		
OUTCOME INDICATORS	2015	2020	2023	2025
Total TB patient notification(in millions)	1.74	3.6	2.7	2
Total patient Private providers notification (in millions)	0.19	2	1.5	1.2
MDR/RR TB patients notified	28,096	92,000	69,000	55,000
Proportion of notified TB patients offered DST	25%	80%	98%	100%
Proportion of notified patients initiated on treatment	90%	95%	95%	95%
Treatment success rate among notified DSTB	75%	90%	92%	92%
Treatment success rate among notified DRTB	46%	65%	73%	75%
Proportion of identified targeted key affected population undergoing active case finding	0%	100%	100%	100%
Proportion of notified TB patients receiving financial support through Direct Benefit Transfers (DBT)	0%	80%	90%	90%
Proportion of identified/eligible individuals for preventive therapy / LTBI s - initiated on treatment	10%	60%	90%	95%

#### Goals of NSP

India has scaled up basic TB services in the public health system, treating more than 19 million TB patients under RNTCP, the rate of TB decline is too slow to meet the 2030 Sustainable Development Goals (SDG) and 2035 End TB targets. Although sufficient insight and expertise exists to inform TB programme decision-making, these resources have often been underutilized in terms of meeting the needs of policy makers for quantitative analysis and improvements in TB control policy and implementation.

Continuation of prior efforts has yielded inadequate declines, and will not accelerate

the progress towards ending TB. New, comprehensively-deployed interventions are required to accelerate the rate of decline of incidence of TB many fold, to more than 10-15% annually. The requirements for moving towards TB elimination have been integrated into the four strategic pillars of "Detect – Treat – Prevent – Build" (DTPB).



Table: 3.2. Explaining the 'DTPB' approach of NSP 2017 -2025

DETECT	HOW DO WE DO IT?
Find all DS-TB and DR-TB cases with an emphasis on reaching TB patients seeking care from private providers and undiagnosed TB in high-risk populations.	<ul> <li>Scale-up free, high sensitivity diagnostic tests and algorithms</li> <li>Scale-up effective private provider engagement approaches</li> <li>Universal testing for drug-resistant TB</li> <li>Systematic screening of high risk populations</li> </ul>
TREAT	HOW DO WE DO IT?
Initiate and sustain all patients on appropriate anti-TB treatment wherever they seek care, with patient friendly systems and social support.	<ul> <li>Prevent the loss of TB cases in the cascade of care with support systems</li> <li>Free TB drugs for all TB cases</li> <li>Universal daily regimen for TB cases and rapid scale-up of short-course regimens for drug-resistant TB and DST guided treatment approaches.</li> <li>Patient-friendly adherence monitoring and social support to sustain TB treatment</li> <li>Elimination of catastrophic costs by linking eligible TB patients with social welfare schemes including nutritional support</li> </ul>
PREVENT	HOW DO WE DO IT?
Prevent the emergence of TB in susceptible populations	<ul> <li>Scale up air-borne infection control measures at health care facilities</li> <li>Testing and treatment for latent TB infection in contacts of bacteriologically-confirmed cases and in individuals at high risk of getting TB disease</li> <li>Address social determinants of TB through intersectoral approach</li> </ul>

BUILD	HOW DO WE DO IT?				
Build and strengthen enabling policies, empowered institutions, human resources with enhanced capacities, and	• Translate high level political commitment to action through supportive policy and institutional structures:				
financial resources to match the plan.	current administrative set up at the national level and matching structures at state level				
	National TB Policy and Act				
	• Restructure RNTCP management structure and implementation arrangement: Substantially augmented HR and HR reforms and TB surveillance network in the country strengthen				
	• Scale up Technical Assistance at national and state levels				
	• Align and harmonize partners' activities with programme needs to prevent duplication				

To summarize, the ultimate impact of this NSP will be transformational improvements in the 'End TB' efforts of India thereby contributing to the health and wellbeing of its population. By taking a Detect – Treat – Prevent – Build approach the national programme can achieve significant positive change and make a real difference in the lives of the many people it serves. The programme is determined to expand coverage, improve quality and reduce out of pocket expenditure to achieve Universal Health Coverage in TB service delivery context.

The NSP 2017-25 for TB Elimination document is available at: https://tbcindia.gov.in

## 3.1 Patient Support Incentives

Majority of TB patients notified are from the

age group of 15-45 years and they are from the lower socio-economic strata of the society. Also, since they are from working group age, TB disease affects the income of the family also while patients are on care. Hence the Ministry of Health and Family Welfare approved incentives for all TB patients notified in NIKSHAY under RNTCP. The financial incentives will support TB patients to prevent catastrophic expenditure, attract notification from private sector and encourage them to complete treatment.

It is proposed that Rs. 500 per month during treatment of TB via Direct Benefit Transfer (DBT) to the patient for nutritional support, reduce out of pocket expenditure (in line with National Health Policy) and incentivize treatment completion for all the projected TB patients and DR-TB patients.

The programme will adopt a DBT mechanism for transfer of monetary support and incentives to patients by linking payment of incentives under RNTCP using Aadhar based DBT (UIDAI), Public Finance Management System (PFMS) and NIKSHAY (online RNTCP MIS).

#### 3.2 Incentives for TB Notification:

Incentives of Rs. 1000 will be provided for notification of TB patients. This will be given at Rs. 500 at notification and Rs. 500 for reporting treatment outcome. The incentives will be provided upon Notification in the TB reporting software i.e. Nikshay through a smooth and transparent manner.

Linkages for provisions of free drugs and diagnostics to private sector patients either through social marketing approach or reimbursements of services.

#### 3.3 Direct Benefit Transfer

# Linking Bank Account, AADHAR and NIKSHAY for direct cash benefits to patients:

The programme adopted a DBT mechanism for transfer of monetary support and incentives to patients. This will ensure the funds reach rightful recipients in a timely manner.



Fig: 3.1. Moving towards digital treatment support

The cornerstones of the DBT mechanism will be:

- i. RNTCP In addition to providing funds for DBT, programme will also identify and review incentives and treatment supports to be provided to the patients
- **ii. Bank Account** Saving Bank account will allow for quick establishment of DBT linkages for patients irrespective of their economic strata or geographic location.
- iii. NIKSHAY As a case based patient identification system, NIKSHAY will allow for a real time tracking of patient eligibility for DBT and ensure quick activation of DBT linkages to patient accounts

iv. AADHAR – AADHAR will act as the unique identifier for patients seeking treatment support via DBT mechanism. It is also hoped that in the future the TB number will align with the AADHAAR identifier.

An eligible amount per month will be provided for TB patient notified in NIKSHAY for nutrition support, encourage completing the treatment and covering the catastrophic cost. Linking of bank account, Aadhaar number and Nikshay identification number will be used for this transaction. Local arrangements are being made to provide the financial incentives to needy patients who are yet to have Aadhaar number and bank account due to any reason.





Hon'ble Prime Minister Shri Narendra Modi with Dr. Poonam Khetrapal Singh, RD, SEARO, WHO





दुनिया भर में TB को खत्म करने के लिए वर्ष 2030 तक का समय तय किया गया है। लेकिन आज मैं ये घोषणा कर रहा हूं कि भारत ने वर्ष 2030 से 5 साल और पहले, यानि 2025 तक TB को खत्म करने का लक्ष्य अपने लिए तय किया है: PM

11:40 AM - Mar 13, 2018

♥ 4,928 ♥ 1,308 people are talking about this

www.tbcindia.gov.in www.nikshay.gov.in www.nikshayaushadhi.in

## **RNTCP Implementation Status**

# 4.1 Case Finding & Diagnosis of Tuberculosis

#### Introduction

SP 2017-25, advocates early identification of presumptive TB cases, at the first point of care be it private or public sectors, and prompt diagnosis using high sensitivity diagnostic tests to provide universal access to quality TB diagnosis including drug resistant TB in the country.

RNTCP achieved complete geographic coverage in March 2006 and since then case notification rates increased till they plateaued and remained stationary. The case notification rates have started decreasing in many parts of the country despite increasing efforts of symptomatic examination in the public sector. The programme is making special efforts for reaching the unreached like active case finding (ACF) campaign, focusing on clinically, socially and occupationally vulnerable populations and shifting from passive to active case finding along with passive case finding in selected populations. For achieving the ambitious targets, the programme has modified its diagnostic approach to DS & DR TB cases.

Since 2007-08, annually, RNTCP screens approximately 20 million symptomatic persons by microscopy for TB and initiates about 1.5 million persons on TB treatment. CBNAAT and Line Probe Assay introduced in 2009 and scaled up from 2012 onwards, have ensured that rapid molecular diagnostics are available throughout the country. In 2017, 7,32,449 patients have been tested using these methods and 38,854 Rifampicin resistant/MDR-TB patients have been diagnosed.

### **Active Case Finding**

Active Case Finding is basically a provider initiated activity with the primary objective of detecting TB cases early by finding symptomatic people in targeted groups and initiating treatment promptly.

Three phases of Active Case Finding in vulnerable population were conducted till December 2017. In third phase, 378 districts covered, around 5.5 crore population screened and 26781 TB cases were diagnosed.





ACF activity being carried out in a State

### **RNTCP Laboratory Network**

TB diagnosis is offered through more than 14,000 designated microscopy centres spread across the country. CBNAAT facilities have been established at District levels for decentralised molecular testing for TB and simultaneous detection of Rifampicin resistance. Reference laboratories have been established at State and National levels which provide Culture and DST services as well as molecular diagnosis. The laboratory network under RNTCP is composed of three tiers for quality assurance of all diagnostic modalities.

Diagnostic algorithm has also undergone revision to accommodate available technologies and optimal use at various levels.

## **National Policy for diagnosis:**

**Drug Sensitive TB:** Direct sputum smear microscopy by Ziehl-Neelsen acid-fast staining/ Fluorescence Microscopy are the primary case detection tool in RNTCP for patients with infectious tuberculosis presumed to be drug sensitive and is also for monitoring their response to treatment.

Drug Resistant TB: Patients at risk of DR TB as defined by the programme (Multi-Drug Resistant TB- MDR-TB), are diagnosed using WHO endorsed rapid diagnostics (WRD) like Cartridge Based Nucleic Acid Amplification Test (CBNAAT) / Line Probe Assay (LPA).Response to treatment for MDR is monitored by follow up culture on Liquid Culture (MGIT) system (critical follow-ups requiring clinical response) and identification of Mycobacterial species is

performed by commercial Immunochromatic test (ICT).

MDR-TB diagnosis is offered to all patients initiated on re-treatment as well as patients who remain smear positive on any follow up including failures of first line treatment and those at high risk such contacts of MDR-TB cases. CBNAAT is also offered for TB diagnosis in key populations such as PLHIV, Children and EP-TB cases, referrals from the private sector for early diagnosis and initiating appropriate treatment.

More recently, the diagnostic algorithm has been modified wherein CBNAAT is offered to cases who are Smear negative but have an X ray suggestive of TB, as well as for new TB cases.

# Structure and Functions of RNTCP Laboratory network:

The RNTCP laboratory network is composed of a three tier system with National level Reference Laboratories (NRLs), State level Intermediate Reference Laboratories (IRLs), and peripheral level laboratories as Designated Microscopy Centres (DMCs).

C&DST laboratories under RNTCP Lab Network are equipped with different diagnostic technologies for DR TB diagnosis, which include conventional Solid culture and/ or newer rapid TB diagnostic technologies i.e. Line Probe assay-LPA and Liquid Culture. Depending upon the availability of necessary infrastructure and resources, these laboratories are equipped with either all three diagnostic technologies or single or any combination of these technologies.




Fig: 4.1. RNTCP Laboratory Hierarchical Structure

### **Laboratory Certification status:**

48 laboratories have been certified by RNTCP for performing solid C & DST, 45 laboratories for performing DST to First line drugs using liquid culture system. Of these, 38 laboratories have additionally been certified for performing DST to second line anti TB drugs. 56 certified laboratories provide First Line-LPA services.

Five batches of National Level Trainings of Trainers on second line LPA were conducted at NTI, Bangalore in the month of March 2017. Onsite trainings in second line LPA were also conducted successfully in all the IRLs/TB C&DST labs with support of the NRLs in subsequent months till August 2017. 50 laboratories have been certified for second-line LPA technology.

List of certified C&DST laboratories are placed at Annexure-5c

Table: 4.1. Laboratory testing performance for the year 2017

Table: 4.1. a. CBNAAT testing (2017)

No. of machines	No. of tests performed	No. of Rifampicin- Resistant TB Detected	Tests for private sector patients	EP-TB samples tested out of total test done	HIV +ve out of total tested
628	10,77,377	37,488	93,618	1,31,428	1,90,218

Table: 4.1. b. LPA performed (2017)

No. of test	No of sensitive to H&R	No of resistant to INH	No of resistant to to INH Rifampicin	
93,989	68,070	7,736	2,243	11,518

Table: 4.2. SLDST performed (2017)

Number of SL DSTs conducted	Number of MDR + FQ resistance detected	Number of MDR + SLI resistance detected	Number of XDR detected
26,832	8,594	826	2,650

## Laboratory Network and Quality Assurance:

At present Culture and DST services are provided through 74 RNTCP certified laboratories which include laboratories from Public sector (IRL, Medical College), Private and NGO laboratories. RNTCP also encourages the Laboratories from Medical Colleges, ICMR, Private sector and NGO sector to apply for certification by providing technical assistance and training of the human resources at National Reference Laboratories.

The programme has a very well established quality assurance (QA) mechanism which follows the WHO system of hierarchal control from the highest level of National Reference laboratories to State Intermediate Reference labs (both IRL and CDST), to CBNAAT at the district/sub district level and then designated microscopy centres at the most peripheral level. The QA has all elements of internal quality control, on-site evaluation and external quality assessment.

QA for the National level laboratories is

provided through the WHO supranational reference laboratory (SNRL) network. One of the SNRL for the South East Asia region is NIRT, Chennai which also serves as a NRL. Quality assurance panel for both first and second line drugs to the SNRL and three other NRLs (NTI Bangalore, NITRD Delhi and NJIL&OMD, Agra) is provided by the WHO coordinating lab (Antwerp) of SRL network.

# Quality Assurance for Culture & Drug susceptibility testing:

EQA for Culture and DST is ensured by a process of pre-assessment, On-Site Evaluation visit to the facility and the actual certification procedure. Quality is maintained by a process of continuous monitoring by annual proficiency panel testing from NRLs to their respective IRLs or diagnostic laboratories (medical college, NGO or Private). The process of certification was adopted from the standard international guidelines, and has been in place from 2005. Culture and DST labs need to satisfactorily undergo certification for Culture and DST, by their respective NRL, through a rigorous process to achieve and maintain the proficiency. This inter-laboratory culture exchange and testing process involves both NRL (PT) panel cultures testing at IRL, and re-testing (RT) of select cultures at the NRL.

The certification is initially granted for a period of two years and shall be subjected to an onsite evaluation within one year of grant of certification and a re-assessment before the end of two years. Thereafter, re-assessment is carried out every two years. Certified laboratories carry out testing activities within the scope of certification (Solid, liquid and LPA) to meet the needs of RNTCP. All Certified laboratories

regularly participate in the Proficiency Testing programmes/rounds conducted by NRLs. The certified laboratory submits quarterly laboratory performance indicators to the NRLs. The data from the performance indicators are analysed by the NRLs and technical guidance provided for corrective actions.

### **Quality Assurance for CBNAAT:**

Until recently quality assurance for CBNAAT had been limited only to instrument guided internal controls. However, in the year 2017, more than one million CBNAAT tests have been conducted. Considering the need of external quality assurance mechanism for CBNAAT, FIND India in collaboration with CDC has initiated projects for Quality assurance of CBNAAT in using dried spot panels, which can be shipped safely and tested at peripheral sites. NTI, Bangalore will be the coordinating National Reference Laboratory for implementation of these projects. Experts from NTI, Bangalore have undergone training in panel manufacture at CDC Atlanta. The panels have been manufactured and validated at NTI. These panels will be used for testing at identified CBNAAT sites in Public as well as private sector in Mumbai. The learning's from the initial implementation will help the programme in developing mechanisms for expansion across the country.

## **Diagnostic Algorithm:**

The diagnostic algorithm is dynamic and has undergone revisions from time to time with the availability of newer technologies and the programme needs. The latest algorithm as included in the revised PMDT guidelines is given below




Fig: 4.2. PMDT diagnostic algorithm

## First National Drug Resistance Survey, India

Understanding the epidemiology of drug resistant TB and knowledge on the rates of drug resistant TB is essential for combating the challenge of DR TB. In order to plan, strategize and refine the quality of services for DR TB, it was crucial to have data on the rates of drug resistance at a National level. Towards this goal, India has conduct the survey.

5280 sputum smear positive patients attending diagnostic centres belonging to 120 TUs (selected as clusters for sampling) were recruited for the Survey. This has been the largest survey conducted globally and for the very first time Liquid Culture was used and DST performed for 13 anti TB drugs.

The survey provides a statistically representative national estimate of the prevalence of antituberculosis drug resistance among new and previously treated patients in India, and will contribute to a more accurate estimate of antituberculosis drug resistance globally.

The results of the survey showed the rates of MDR among new TB patients to be 2.84% and that in previously treated to be 11.60 %.

## Augmenting the laboratory capacity

15 laboratories with TB containment facility has been established and the existing laboratory network augmented with 50 GT Blots and 26 Liquid culture systems. Towards Universal testing for Rifampicin resistance as well as diagnosis of TB among vulnerable population, 507 additional CBNAAT machines have also been deployed across the country.

## **Scale-Up of CBNAAT Facilities:**

In addition to the existing 628 Machines, 507 machines have been procured and deployed to cover all districts of the entire country. List of CBNAAT are placed at Annexure 5b.

#### **Second Line LPA Services:**

Reference Laboratories have also initiated -Second Line LPA a diagnostic prerequisite for introduction of shorter treatment regimen for Drug resistant TB.

# **Establishment of Genome Sequencing Facilities**

Genome sequencing facilities are being established at six Reference Laboratories, for surveillance of drug resistance, for providing information on transmission dynamics and molecular epidemiology. Of six sites, five sites (NITRD Delhi, NDTB Delhi, NTI Bangalore, JJ Hospital Mumbai, IRL Ahmadabad) are being equipped with whole Genome sequencer and one site (IRL, Guwahati) with Pyro sequencer.

#### **Newer Initiatives:**

### Joint Assessment of the Tuberculosis Diagnostic Network of India

The first ever Joint International Assessment of the Tuberculosis Diagnostic Network of India was conducted by an experienced group of National and International experts with support of USAID. The key objective of the assessment was to evaluate the current practices and algorithm and propose evidence-based short and medium term interventions to improve access, capacity and quality of the TB diagnostic network to increase detection of TB and MDR-TB in line with NSP targets.

The key focus areas were:

Overall placement, quantity and utilization of appropriate diagnostic technologies

- Availability and use of correct diagnostic algorithms, guidelines and policies
- Laboratory infrastructure and appropriate bio-safety measures
- Equipment validation and maintenance
- Specimen transport and referral mechanisms
- Management of laboratory commodities and supplies
- Laboratory/diagnostic network information and data management systems
- Laboratory quality management systems
- Adequately trained staff throughout the network
- Supervision, monitoring and quality assurance

### **Major recommendations**

- Develop state-specific performance improvement plans in order to enable wellfunctioning states to move quickly and lagging states to catch up
- Translate PPM policy into implementable activities by developing and implementing specific guidelines to engage private providers and laboratories, along with monitoring of key indicators to measure process and impact
- Fill-up presently vacant positions and build a sustainable HR strategy with adequate numbers of staff at all levels working under appropriate remuneration and in safe facilities and working conditions
- Strengthening of specimen referral

India TB Report 2018 29

- systems and fill gaps observed in specimen transportation
- Deploy electronic data systems across all levels to ensure that the system is userfriendly and allows people to do their jobs better and more efficiently



JIA team with DTO and staff at DTC Mathura during the assessment

Build capacity of NRLs and IRLs to be quality champions within the network and reenergize regular supportive supervision and EQA to lower levels with frequent monitoring and evaluation of the effectiveness and impact of supervision.



Onsite training in SL LPA at JLNMCH Bhagalpur, Bihar



Joint International Assessment Team

# Laboratory Information Management System (LIMS)

A Laboratory Information Management System (LIMS) is been developed with support from FIND. Implementing LIMS - will ensure providing accurate & timely information for the patient care, establishing a standardised process of data transmission & recording, integration of the Lab information with the National Information System, streamlining the process of entering data in ICT tools. LIMS will be implemented in Laboratories providing Culture and DST services.

#### **NABL** Accreditation

National Accreditation Board for Testing and Calibration Laboratories is an autonomous society providing Accreditation (Recognition) of Technical competence of a Medical laboratory for a specific scope following ISO 15189:2012 Standard.

IRL. Lucknow has achieved the NABL accreditation. Ten labs have successfully submitted their applications to NABL for the process of assessments over the next few months before NABL formally provides them accreditation. These labs include SMS Medical College Jaipur, IRL Guwahati, NRL JALMA Agra, NRL BMHRC Bhopal, IRL Nagpur, IRL NDTB Centre Delhi, NRL RMRC Bhubaneswar, IRL Cuttack, NRL NITRD, Delhi and NRL NIRT, Chennai.

#### **TrueNat**

TrueNat, a new indigenous diagnostic tool for use in peripheral settings has been validated by ICMR. The operational feasibility of TrueNat testing was also carried out at 100 Designated Microscopy Centers in 50 districts of the country. The results of the TrueNat validation study and feasibility study were reviewed by the Expert committee on TB diagnostics at ICMR, and have recommended the use of TrueNat MTB and TrueNat MTB Rif under RNTCP.

#### 4.2 Treatment of TB Services

Universal access to free, standard treatment services for all TB patients in the country encompasses an ambit of services in and around each patient's care cascade. Strengthening of these patient centred treatment services in RNTCP with enhanced capacity to rapidly accommodate new drugs and treatment modalities will be the cornerstone of the current NSP.

The technical and operational guidelines-2016 for TB control in India, define the major groups of TB patients who are offered standard treatment regimens. Patients are classified based on drug susceptibility results; the categories are drug-sensitive TB, and mono, poly, multi and extensively drug resistant TB. For drug-sensitive TB patients, the thrice weekly intermittent TB regimen being used since programme inception has been switched to a daily FDC regimen for treatment of all TB patients. The principles of treatment for drug-sensitive TB with a daily regimen is to administer a daily fixed dose combination of first-line anti-TB drugs in appropriate weight bands for pulmonary and extra-pulmonary TB in all age groups.

#### The major initiatives taken in 2017 are:

 Expansion of Daily Regimen for treatment of TB across the country

- ii. Scale up of Bedaquiline
- iii. Conditional Approval of Delamanid
- iv. Release of Guidelines on PMDT in India
- v. National ToT on Guidelines on PMDT
- vi. Introduction of MERM boxes

# **Expansion of Daily Regimen throughout** the country

Guidance material on awareness of Daily regimen developed by CTD was shared with the States. ACSM activities taken up in the States included TV campaign in 7 States, Radio Campaign, Digital media campaign in 17 States, Outdoor media campaign in 12 States. All patients diagnosed and put on daily regimen in Public sector since 30<sup>th</sup> October 2017 throughout the country.

## **Programmatic Management of Drug Resistant TB Services**

# Background and framework for effective control of drug-resistant tuberculosis

After successfully establishing RNTCP services across the country in 2006, the PMDT services were introduced in 2007 and complete geographic coverage was achieved by 2013. During 2011-12, there was a massive scale-up of all these facilities with concerted efforts of multiple stakeholders resulting in countrywide coverage by 2013. Later in 2014, baseline secondline DST facilities were established in a few intermediate reference laboratories, which also got scaled-up to the entire country in 2015. The progress of DR-TB treatment coverage is shown in the below graph.




Fig: 4.3. DRTB Finding and Treatment Initiation Effort, 2007-17

To begin with DR-TB services were offered to the subset of TB patients having highest risk to develop drug resistance i.e., treatment failures. This was followed by a horizontal and vertical scale-up. Definite criteria were set to assess the risk and eligibility for the drug susceptibility test (DST). The DST was thus offered to TB patients who remained smear positive during followup; to previously treated patients; those who were HIV positive and people who had contact with a known DR-TB patient. This would then lead to universal DST, i.e., DST to all diagnosed and notified TB patients. To conduct this, huge laboratory capacity in terms of geographic coverage, DST technology, trained laboratory personnel, quality assurance and certification are required. The country expanded its diagnostic capacity to a wide network of state and regional level intermediate reference laboratories with solid and liquid culture DST and Line Probe Assay (LPA) and district level network of Cartridge Based Nucleic Acid Tests (CBNAAT).

Providing treatment to diagnosed DR-TB patients is extremely important. To begin with, only MDR-TB patients were offered treatment with a standard second-line regimen. Later, treatment with standard regimen was offered to extensively drug resistant (XDR) TB patients and MDR-TB with additional resistance to fluoroquinolones or second-line injectable. Procurement and supply chain management of second-line drugs is complex, since no standardized patient-wise boxes are manufactured and drugs do need temperature regulated storage and repacking.

Since 2016, new drugs like Bedaquiline (Bdq) are made accessible to DR-TB patients through expanded access under RNTCP. In 2016, with the

release of the Revised Technical and Operational Guidelines, regimens to treat other forms of drug resistance, such as mono and poly resistance to first and second-line drugs were also included and this has been further solidified in the Guidelines on PMDT in India, 2017

# Regimen type (with or without newer drugs)

Designing a regimen is the prerogative of the DR-TB Centre Committee. The regimen could be with or without inclusion of newer drugs like BDQ and would be classified into the following types;

1.	MDR/RR-TB	At the
	a) Shorter MDR-TB Regimen	DDR-
	b) Conventional MDR-TB	TB
	Regimen	Centre
2.	H Mono/Poly Drug-Resistant TB	
3.	MDR/RR-TB	
	a) Shorter MDR-TB Regimen	
	b) Conventional MDR-TB	
	Regimen	
4.	H Mono/Poly Drug-Resistant TB	
5.	MDR/RR-TB with additional	
	resistance to any/all FQ or SLI	At the
6.	XDR-TB	NDR-
7.	Mixed pattern resistant TB	ТВ
	a) with H mono + FQ/SLI/Lzd resistance	Centre
	b) with MDR/RR-TB + FQ/SLI ± Lzd resistance	
	c) Other patients who need careful regimen designing	
	later	
	d) Non tuberculosis mycobacterium (NTM)	

### Scaling-up of Bedaquiline (BDQ) Services

BDQ has been given approval for use along with the background regimen under conditional access through the Revised National TB Control Programme (RNTCP) PMDT services in India. In absence of a phase III trials, the Apex Committee and DCGI under the Ministry of Health and Family Welfare for supervising clinical trials on new chemical entities approved the use of BDQ under RNTCP through conditional access.

Initially BDQ has been introduced at 6 sites-NITRD, New Delhi, Rajan Babu TB Hospital, New Delhi, BJ Medical College, Ahmedabad, Gujarat, GHTM Tambaram, Chennai, Tamil Nadu, Guwahati Medical College, Guwahati, Assam, GTB Sewree, Mumbai, and Maharashtra. Currently, the drug is being used in the selected six sites to establish the safety profile due to concerns on drug's cardio-toxicity which if not monitored adequately, may prove to be fatal, in addition to the other side effects of the drug. Accordingly, the programme has taken a cautious and systematic approach to first check the safety profile of the drug in a few centres.

900 patients have been initiated on BDQ containing regimen at 21 sites till the end of 2017. The programme will expand the usage of BDQ to all the states as per the preparedness. Capacity building of all the states has been initiated. Cascade trainings of all the health staff involved in BDQ services is under process.

### Conditional Approval for Delamanid

Delamanid is a recently approved drug for treatment of TB conditional use under programmatic settings only. The Phase III clinical trial results on safety and effectiveness of the drug is yet to be published. A series of high level meetings and consultations at the level of Secy. (DHR) and DG, ICMR on fast-tracking regulatory approval of Delamanid through Central Drugs Standard Control Organization (CDSCO), the national regulatory body for Indian pharmaceuticals and medical devices headed by Drug Controller General of India (DCGI) as well as its introduction through a dual mechanism i) under programmatic mode through conditional access and ii) under research mode for combination therapy with other newer drugs to further shorten the duration of MDR-TB treatment through Indian Council for Medical Research (ICMR).

In absence of Phase III clinical trial results, following conditional approval by the subject expert committee under CDSCO in June 2017, the DCGI has issued the permission to import finished formulations of Delamanid (50 mg) tablets in August 2017 for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. In this regard, the programme has prepared the guidelines for use of 400 courses

of Delamanid through donation which will be implemented in 7 states.

### **ICT Enable Adherance Systems**

## a) 99DOTS: Improving TB Medication Adherence

If patients discontinue TB treatment before finishing the 6-8 months course, or are non-adherent, not only do they jeopardize their recovery, they also risk the development of drug resistant TB. 99DOTS (www.99dots.org) is an innovation that seeks to address this issue by using basic mobile phones and augmented packaging for medication (patients call toll-free lines which are visible when they dispense pills). Once the 99DOTS platform gets this real-time adherence information it can be used in multiple ways (Web dashboard, mobile application SMSs) and allow staff to do differentiated care of patients.

## **Key Highlights**

- Universal envelopes designed (much easier supply chain compared to weight band wise envelopes); specifications approved and sent to states
- Major technology updates in web application, mobile app, SMSs for staff and patients, reports based on user feedback. Customized functionalities for all levels of users (PHI, TU, District, State, National) in both mobile app and website.
- Nikshay integration (authentication, notification)
- Integration with MERM pill box (same platform supports both 99DOTS and MERM)

#### 99DOTS Milestones

ART	<ul> <li>Launched acro (almost) all AF Centres in India f adult DS TB-HI Patients</li> </ul>	registered in
RNTCP	<ul> <li>Mumbai launched Feb 2017</li> <li>5 states which g FDCs (MH, KL, E HP, SK) launched</li> <li>RNTCP approve the implementation of 99DOTS across the country</li> </ul>	DS TB patients registered
Private sector	<ul> <li>Deployed in Mumb (PATH) and Pati (WHP)</li> </ul>	

99DOTS is a collaboration between CTD, NACO, Everwell Health Solutions Pvt. Ltd and has been supported by various donor agencies along with a lot of implementing partners (PATH, WHP etc.)



### b) Introduction of Real-Time Medication Event Reminder-Monitor Device (RT-MERM)

The RT-MERM technology (i) is highly accurate, affordable, re-usable, and suitable for TB medications, (ii) provides programmable visual and audible reminders of daily dosing and of

monthly refill, and (iii) compiles and transmits automatically detailed, and patient-specific information regarding medication taking and medication adherence.

This reminder-monitor utilizes an innovative two-part, consisting of a container (the "Container") that will hold the patient's medications and a small electronic module housed within the Container (the "Monitoring Technology") that will transmit captured information. When the Container is opened, it records the date and time of each such medication taking event, store the date/time data, and automatically transmits (via integrated, affordable 2G data transmission capability) such date/time dosing information for centralized collection, analysis, and use by health care providers via systems such as eNikshay or

99DOTS. The components of the RT-MERM are shown in Figure below:

#### **Patient-centric Care**

Successful treatment and care can only result when patient preferences, values and needs are satisfactorily addressed along with PMDT services. These include ensuring that the diagnosis of DR-TB is early, accurate and affordable; and the most effective treatment is delivered early and provided in a manner that is easily accessible to and adhered by the patient, affordable and socially acceptable. At the same time it must ensure that the confidentiality and dignity of the patient is protected. It is the responsibility of the health system to make sure that the patient is treated successfully within the society s/he belongs to, enjoying all support




Fig: 4.4. Components of the RT-MERM

which the community would otherwise provide to its members so that the new chain of infection is arrested at source and the cured member enriches his/her material, social and cultural assets. Prevention, management and mitigation of stigma and discrimination are essential elements of a patient-centred care approach to TB management.

#### 4.3 TB-HIV

### **Background**

Tuberculosis and HIV duo forms the deadly synergy- the patients with these diseases more often will have unfavourable outcomes. HIV infection increases the risk of progression of latent TB infection to active TB disease thus increasing risk of death if not timely treated for both TB and HIV. Correspondingly, TB is the most common opportunistic infection and cause of mortality among people living with HIV (PLHIV), difficult to diagnose and treat owing to challenges related to comorbidity, pill burden, co-toxicity and drug interactions. HIV prevalence among incident TB patients is estimated to be 4.00%. 87,000 HIVassociated TB patients are emerging annually. By numbers India ranks 2nd in the world and accounts for about 10% of the global burden of HIV-associated TB. The mortality in this group is very high and every year 12,000 people die every TB/HIV co-infected patients.

#### **TB-HIV Collaborative Activities:**

Revised National Tuberculosis Control Programme (RNTCP) and National AIDS Control Program (NACP) started initially in the year 2001. Since then, TB-HIV activities have evolved time to time in line with updated scientific evidences prevailed. National Framework for joint TB-HIV

collaborative activities was developed under which National and State TB/HIV coordinating mechanism were put in place. Service delivery level coordination bodies were established at district level. Components such as dedicated human resources, integration of surveillance, joint training, standard recording & reporting, joint monitoring & evaluation, operational research were strategically implemented and nationwide coverage was achieved in July 2012. At the National TB-HIV Coordination Committee (NTCC) and National Technical Working Group (NTWG) regularly monitor and suggest on key policy related to TB/HIV Collaborative activities.

### **Progress**

Interventions to reduce the burden of TB among people living with HIV include the early provision of antiretroviral therapy (ART) for people living with HIV in line with WHO guidelines and the Three I's for HIV/TB: intensified TB case-finding followed by high-quality anti-tuberculosis treatment, isoniazid preventive therapy (IPT) and infection control in HIV care setting. There has been significant improvement on above indicators in recent years. India adopted all recommendations suggested by the World Health Organization recommended TB/HIV collaborative activities.

HIV testing of TB patients is now routine through provider initiated testing and counselling (PITC), implemented in all states. At Country level, as of 4<sup>th</sup> Quarter (Oct-Dec) 2017, 75% of TB patients knew their HIV status which has increased from 11% in 2008. In 2017, 1097755 TB patients (75% of total TB patients notified) were tested for HIV, 3% among whom were diagnosed as HIV positive and were offered access to HIV care.




Fig. 4.5. Trends in Number (%) of registered TB patients with known HIV status, 2008- 2017, National

The updated WHO TB/HIV policy of 2012 recommended implementation of PITC among presumptive TB cases. Considering the country evidence and global recommendation, the National Technical Working Group on TB/HIV decided to implement PITC among presumptive TB cases in all high HIV prevalent settings in India (A and B category districts) in a phased manner. Routine screening of Presumptive TB cases for HIV is being implemented in phase wise manner throughout the country.

Similarly among HIV-infected TB patients diagnosed in 2016 (100%) were put on (co-

trimoxazole preventive therapy (CPT). The coverage of ART among TB patients who were known to be HIV-positive reached 87% in patients registered in Oct-Dec 2016, up from 49% in 2008.

Intensified TB case finding has been implemented nationwide at all HIV Care centres (at Integrated Counselling and Testing Centres (ICTCs) and ART centres. As of December 2017, 536 ART centres and 1120 link ART centres are operating in the country. Table below shows the trend of intensive case finding at ICTC and ART centres in India.

Table: 4.3. Trend of Intensive case finding at ICTC India

Year	Total clients	Presumptive TB cases referred	Total TB cases Detected	Total Put on DOTS	Proportion referred	Proportion detected TB	Proportion Put on DOTS
2011	9774581	580695	55572	42223	6%	10%	76%
2012	9193113	552350	46863	36842	6%	8%	79%
2013	7264722	620539	64506	45471	9%	10%	71%
2014	8383140	726805	45597	30922	9%	6%	68%
2015	11799964	941285	63134	41725	8%	7%	66%
2016	13773132	1088814	70836	45432	8%	7%	64%
2017	15415049	1152122	69914	44734	7%	6%	64%

In proportion ART and ICTC centres contributes to around 6.3% of case finding of the RNTCP (Table below).

Table: 4.4. Contribution of ICTC and ART centres in TB case detection

Year	Total TB cases Detected (ICF ICTC+ ART)	Total cases Put on DOTS	Total TB cases notified under RNTCP	Percentage Contribution of ICF in TB notification
2010	67323	53503	1521438	3.5%
2011	84007	65996	1515872	4.4%
2012	74875	61252	1467585	4.2%
2013	89420	68595	1410880	4.8%
2014	73298	81742	1443942	5.7%
2015	100044	69239	1423181	4.9%
2016	108696	77158	1424771	5.4%
2017	112205	90947	1444175	6.3%

Table: 4.5. Year-wise treatment outcome of TB HIV co-infected patients 2010-2016

Year	All TB-HIV Total Case Registered	Treatment Success	Died	Failure	Lost to follow up	Transferred out	Treatment regimen changed
2010	43093	77%	13%	1%	6%	2%	0%
2011	47097	78%	11%	5%	4%	1%	0%
2012	34134	77%	13%	1%	7%	1%	0%
2013	45911	77%	13%	1%	7%	1%	0%
2014	44257	76%	13%	1%	6%	2%	1%
2015	38894	77%	14%	1%	6%	2%	1%
2016	39702	77%	14%	1%	6%	1%	1%

Intensified case finding activities in ICTC and ART centre is placed at Annexure-3 A &~B



Hon'ble Prime Minister Shri Narendra Modi with Dr. Lucica Ditiu, Executive Director, Stop TB Partnership





TB के मरीजों की सही पहचान हो, Active Cases के बारे में समय पर पता चले, जो दवाइयां दी जा रही हैं, वो प्रभावी हैं भी या नहीं, drug-resistant TB तो नहीं है, इन विषयों को ध्यान में रखते हुए सरकार द्वारा व्यापक स्तर पर कार्य किया जा रहा है: PM 11:42 AM - Mar 13, 2018

♥ 1,670 ♦ 486 people are talking about this

A

www.tbcindia.gov.in www.nikshay.gov.in www.nikshayaushadhi.in n recent years, understanding of the role of private providers has increased considerably as a result of patient pathway surveys, standardized patient studies, and analyses of private drug sales. Recent publication from the programme estimating TB patients in private sector based on drug sales in the market gave more insight into the magnitude of the problem in private sector.

Effective engagement of all health care providers (private practitioners, chemists, laboratories, NGOs) at a scale is crucial to achieve Universal Access to TB Care. As majority times, these providers are first contact for care of patients. Since the inception of RNTCP, multiple prior interventions through various strategies have been deployed to engage NGOs and Private Providers for TB control efforts.

National Health Policy 2017 has recognized that social security framework in the health sector cannot be realized without strategically engaging the private sector and recommended the Government to take stewardship role. Effective engagement of the private sector on a scale commensurate with their dominant presence in Indian healthcare is crucial to achieve Universal Access to TB Care.

RNTCP has 22 partnership options to engage with NGOs and Private Practitioners for supporting ACSM, Diagnostic, Treatment and Programme Management activities of RNTCP. The NGOs and private practitioners are engaged through available Partnership options. Through these efforts, ~1900 collaborations with NGOs were made. In general States opt for Designated Microscopy Centre scheme followed by ACSM scheme, specimen collection and transport, C&

DST laboratories, TB units. More than 80 urban slum collaborations were established.

# Engagement of NGO's/Private Practitioners through partnership options

#### 1. The Union

### a) Project Axshya achievements in 2017

Project Axshya, a unique civil society initiative, has continued its path-breaking work towards improving access to quality TB care and support. The project is working in tandem with the flagship Revised National TB Control Programme (RNTCP). It has played a key role in our goal towards universal health coverage making quality TB diagnostics and treatment available to all.

Working in partnership with 7 sub-recipient partners, over 1000 local NGOs and nearly 15,000 community volunteers The Union through Project Axshya's various innovative interventions has made the following achievements in 2017 (till Sep 2017).

- Reached out to over 17 million people from various vulnerable and marginalised communities.
- Facilitated identification and testing of nearly 220,000 presumptive TB cases. This includes collection and transportation of sputum samples of nearly 190,000 presumptive TB cases.
- Facilitated diagnosis and treatment initiation of nearly 20,000 patients.
- Sensitised and engaged 5000 qualified private practitioners, private hospitals and private laboratories and facilitated notification of over 43,000 patients from the private sector.

- Overall nearly 63,000 TB patients were notified from active case finding and through private sector to RNTCP.
- Sensitised nearly 26,000 TB patients including 9,600 women on their rights and responsibilities through patient charter.

## Role of Community Volunteers in improve TB services among tribal populations in India - An experience from Axshya Project

The Union's Project Axshya is addressing the need for better access to quality TB services in India's remote tribal areas. Community volunteers or Axshya Mitras form the backbone of this initiative. Tribals form a high risk group for the national TB control programme.

Vulnerabilities range from poor access to mainstream health systems, combined with poverty, under-nutrition, tobacco and alcohol abuse. This makes management of TB and other communicable diseases a challenge.

In the eastern state of Jharkhand, tribals constitute 28% of the state's population. In Sahibganj district, Axshya Mitras raise community awareness on TB through public meetings with the village health and sanitation committees. They go house to house to help identify people with TB symptoms and encourage them to seek diagnosis and treatment. Axshya Mitras are trusted by the community and are accountable to the health system for promoting better access to TB services.

### **Key Achievements (Till Sep 2017)**

Global Fund Indicators	Target	Achievement	% of achievement
Total number of TB cases notified	59250	62764	106%
Number of TB cases (all forms) notified among key affected populations/high risk groups	45000	48832	109%
Number of TB cases notified through Non-NTP providers - private/non-governmental facilities	38300	43521	113%
Number of Axshya Villages established	6000	8118	135%
Number of prison inmates sensitized about TB and screened for TB symptoms.	37500	37506	100%
Number and percentage of women TB patients of all the TB patients sensitised on their rights and responsibilities	7250 (25%)	9641 (36%)	146%
Number of Axshya kiosks providing flexi-DOT and other services	75	67	89%
Percentage of cases with drug resistant TB (RR-TB and/or MDR-TB) started on treatment for MDR-TB who were lost to follow up at six months	380/3000 (12 %)	167/4202 (4%)	300%



Community Volunteer conducting Active Case Finding in Sahibganj

The district of Sahibganj borders two other states and is within a conflict-ridden area. It has many hard to reach settlements with hilly terrains. High rates of malnutrition and poor living conditions further contribute to people's vulnerability to TB. A majority of the population here are Santhal tribals. Agriculture, stone crushing and daily wage labour is their main source of livelihood.

Axshya Mitra Raphael Hansdak has been working in Pathna block of the district since 2011. He promotes TB awareness through community meetings and does active case finding by going house to house. He encourages those having TB symptoms to get sputum tested. Where people are unable to go, he does sputum collection and transportation to the nearest DMC (Designated Microscopy Centre). Of the 245 sputum collection he has done, nearly 10% patients (22) tested positive. Among these 22 patients, 18 were men and the rest women; 16 have been cured of TB completely and 3 are currently receiving treatment.

Hansdak's relentless work has helped save lives. It has gained him respect of the community and the district TB officer and other health government staff alike. He is responsive to the community's needs: Sometimes this means accompanying patients to initiate the treatment, or ensure follow up until they complete treatment. His empathetic nature has motivated TB patients to improve their health seeking behaviour. For instance, a TB patient who had an alcohol problem is now fully recovered from TB and has adopted a healthier lifestyle.

The 15,000 Axshya Mitras under the project are playing a crucial role in addressing needs of vulnerable communities such as India's tribal population. From January-December 2016 they conducted over 18,000 community meetings, visited 4 million houses, leading to 200,000 symptomatics examined (including sputum collection and transportation of 166,000). This resulted in diagnosis of 18,000 TB patients who were put on treatment.

Project Axshya is a civil society initiative in India implemented by The Union and seven civil society partners with support from the Global Fund to Fight AIDS, Tuberculosis and Malaria. Project Axshya uses creative solutions to expand access to TB information and services, increase the accountability of service providers and empower communities in 285 districts and 40 urban sites across 19 states in India.



Raising awareness through street play

### Challenge TB- India

#### b) The Union, PATH and FIND

Under the stewardship of Ministry of Health and Family Welfare, Challenge TB(CTB) has increased political will and leadership to tackle TB in India through a high-powered Call to Action for a TB Free India initiative, implemented by International Union of Tuberculosis and Lung Disease (The Union).

Challenge TB has made impact through innovative campaigning, and has developed partnerships and sustained engagement with the key stakeholders including members of parliament, representatives of the private health sector, corporations, civil society organizations, media experts, research and academia, and the affected community, for concentrated efforts and collective impact for eliminating TB from India Understanding the need for collective

action through multi-sector engagement for TB elimination, Call to Action for TB-free India has conducted the following key activities:

- Developed a 360-degree mass media campaign featuring Mr. Amitabh Bachchan, a highly revered Actor in Indian Cinema and TB survivor himself
- Launched India TB Caucus a network of elected representatives committed to end TB.
   The caucus is a part of the Global TB Caucus;
- Partnered with the Global Fund, World Health Organisation and Himachal Pradesh Cricket Association to organize a national summit to build political will and mobilize support from key stakeholders to end TB in India;
- Initiated a partnership with International Labor Organization in India and (ILO) in 2017. Draft workplace policy for TB and



TB-Free India Summit, April 2017

From left to right: Gurpreet Singh Ghuggi, Former Convenor of AAP; Mr. Christoph Benn, Director of External Relations, The Global Fund; Mr. Mark A White, Mission Director, USAID India; Shri. Anurag Thakur, Member of Parliament, Bhartiya Janta Party; Shri.Jagat Prakash Nadda, Union Minister of Health & Family Welfare; Mr. Jose' Luis Castro, Executive Director, The Union; Mr. Anil Kumar Sharma, Minister for Rural Development, Panchayati Raj and Animal Husbandry, Govt. of Himachal Pradesh; Mr Aftab Shivdasani, Actor. Photo Credit: The Union-USEA

HIV has been developed in accordance with National Strategic Plan 2017, to ensure coherence and collective impact.

 Provided technical assistance to the corporate sector and civil society organizations.

Challenge TB is now concentrating its efforts towards Multi-drug resistant TB (MDR-TB) in India. The project intervenes primarily to provide access to rapid diagnosis, capacity building, linkages with the private sector and improving management of DR-TB in the public and the private health sector. It supports the introduction of new drugs (Bedaquiline) and strengthening Programmatic Management of Drug-resistant TB (PMDT) services in the country. All Challenge TB partners including The Union, PATH and FIND, are focused on improving patient-centered treatment and care services. The project supports BDQCAP sites through technical assistance, human resource, equipment including ECG machines and filling up other critical gaps

FIND with KNCV, under Challenge TB, primarily focuses on expansion of the access to rapid diagnostics through the use of GeneXpert machines (set up in public sector labs) and outreach to key pediatric centers in five major metropolitan areas.

Under CTB-India, **PATH** enables early diagnosis, access to quality diagnostic and treatment modalities as well as adherence to treatment for DR-TB patients in the private sector. PATH plays a crucial in role mapping of the private sector followed by accessing CBNAAT testing in public sector, providing PTE, linking treatment to the public sector, tracking adherence, linking to social schemes linkages as well as community mobilization.

Particular	Performance ( till Sep 2017)
TB Stories covered in media	428
ACSM materials developed	113
India TB Caucus	Formed
Private sector partnerships to implement TB program	17
DR TB patients on BDQ containing regimen supported for follow up and ADR management and reporting	698
DR TB patients diagnosed among private sector notified patients	440
DR TB patients among privately notified TB patients linked to public sector treatment	300
DR TB patients among privately notified TB patients linked to social support/welfare schemes	40
HIV-TB services provided to privately notified TB patients	4946
Private providers sensitized for Pediatric TB	4393
Presumptive pediatric TB cases tested	90270
Pediatric TB patients diagnosed	1880

## 2. Foundation for Innovative New Diagnostics (FIND)

Accelerating access to quality TB care for presumptive paediatric TB cases through improved diagnostic strategies

FIND, in consultation with the RNTCP and with funding support from USAID, began implementing a novel paediatric initiative in April 2014 to improve the diagnosis of TB in children using GeneXpert in four cities namely, Delhi, Kolkata, Chennai, and Hyderabad. In 2016, the project was extended to an additional five cities, namely, Visakhapatnam, Surat, Nagpur, Guwahati and Bangalore. The current project provides a comprehensive diagnostic solution for paediatric TB in the intervention cities. This solution is optimised by additional high-throughput Xpert labs located within the public sector reference labs. Detailed mapping of potential referral institutions (both public and private) was carried out, followed by one to one meetings and Continuing Medical Education (CMEs) for these facilities/providers. Upfront Xpert-based diagnosis was offered to all children with symptoms of pulmonary and extra-pulmonary TB from linked facilities, free of cost, through a hub-and-spoke model. Rapid specimen transport and a reporting mechanism using e-mails and SMSs were established.

The activities at the initial 4 sites had gained significant momentum during the project tenure, with an increasing number of providers getting engaged in each successive quarter. These sites were transitioned, in a phased manner, to the

National TB Program (RNTCP) by the end of March 2017. In addition, in consultation with CTD, the project was extended to cover one additional city, Indore, in August 2017.

### Key achievements are listed below:

- A total of 29,369 presumptive pediatric TB and DR TB patients have been tested over the last one year in the intervention cities. Of the total tested, 1,866 (6.4%) children were diagnosed as Xpert-TB positive under the project. Further, out of these diagnosed TB cases, 175 (9.4%) children were diagnosed with rifampicin resistance. Positivity on microscopy, for these children, was only 1.6% which highlights a fourfold increased detection rate on Xpert over microscopy.
- A total of 4,393 providers were reached through one-to-one meetings and CMEs of which 1245 were engaged under the project. Of these, 745 were from the private sector and the rest from Public sector.
- In spite of the increased workload, the key project performance parameters were maintained. Valid results were provided to 99.7% of the cases by ensuring retesting of initial test failures.
- For 95.4% of the cases enrolled, specimens were tested and results reported to providers within 24 hours of receipt at lab.
- Of the total TB cases diagnosed under the project, information on initiation of treatment is available for 85.3% patients so far.



#### 3. World Health Partners

## A. Public Private Interface Agency (PPIA), Patna, Bihar

World Health **Partners** (WHP) the implementer of Public Private Interface Agency (PPIA), a project supported by BMGF, covering a population of 6.4 million in the district of Patna, Bihar. The objectives of PPIA are to facilitate early diagnosis and treatment with free diagnostics and anti-TB drugs, increase private sector TB case notifications, and ensure treatment adherence and treatment completion. Notifications are facilitated via a mobile call to a Call Centre and free services provided through an electronic voucher system.



The PPIA program in 2017 engaged a cumulative of 601 formal providers and notified over 19,467

private sector cases, contributing to over 85% of total TB case notifications in the district. The program achieved 61% patient coverage of the private sector, as determined by anti-TB drug sale data collected by a third party agency. The program has integrated with the State with the provision of GoI FDCs to 3,794 privately treated patients through a FDC supply chain model and with substantial increases in the utilization of GoI supported CBNAAT services by private providers. In August 2017, PPIA piloted new adherence technologies of 99DOTS and MERM in order to improve patient adherence management and treatment outcomes and achieve a cost-effective, differentiated care model.

Table: 5.1. Key achievement of the Patna Project

District (s) Covered	Patna
Total Population Covered	6.4 millions
Number of Private Formal MBBS/+ Provider Engaged	601
Number of TB Case Notifications	19,467
Number of Notified Cases Initiated on Free Drugs	18,550
Number of Notified Cases Initiated on GoI FDCs	3,794
Proportion of Pulmonary Cases Microbiologically Confirmed	34%
Proportion of Pulmonary Cases Receiving a DST (CBNAAT)	56%
Number of DR-TB Cases Notified	383

# B. Tuberculosis Health Action Learning Initiative (THALI), West Bengal

WHP is the implementer of Tuberculosis Health Action Learning Initiative (THALI) project, in partnership with Child in Need Institute, John Snow, Inc., and Global Health Strategies. The project is supported by USAID in five districts of West Bengal. The objectives of THALI are to strengthen urban TB control through community outreach and mobilization; private sector engagement; research, evaluation, and knowledge dissemination; and strategic advocacy and media relations in order to create a pathway for the government to integrate successful models.

THALI has engaged 1,072 Formal MBBS+ providers across six districts and notified 7,922 private sector TB cases, facilitated by mobile calls through a Call Centre. Community outreach and sensitization activities have resulted in 1,284 presumptive TB cases registered, out of which 53TB cases were notified and initiated on treatment. The project also partnered with 8 NGOs to implement a "TOUCH" Agent model, in which key community members serve as change agents to build awareness and generate demand for THALI services, facilitate referrals for diagnostic and treatment services, and manage adherence of high-risk patients. THALI has also established a key partnership with the Kolkata Municipal Corporation's (KMC) Health department by signing a Memorandum of Understanding (MoU) with the civic body to officially become KMC's strategic partner in creating a TB-Free Kolkata Mission.

#### 4. REACH: TB Call to Action

In 2017, REACH continued to implement the TB Call to Action project, supported by USAID, in four key states – Bihar, Jharkhand, Assam and Odisha. Through this project, REACH is working to amplify and support India's response to TB by involving previously unengaged stakeholders

and broadening the conversation around the disease. The project's objectives are to strengthen and support the community response to TB and to advocate for increased financial, intellectual and other resources for TB.

### The key highlights of the Project include:

- The introduction of the REACH pharmacy model in all priority states to increase the engagement of private pharmacists and chemists and strengthen referrals and linkages with the RNTCP
- The formation of a Task Force for Mainstreaming of TB by the Govt. of Jharkhand, which is an outcome of the intersectoral coordination meeting organized by REACH.
- The design and rollout of the Employer Led Model for TB Prevention and Care, based on NACO's ELM initiative, to engage industries for improved access to TB services for employees. REACH is currently implementing the ELM in two districts of Assam.
- The sustained engagement of TB survivors through a series of capacity-building workshops designed to improve their knowledge of TB as well as their advocacy skills. The first workshop brought together 32 survivors from six South-East Asian countries and was held in New Delhi in April 2017.
- by TB with over 100 survivors and affected communities as members. In Bihar, the participants formed their own network -

'Ummeed – TB Muktiki Ore ek Pahal' (Hope: a step towards being TB-free).

The Involvement of celebrities as state TB Ambassadors in priority states including Ms Deepika Kumari, Indian Archer as State Ambassador for Jharkhand; Actor Mr Kuna Tripathy, Sand artist Padma Shri Sudarshan Patnaik and musician Padma Shri Prafulla Kara as State Ambassadors for Odisha; and Actor Mr Rajesh Kumar as State Ambassador for Bihar.

## 5. The Clinton Health Access Initiative (CHAI)

Aiding RNTCP's mission to provide timely and quality DR TB diagnosis and treatment to people across the country, Clinton Health Access Initiative (CHAI) supports the program in strategic, operational and analytical aspects at central and state levels, as needed. In the last year, CHAI supported CTD in development of National Strategic Plan, provided data-driven insights in areas such as PMDT scale up, guidelines revision, and sample collection to result delivery processes.

Additionally, CHAI is part of the Technical Support Group (TSG) in Mumbai and has played a critical role in strengthening the private sector activities on behalf of the City TB Office, Municipal Corporation of Greater Mumbai (MCGM). CHAI has been instrumental in strengthening the PPM activities as well as designing the integration of the PATH-PPSA model into the government system. In Chennai, the Greater Chennai Corporation (GCC) under the umbrella TB Free Chennai Initiative leads a broad consortium composed of the National

Institute of Research for Tuberculosis (NIRT), REACH (a Chennai based NGO) and CHAI. In its capacity as the TSG, CHAI is supporting the Greater Chennai Corporation (GCC) in:

- Roll out of the new diagnostic algorithm and universal access to DST- 15 GeneXpert machines have been installed and operational in public health facilities
- Targeted case finding among vulnerable populations through the introduction of Mobile Diagnostic Units (MDUs)
- Strengthening the public- private support agency

In addition to the above, CHAI is also supporting the GCC in directly implementing a private sector lab engagement programme.

## 6. World Vision India - Project Axshya Update 2017

World Vision India implements project Axshya by a consortium of civil society organizations brought together with an aim of providing significant contribution to eliminate TB from India. Project Axshya (meaning TB free) was launched with the assistance of Global Fund



India TB Report 2018 51

Round 9 Grant since April 2010 in 74 districts of 8 states (Andhra Pradesh, Bihar, Chhattisgarh, Jharkhand, Madhya Pradesh, Odisha, Telangana and West Bengal) of India as a 'specialized' TB care and control initiative of the NGO TB-Consortium (NTC).

Project Axshya completed the first phase in March 2013. The second phase concluded in September 2015 and eventually entered into the New Funding Model (NFM) phase with effect from October 2015 which continued till 31 December 17. It is significant that in the first two phases of Axshya project from April 2010 to September 2015, about 240,974 presumptive TB cases were referred by the project; 193,785 persons were tested in Designated Microscopy centres (DMC). A total of 20,728 patients were diagnosed with TB and 19,175 were started on DOTS treatment within seven days of diagnosis.

The NFM or the final phase of Axshya was implemented in 70 districts (65 old districts of the project and 5 new districts) of the same 8 states with World Vision India as the Primary Recipient (PR) and the same six NGO partners as the Sub Recipients SRs.

#### **Key Achievements:**

- Community referral: Around 4906 TB patients were detected through the referrals of the unqualified private providers whom the project had sensitized.
- Private sector notification: The project had sensitized around 5000 private doctors and facilities in 100 cities located in 70 projectdistricts on TB notification and assisted them

to notify the TB cases. Around 27,476 private TB patients were notified in NIKSHAY System of RNTCP. Of which 4000 TB patients have been notified through the Adherence Care Treatment and Support (ACTS) software developed by WVI team in collaboration with Kavin Corporation

- INH-prophylaxis: The project initiated INHprophylaxis to around 2832 children-contacts of affected TB patients in project districts
- **HIV testing:** The project assisted around 14496 TB patients to utilise the HIV testing services at the ICTC (Integrated Counselling & Testing Centre).
- Counselling of MDR TB patients: The project brought around 1423 MDR-TB patients under home-based counselling and food supplementation services.

## 7. Tata Institute of Social Sciences – Project Saksham Pravaah

Saksham Pravaah, a Tata Institute of Social Sciences project, supported by the Global Fund in partnership with the Central TB Division (CTD), Ministry of Health and Family Welfare, has been providing psychosocial counselling to DR-TB patient and caregivers through Saksham DR-TB counsellors, based on the social structural approach to disease prevention and control in Mumbai, Maharashtra, Gujarat, Karnataka and Rajasthan

#### Role of Saksham DR TB Counsellors

 Register Drug Resistant (DR) TB patients (New & Existing) for counselling services and provide regular counselling to ensure treatment adherence.

- Undertake regular home visits to DR-TB patients within the district for providing follow up counselling.
- Provide counselling services to family members of the DR-TB patients and refer them for TB diagnosis if required.
- Liaise with District TB staff to monitor treatment adherence of TB patient at community level
- Link DR-TB patients to social protection schemes and other health services as required.
- Motivate DR-TB Patients for "Follow-up Sputum Test".
- Refer DR-TB Patients to appropriate Health Services for ADR management.
- Provide counselling for de-addiction or refer to de-addiction services.

In 2017, Saksham DR-TB counsellors have registered 96% of DR-TB patients who were initiated on treatment by RNTCP for counselling services. Understanding the importance of involving caregivers as partners in treatment completion, 89% patient caregivers were also provided counselling. 71% of the patients were given first follow up home visit within the same quarter. The counsellor reinforces the adherence messages and address barriers to adherence during every follow up counselling. Around 80% of priority based follow up visits were done at home, rest were in health posts and other areas like religious places, market etc.

Counsellors identify and provide support to patients who interrupt their treatment. Of the total treatment interruption instances, 81% patients were counseled and were retrieved back on regular treatment. Adverse events due to DR-TB treatment being one of the most important reasons for treatment interruption and the project is focusing on ADR referrals so as to ensure prompt management of ADR's.

As on 31st December 2017, 89% of the Saksham registered DR-TB patients are continuing on treatment. The project intervention adopts a psycho-social approach in addition addressing the social factors through linking patients to various social protection schemes. The Project also provided social protection linkages like helping DR-TB patients acquire Aadhaar card, ration card, bank account etc. Hearing aids were provided to 11 patients who suffered hearing loss due to adverse reaction of DR-TB drugs. Furthermore, project have also provided nutrition linkages to patients in order to help them adhere to the treatment.

Saksham Pravaah has also launched an app named 'Saksham Against TB' (SAT) for registration and follow up of DR-TB patients and their caregivers, recording of loss to follow ups and treatment retrievals, social protection linkages etc. Proposal to sync SAT-App with Nikshay is also being considered in the current phase.

Table: 5.2. No. of DR-TB patients registered for counselling services

State/City*	Registered				
	DR-TB cases under RNTCP	Saksham Reg. for follow-up	MDR	XDR	%
Mumbai	4145	3926	3574	352	94.7%
Maharashtra	2903	2746	2520	226	94.5%
Gujarat	2358	2356	2050	306	99.9%
Rajasthan	2136	2071	1969	102	96.9%
Karnataka	1028	1007	988	19	97.95
Total	12570	12106	11101	1005	96.3%

<sup>\*</sup>only selected sites

Table: 5.3. No. of patients and Caregivers registered for counselling under Saksham Project

State/City	Saksham patients	Caregivers	%
Mumbai	3926	3237	82.4%
Maharashtra	2746	2510	91.4%
Gujarat	2356	2010	85.3%
Rajasthan	2071	1836	88.6%
Karnataka	1007	945	93.8%
Total	8180	7301	89.2%





Saksham DR-TB counsellor – counselling a patient and caregiver

Table: 5.4. Successful linkages for social protection under Saksham

State/City	No.	Туре				
Mumbai	105	93-nutrition, 1- education, 10-social security/bank/Aadhaar card, 1-livelihodd/income generation				
Maharashtra	436	Nutrition Support for 410 patients and Benefits of other govt. schemes for 26 patients				
Gujarat	878	[Health=78; Insurance=3; Livelihood=3; Nutrition= 68; Social Protection Scheme: 13; Others; 47 which include help for bank a/c, Aadhaar card, govt. certificates, etc.]				
Rajasthan	409	Insurance=62; Nutrition= 200; Livelihood =11, Cough Hygiene = 148, Silicosis = 6, Others; 20 which include help for bank a/c, Aadhaar card, govt. certificates, etc.]				
Karnataka	668	364 - Social protection schemes , 258- Nutrition support and 46- helped for open the bank account				
Total	2496					

## 8. Tibetan Voluntary Health Association (TVHA)

Under the Global Fund grant, through a two stage screening, TVHA conducted intensified screening of active TB cases among the Tibetans living the 15 Tibetan settlements in India spread all over India i.e. Karnataka state in South India, Chhattisgarh and Odisha in Central India, Arunachal Pradesh in North East India and Doon Valley (Uttarakhand) & Sirmour region (Himachal Pradesh) of North India. These include people living in congregated settings like schools and monasteries. Also household level visits were carried at each of the 15 settlements.

First stage symptom screening was conducted though a questionnaire by the school nurses or the TVHA outreach staffs at schools and at the household level symptom screening was carried out by the TVHA outreach workers. Then a TVHA doctor/health facility did the second level examination and investigation. In North India a team from Primary Care hospital based at Dekyling near Dehra Dun travelled to some of the remote schools (from the PHC) in a mobile bus which has sputum smear microscopy and x-ray facility.



TVHA staff conducting Household Line listing

India TB Report 2018 55

#### 9. Karnataka Health Promotion Trust

### **Tuberculosis Health Action Learning Initiative**

The **USAID-funded** THALI project implemented by Karnataka Health Promotion Trust(KHPT) in Karnataka and Telangana. THALI partners include TB Alert India, its implementing partner for Hyderabad and Telangana, and St. John's medical College, Bengaluru, its technical partner. KHPT implements the project directly in Bengaluru and Karnataka. The initiative is a patient and family-centered TB prevention and care program supporting vulnerable people gain access to quality care services from health care providers of the patient's choice. It works in alignment with the national strategic plan for TB control and in collaboration with RNTCP. THALI efforts focused on the two cities of Bengaluru and Hyderabad in 2017 and intends to expand to additional geographies in 2018 and 2019.

#### Highlights of 2017

A 'TB to Health' campaign was conducted in Bengaluru and Hyderabad from World TB Day (March 24) to World Health Day (April 7).



An awareness program organized by THALI during the 'TB to Health' campaign in Bengaluru



Visit of the Mark A. Green, Administrator, USAID, to STDC, Hyderabad

Intensified awareness activities were carried out in both cities through mid-media and outreach activities. TB kiosks were also set up at medical colleges and private tertiary care hospitals to reach out to health care providers and patients. The Government of Telangana announced its commitment to end TB at the World TB Day event where Ms. Katherine B. Hadda, US Consul General, Hyderabad, released an End TB Brochure, along with other state dignitaries.

The Hon. Mark A. Green, Administrator, USAID, visited the Telangana State Training and Demonstration Center (STDC) on November 30 2017. The event was organized by THALI in collaboration with the Telangana state government and RNTCP, and REACH. Mr. Green witnessed the state-of-the-art TB diagnostic facility at the STDC, met with TB survivors, and interacted with representatives of state and national health administrators and RNTCP program managers, corporate and private health sectors, media and the public. Acknowledging the Indo-US partnership on TB, Mr. Green spoke on USAID's commitment to support India's efforts to eliminate TB by 2025.

## 10. Indian Council for Medical Research (ICMR)

Targeted Intervention to Expand and Strengthen TB Control among the Tribal Population under RNTCP, India (TIE-TB Project)

A large and deprived tribal population in India estimated at an approximately 104 million (8.6% of the total population) with a huge burden of TB requires services which are, truly & certainly, accessible and available. The extreme remoteness, intense deprivation from even a day's square meal and the harsh and isolated living environments primarily contribute to high vulnerability of and poor access to healthcare by these populations. As such, provision of TB services to the tribal population is not simply an issue of reducing the burden of TB in numbers but is a 'Standard of Care' issue.



The Indian Council of Medical Research (ICMR) under the Department of Health Research/Ministry of Health & Family Welfare/Government of India, in collaboration with Central Tuberculosis Division (CTD)/Department of Health & Family Welfare/MOHFW/GOI has undertaken the TIE-TB project in certain defined hard to reach, tribal areas spread over

the central and western parts of India to improve the convenience of TB services for the tribal population. This project has been funded by the Global Fund for AIDS, TB & Malaria.

The most significant aspect of the project is the deployment of the Mobile TB Diagnostic Van (MTDV) equipped with X-ray facilities and Sputum Microscopy facilities which are offering diagnostic services for Tuberculosis at the doorstep of the patient's home in difficult to reach areas of the tribal populations. This project has been initially undertaken in 5 States and 17 districts. 35 MTDVs, have been fabricated and equipped with sputum microscopy services and X-ray facilities and have been positioned in the 5 states of Madhya Pradesh, Gujarat, Chhattisgarh, Rajasthan and Iharkhand in difficult to reach areas of the tribal belts. The vans have initiated services and accordingly to a defined route plan, they are visiting the difficult to reach tribal areas and providing sputum services and also Chest X-ray services to presumptive TB patients.

The project is being implemented in 5 States and 17 districts covering a total population of approximately 17.65 million. This intervention is expected to improve the 'Standard of Care' among these extremely deprived populations. The efforts are expected to improve early seeking of care, reduction in out of pocket expenditure of individual patients and curbing of the individual patients from being directed to multiple providers for treatment which results in huge economic burden to the patient and his family. The MTDVs have been operationalized at variable points of time and regular reporting of data is being initiated at the time of writing this report.

India TB Report 2018 57



Hon'ble Prime Minister Shri Narendra Modi with Mr. Peter Sands, Executive Director, The Global Fund





TB को भारत से मिटाने के लिए राज्य सरकारों की भी बड़ी भूमिका है। Co-operative Federalism की भावना को मजबूत करते हुए, इस मिशन में राज्य सरकारों को अपने साथ लेकर चलने के लिए मैंने खुद देश के सभी मुख्यमंत्रियों को चिट्ठी लिखकर इस अभियान से जुड़ने का आग्रह किया है: PM

11:45 AM - Mar 13, 2018

 $\bigcirc$  1,450  $\bigcirc$  433 people are talking about this

•

www.tbcindia.gov.in www.nikshay.gov.in www.nikshayaushadhi.in NTCP is being implemented in line with the National Strategic plan. Under 12<sup>th</sup> Five Year Plan, NSP 2012-17 for TB control approved for a period of five years has come to an end in 2017. The new NSP 2017-25 for TB elimination is approved for the coming five years. RNTCP is centrally sponsored scheme under NHM to implement the programme activities as envisaged under NSP 2017-25 as per RNTCP guidelines.

The procedures for the financial management are being followed as per the manuals and guidelines available on the program website (Financial Manual for RNTCP). The financial management arrangements to account for and report on program funds, includes both Domestic Budgetary Support (DBS) and External Aided Component (EAC). The arrangements are as follows:

- a. Institutional arrangements: Central TB Division (CTD), being a part of the National Health Mission (NHM) holds the overall responsibility of the financial management of the program. Similarly, at the state and district level, the State TB Cell and the District TB Centre are responsible respectively.
- **b. Budget:** Program expenditures are budgeted under the Demand for Grants of the MoHFW

Flexible Pool for Communicable Diseases funding arrangement. These are reflected in two separate budget lines- General Component (GC) and Externally Aided Component (EAC).

- c. Funds flow and Releases: The fund flow remains within the existing financial management system of the MoHFW, which operates through the centralized Pay and Accounts office. Release of funds to states is done in instalments through State Treasury.
- d. Sanctions & Approvals: All procurements of commodities are processed by the Empowered Procurement Wing (EPW) and approved by the Secretary and Union Minister in line with the delegation of the financial powers. All funds releases for commodity advances for approved contracts are routed through the Integrated Finance Division (IFD) and processed by the Drawing and Disbursing Offices (DDO) and Pay and Accounts Office (PAO). All the program expenditures follow the standard government systems of the PAO and are subject to control as per the General Financial Rules (GFR) of the Government of India. Payments are made through electronic funds transfer through treasury since the financial year 2014-2015.

Table: 6.1. Financial Performance of RNTCP in 12th Five Year Plan:

Description	2012-2013	2013-2014	2014-2015	2015-2016	2016-2017	2017-18	Total
Budget requested	700	800	1358	1300	1000.00	2200.00	7358.00
Budgetary estimates/approval	710	710	710.15	640	640.00	1840.00	5250.15
Total Releases to states	224.72	323.52	373.87	483.19	533.17	425.94*	2364.41
Expenditure (Plan)	566.39	527	639.94	639.86	677.78	1324.24*	4375.21

<sup>\*</sup>Till 7th February 2018 #Figures In crores

- e. Accounting: The accounting records for all payments are made against approved budget. Budget lines are maintained by the Principal Accounts Officer and compiled by the Controller General of Accounts (CGA). The compiled monthly accounts are reconciled with the CTD record of transactions.
- f. Financial reporting: A financial report is submitted by CTD to MoHFW and the donors like The Global Fund and World Bank on periodic intervals based on the compiled monthly accounts and CTD's own record of expenditures,
- g. External Audit: The audits are being conducted as per the standard terms of reference. The audit reports are being made available as per the agreement. At state level audits are being done as per state NHM manual and guidance for audit by empanelled chartered accountancy firms of the State. All the states are required to submit the annual audit report to CTD by 30<sup>th</sup> September.

# Donor and External Aided Financing for RNTCP:

The goal of the donor supported funding to the program is in line with the National strategic plan to achieve 'Universal access to quality diagnosis and treatment for all TB patients in the community'. The donor supported funding contributing to the program under NSP 2012-2017 is from The Global Fund and USAID.

#### The Global Fund

Central TB Division (CTD), MoHFW has been a Principal Recipient (PR) of the Global Fund Grants since Round 1, 2003. This grant support has substantially increased over the years for the TB control programme under the New Funding Model (NFM) for the implementation period 01st October 2015 to 31ST December 2017.

The Grant is supporting in scaling up of program activities across country including establishment of 15 Liquid culture laboratories, 26 units of MGIT equipment set, 4 Units of Genome sequencing equipment, 50 Units of GT Blot, 2560 Units of FL LPA Kits, 45 Mobile Vans for Active Case Finding, 20,000 IT Tablets, Procurement of 35 Mobile Vans for strengthen access to RNTCP services in the tribal population with the use of Mobile Digital X-ray and Sputum Microscopy Vans for Geographically Remote Places (Spatial Targeting), deployment additional 200 **CBNAAT** machines. procurement of First line and Second line drugs, strengthening of supply chain management system, Establishment of IT enabled Supply Chain Management System (Nikshay Aushadhi), scale up of Public Financial Management System (PFMS), etc. The sub-recipients under the Global Fund NFM Grant are:

- States of Andhra Pradesh, Bihar, Chhattisgarh, Haryana, Jharkhand, Karnataka, Orissa, Telangana and Uttarakhand
- Indian Council for Medical Research (ICMR)
- World Health Organization (WHO)
- Foundation for Innovative and New Diagnostics (FIND)
- Tata Institute of Social Sciences (TISS)
- Tibetan Voluntary Health Association (TVHA)

Way Forward: The RNTCP Global Fund next funding proposal has been approved by the Global Fund Secretariat for Central TB Division (Principle Recipient) for the period from 1st January, 2018 to 31st March 2021. The grant broadly supports in the areas of Procurement of Second Line Drugs, Newer Drugs, INH & Pyridoxine for IPT, 500 CBNAAT machines, CBNAAT cartridges, Patient Incentive Support, Counselling of DRTB Patients, Technical Support Network, Operational Research Activities, Active Case Finding, Contribution to Green Light Committee (GLC) and strengthening of RNTCP SCM system including up-gradation of GMSD, SSD, DDS & TU.

#### **USAID**

RNTCP has rolled out newer drug Bedaquiline in the selected Six sites of Five States in the first instances under Conditional Access Programme (CAP). The 10,000 course of newer drug Badaqualine has been committed by the USAID to the RNTCP Programme as a donation through Global Drug Facility (GDF). Out of which 3500 courses have already been delivered and balance 6500 courses are expected to be complete by Dec 2018.

## **World Bank Project**

Central TB Division is implementing the "Accelerating Universal Access to Early and Effective Tuberculosis Care" Project with an IDA Credit. The development objective of the project is to support the aims of India's National Strategic Plan (NSP) for Tuberculosis Control to expand the provision and utilization of quality diagnosis and treatment services for people suffering from tuberculosis. The project became effective

on June 26, 2014 and considering the viability of the project the closing date has revised from 31-03-2017 to 31-03-2018. While the Credit supports implementation of the National Strategic plan for TB control. The project has three components:

**Component 1:** New strategies to reach more tuberculosis patients with earlier and more effective care in the public and private sectors

**Component 2:** Scale-up and improve diagnosis and treatment of drug-resistant tuberculosis.

**Component 3:** Expand public tuberculosis services integrated with the primary health care system.

The project has been restructured on a hybrid model consisting of Disbursement Linked Indicators (DLI) and Procurement of commodities and services.

Under the current World Bank Project, TB patients have directly benefited from treatment in accordance with the WHO DOTS, meeting the annual target of 4.6 million patients for calendar year 2016.

The project is on track to achieve its Development Objectives by the closing date of March 31, 2018. The project has fully disbursed Credit allocated to procurement of first and second line anti-TB drugs, fixed dose combination of drugs for daily regimen pilot and lab equipment. Of the thirteen disbursements linked indicator results agreed for the project, six results have been achieved in the past and Credit allocated to them disbursed. An additional three results have been assessed as achieved by the independent verification agency and

disbursements towards these have been certified. The project has disbursed over 87.17% of the IDA Credit.

Way Forward: In order to achieve ambitious target of NSP 2017-25 the programme is looking forward World Bank funding support for coming years. The Programme has initiated new World Bank Preliminary Project Proposal on "Moving towards Elimination of Tuberculosis 2018-2022" with an IBRD Loan, through a multi-phased programmatic approach with commitment

for first three years and annual and bi-annual commitment, thereafter. It was developed in consultation with the Bank.

The Global Fund considered this project proposal as quality demand, in light of it being an innovative financing mechanism leveraging substantial additional financial resources. The Global Fund has principally agreed to provide additional grant support as a buy down with World Bank, the potential additional buy down in the subsequent years.



Hon'ble Prime Minister Shri Narendra Modi with Prof. (Dr.) Nila Djuwita F. Moeloek, Hon'ble Health Minister, Indonesia



www.tbcindia.gov.in www.nikshay.gov.in www.nikshayaushadhi.in Ensuring uninterrupted supply of good quality Anti TB Drugs, commodities and diagnostics for the smooth functioning of the Programme and Patient's care is an essential component of DOTS strategy under RNTCP.

Procurement of Anti-TB drugs, equipments and diagnostics is done centrally through a well-defined procurement mechanism using Domestic Budget, The Global Fund & USAID support. To ensure procurement of good quality drugs, procurement is being done by a Central Procurement Agency viz. Central Medical Services Society (CMSS) and The Global Fund through the Global Drug Facility (GDF)/UNOPS by their authorized procurement agent i.e. International Dispensary Association Foundation (IDA). The Procurement and Supply chain management of drugs and other related activities at Central level is administered by an official at the level of Addl. DDG (TB) being supported by consultants.

The programme with regard to Procurement & supply chain management has achieved new initiatives during the last year like implementation of Nikshay Aushadhi application for managing drug inventory, procurement of Tablet computers & Mobile Vans etc.

### **Summary: Achievements and Activities**

- 1) Implementation of Nikshay Aushadhi
- 2) Expansion of Daily Regimen
- 3) Stock of Anti TB Drugs
- 4) Introduction of Shorter Regimen
- 5) Procurement of Tablet Computers
- 6) Procurement of Mobile Vans

- 7) Expansion of Bedaquiline
- 8) Procurement of Delamanid
- 9) Procurement of CB-NBAAT machines
- 10) Quality Assurance of Anti TB Drugs
- 11) Training on Nikshay Aushadhi

**Implementation** of Nikshay Aushadhi: RNTCP with support of C-DAC has developed a web based application "Nikshay Aushadhi" for the management of Anti TB Drugs and other commodities under RNTCP. application has been customized as per the needs of Programme and will further strengthen the logistics and supply Chain Management by ensuring real time monitoring, recording and reporting of Anti TB Drugs and commodities at all the levels. The national level Trainings of trainers (ToT) on "Nikshay Aushadhi" were completed in 2017 and application has now been made functional across the country from December'2017. Further, mobile app for Nikshay-Aushadhi on android version is also under development phase and is expected to be available by mid of 2018.

Expansion of Daily Regimen (FDCs): Daily regimen was initially rolled out in five states namely Sikkim, Maharashtra, Kerala, Himachal Pradesh & Bihar in 1Q-2017. However, following the directions of Honorable Supreme Court of India to roll-out daily drug regimen across the country by Oct'2017, programme with support of the central & states authorities has successfully rolled out daily drug regimen within the scheduled time across the country. The drug sensitive TB patients (adult & pediatric) are now being treated across the country with daily

regimen drugs (FDCs). Further, to ensure easier administration and acceptance of daily regimen formulations (FDCs) by pediatric patients, the same is being procured in flavoured dispersible form.

Stock of Anti TB Drugs: As daily regimen has been implemented across the country for adult & pediatric patients, programme is ensuring sufficient supply and procurement of drugs for smooth transition from intermittent regimen phase to daily regimen. Accordingly, stock position of all states is being monitored closely at central Level to ensure availability of drugs at all levels. Further, programme is continuously monitoring the procurement processes being undertaken by CMSS and The Global Drug facility (GDF) to ensure that all the ongoing procurements are materialized in a timeframe manner.

With regard to the treatment of drug resistant TB patients under RNTCP, sufficient 2nd line drugs are being procured through GDF/IDA & CMSS and issued to states as per the requirement. For implementation of Isoniazid Preventative Therapy (IPT), procurement of Tab Isoniazid-100mg & 300mg and Pyridoxine-25 & 50mg have been initiated by the programme through CMSS. The procurement of Tab INH-300mg has already been finalized and supplies are expected to start reaching consignees from 1Q-2018 onwards.

Introduction of Shorter Regimen: Introduction of shorter regimen for MDR TB patients is expected to be rolled out across the country from 1Q-2018 onwards. The supply of requisite drugs for shorter regimen has been started reaching consignees and programme is in the process of

issuing drugs to respective states accordingly. Further, to ensure timely procurement and uninterrupted supply of requisite drugs for shorter regimen, indent has already been submitted to procurement agency in 2017.

**Procurement of Tablet Computers:** To enhance implementation of Nikshay Aushadhi, Nikshay and other digital innovations under RNTCP, Programme has successfully finalized the procurement of 20K of Tablets Computers in Dec'2017. The supply of Tablet Computers to respective states / consignees has been started and is expected to be completed by 1Q-2018. The Tablet Computers will be delivered to Central, States & GMSDs officials for enhancing various digital activities under RNTCP. The Tablet computers supplied to states will be further distributed to State TB Officer's, State/Districts Pharmacists, Lab technician/s, STS, STLS, DMCs etc. Further, to ensure optimum utilization of Tablet Computers, states have been requested for making provision for arrangement of Sim cards, suitable tariff plans for internet facility.

**Procurement of Medical Mobile Vans:** To support states for undertaking Active Case Finding for diagnosis of TB Patients and to





fulfill gaps under the diagnostics policy of RNTCP, Programme has successfully procured 45 Medical Mobile Vans. The distribution of medical mobile vans to respective states/ consignees has already been started and supply of Mobile Vans is expected to be delivered by 1Q-2018. The Medical Mobile Vans have been fitted with Cartridge Based Nucleic Acid Amplification Test (CBNAAT Machine) along with other essentials like Gen-set, Refrigerator, UPS, Printer, Air Conditioner etc. These Mobile vans will facilitate in early diagnosis of MDR-TB and TB in high risk population through Active Case Finding.

Expansion of Bedaquiline: Initially Bedaquiline has been introduced at six sites in 5 states under Conditional Access Programme (CAP) in March 2016 and procurement of the same was done accordingly. However, following the recommendations of National Expert Committee on diagnosis and management of TB under RNTCP for expansion of Bedaquiline use, programme has already initiated the procurement of 10,000 Patient courses through USAID. Supply of 3,500 patient courses has already been received by the programme and

based on preparedness / expansion plan of states, BQ is issued to all the states.

Procurement of Delamanid: Delamanid is a recently approved drug for treatment of MDR/RR-TB patients under Conditional Access Programme (CAP). Initially, procurement for 400 patient courses of Delamanid will be done through donation for use in seven selected states under conditional access programme. The logistics and supply chain management guidelines of Delamanid has been finalized by the programme.

Procurement of CBNBAAT machines: In addition to already installed 638 CB-NAAT machines across the country, procurement of additional 507 CB-NAAT machines was finalized in 2017. The supply & installation of additional CB-NAAT machines have already been stared and it is expected that CBNAAT machines will be delivered / installed at respective sites by 1Q-2018. Further, to ensure uninterrupted supply and availability of cartridges, procurement of about 26.0 lakh cartridges were finalized in 2017, with all supplies expected to be completed by 1Q-2018.

Quality assurance of Anti TB drugs: Ensuring procurement of quality drugs and efficacy of drugs upto the consumption level is one of the main objective of the Programme. Accordingly, procurement of Anti TB drugs (1st line, MDR & XDR) is being done only from WHO Pre-Qualified, WHO GMP & ERP approved suppliers with mandatory pre-dispatch inspection and testing of drugs being supplied to RNTCP consignees by the suppliers. Further, programme has hired an independent lab to ensure the quality and

India TB Report 2018 69

efficacy of anti TB drugs lying at RNTCP drug stores. Random samples of anti TB drugs lying at different stores are being collected and tested as per the RNTCP quality assurance Protocol.

Training & Capacity Building Workshops on Nikshay Aushadhi: To ensure that states are able to manage drug logistics, inventory and supply chain management smoothly through "Nikshay Aushadhi", national level trainings for master trainers for all states were conducted by Central TB Division in 2017. Based on master trainings, further cascade trainings on "Nikshay Aushadhi" were conducted by respective states for concerned officials at different levels to ensure smooth functioning of Nikshay Aushadhi application. As the application is being updated and customized intermittently as per experiences gained and requirements from users, refresher trainings on Nikshay Aushadhi are also under consideration of the programme.







Y

TB से मुक्ति का ये मिशन भले ही भारत में हो या किसी भी देश में, frontline TB physicians और workers की बड़ी भूमिका होती है। इसके साथ ही हर वो व्यक्ति जो TB से ग्रसित होने के बाद रेग्यूलर दवा लेता है, अपना इलाज कराता है और इस बीमारी को हराकर दम लेता है, वो भी प्रशंसा का पात्र है: PM

11:46 AM - Mar 13, 2018

 $\bigcirc$  1,765  $\bigcirc$  523 people are talking about this

0

www.tbcindia.gov.in www.nikshay.gov.in www.nikshayaushadhi.in dvocacy Communication & Social Mobilization (ACSM) is an important and integral component of RNTCP program as proposed in National Strategic Plan (2017-2025). ACSM refers to a set of interventions that are used to improve tuberculosis (TB) control, particularly with the objectives of improving case detection and treatment adherence and TB-control strategy to ensure long-term, sustained impact.

It creates positive behaviour change, influences decision-makers, and empowers communities to change. Issues that can be addressed through ACSM are delayed detection and treatment, lack of access to TB treatment, difficulty in completing treatment, lack of knowledge and information about TB that can lead to stigma, discrimination & delayed diagnosis and/or treatment.

## Media Campaign at National level

## World TB Day:

The Ministry of Health & Family Welfare (MoHFW), Government of India in collaboration with WHO Country Office, India organized World TB Day 2017 with the underlying theme of UNITE TO END TB: Leave no one behind.

Speaking on the occasion, Shri J. P. Nadda,

Union Minister of Health & Family Welfare said, "Ensuring affordable and quality healthcare to the population is a priority for the government and we are committed to achieving zero TB deaths and therefore we need to re-strategize, think afresh and have to be aggressive in our approach to end TB by 2025."

In his address, Dr Henk Bekedam, WHO Representative to India highlighted, "The National Strategic Plan for Tuberculosis Elimination 2017-2025 is a major step forward in India's fight against TB; it is about building partnerships towards ending TB."

#### The following initiatives were launched:

- Annual TB Report 2017
- Guidance document on Nutrition Support for Tuberculosis Patients
- National Framework for Joint TB-Diabetes collaborative activities
- A TB awareness media campaign
- 'Swasth E-Gurukul': A digital e-learning platform

Dignitaries were graced the occasion; Mr C. K. Mishra, Secretary Health, MoHFW; Dr Jagdish Prasad, Director General Health Services, MoHFW; Dr Arun Panda, Additional Secretary & Mission Director, National Health Mission, MoHFW; Mr Arun Kumar Jha, Economic Advisor, MoHFW; Dr Sunil Khaparde, Deputy Director General (TB), MoHFW; and other senior officers of the Health Ministry, representatives of WHO, World Bank and other development partners.



### i) Audio-Visual Campaign-

TV campaign in Doordarshan was started from September 2017 to January 2018 through Directorate of Advertising and Visual Publicity (DAVP). On 1<sup>st</sup> Nov. the campaign started in satellite channels with seven regional languages. (Bengali, Gujarati, Kannada, Marathi, Malayalam, Tamil, Telugu). Further one month campaign started from 28<sup>th</sup> February 2018 to 27<sup>th</sup> March 2018.

Radio campaign started in September 2017 with All India Radio (AIR) has now reached to FM and community radio catering larger number of audiences. The campaign in T.V and Radio was on as the first phase of audio-visual media campaign till 31<sup>st</sup> Dec 2017 through Directorate of Advertising and Visual Publicity (DAVP). Further one month campaign started from 28<sup>th</sup> February 2018 to 27<sup>th</sup> March 2018.

#### ii) Digital Media Campaign-

Digital media campaign launched on 7<sup>th</sup> Nov. 2017 for 28 days in the first round of digital media campaign in 17 states (Arunachal Pradesh, Assam, Bihar, Chandigarh, Delhi, Haryana, Jharkhand, Madhya Pradesh, Maharashtra, Manipur, Meghalaya, Nagaland, Rajasthan, Punjab, Sikkim, Tripura, Uttar Pradesh) through National Film Development Corporation of India (NFDC). The campaign has been launched with a good number of 3900 theaters in the country with 4 shows each day in each theater.

#### iii) Outdoor Media Campaign-

Outdoor media campaign launched from 23<sup>rd</sup> Nov 2017 for 1 month through DAVP in 13 states includes 20 bus queue shelters in every state, Airport hoarding at Mumbai & Delhi Airport,

8 Cantilevers in Delhi NCR. The 13 states are

Andhra Pradesh, Assam, Delhi, Goa, Jharkhand, Maharashtra, Punjab, Rajasthan, Tamil Nadu, Telangana, Uttarakhand, Uttar



Pradesh and West Bengal through Directorate of Advertising and Visual Publicity (DAVP). The posters also designed Tamil language for the publicity in Tamil Nadu.

#### iv) Print Media Campaign-

Advertisement on TB notification went in 252 newspapers including English, Hindi and 167 regional newspapers on 10<sup>th</sup> September 2017 through DAVP.

#### News clip



#### v) Social Media Campaign-


The DDG-TB Twitter handle has been operational from August 2017 for creating mass awareness about tuberculosis through social media.

India's most loved RJ "Khurafaati Nitin" and

"Anand Kumar Super 30" from Bihar has been launched officially from the tweeter handle of DDG - TB.

#### vi) New IEC Material on Daily Regimen-

New IEC materials such as TVC spot, radio spot, posters, info graphic and a video film on Daily Regimen have been developed and shared with all 36 States/UTs in the month of December 2017.



## World AIDS Day at Jawarhar Lal Nehru Stadium-

An event was organized on 1st of December, 2017 by NACO in collaboration with Central TB Division and Delhi State TB cell on TB-HIV. More than 2,500 attendees were attended the event at Jawahar Lal Nehru Stadium, New Delhi.

Inauguration of CBNAAT machine & its Cartridge by Hon'ble MoS (Health & Family Welfare) was a historic moment. Hon'ble MoS (Health & Family Welfare) spent some time to understand the efficiency of the machine and cost effectiveness for PLHIV. She also enquired about the displayed guidelines and its availability at state level. New IEC material, various Guidelines, Videos/ TV Spots and standees on

TB-HIV were made available for display and distribution among attendees.



Inauguration of the event by Hon'ble MoS (Health & Family Welfare) and Secretary (Health & Family Welfare)



Inauguration of CBNAAT machine & its Cartridge by Hon'ble MoS (Health & Family Welfare)

## "Nikshay Patrika" a Quarterly Newsletter by Central TB Division:

Team of Central TB Division has come up with quarterly NIKSHAY PATRIKA which encapsulates latest development from the field

of TB control in India. The patrika play a catalyst role in disseminating information regarding progress towards TB elimination.

The inaugural issue of "NIKSHAY PATRIKA" newsletter unveiled by Smt. Preeti Sudan,

Secretary (Health & Family Welfare) in the presence of Shri Manoj Jhalani, AS&MD, Shri Arun Kumar Jha, Economic Advisor, and Dr. Sunil Khaparde, DDG-TB during the video conference on 16th January 2018 at Nirman Bhawan.



State level Media Campaign:



World TB Day (2017) celebration Arunachal Pradesh



World TB Day (2017)celebration Arunachal Pradesh



Active Case Finding (Maharashtra)



Active Case Finding (Nagaland)




IEC in Tamil language



IEC in Tamil language



Active Case Finding (Uttar Pradesh)







TB का मरीज अपनी इच्छाशक्ति से जिस तरह इस बीमारी पर विजय प्राप्त करता है, वो दूसरों के लिए भी प्रेरणा का काम करता है। मेरा दृढ़ विश्वास है कि मरीजों की इच्छाशक्ति और अपने passionate TB workers के सहयोग से भारत के साथ ही दुनिया का हर देश अपने लक्ष्य को प्राप्त करने में सफल होगा: PM

11:48 AM - Mar 13, 2018

 $\bigcirc$  1,971  $\bigcirc$  560 people are talking about this

θ

www.tbcindia.gov.in www.nikshay.gov.in www.nikshayaushadhi.in

## **Background**

he Revised National Tuberculosis Control Program (RNTCP) has been actively involved in conducting research since inception in the form of Operational Research (OR) which helps the programme to develop incountry evidence to guide the policy decisions from time to time. As new evidence became available, RNTCP has made necessary changes in its policies and programme management practices.

The new National Strategic Plan for TB 2017–2025 aims to accelerate progress towards the goal of ending TB by 2025 and to achieve this goal RNTCP is incorporating innovative and more comprehensive approaches to TB control. An effort of RNTCP to promote OR has resulted in success and most of the studies are linked to the main priorities of TB control. OR aims to improve the quality, effectiveness, efficiency and accessibility (coverage) of the control efforts.

As the programme requires in depth knowledge and sufficient evidence to optimize policies, improve service quality and increase operational efficiency, mechanisms for strengthening operational research have been put in place to leverage the enormous technical expertise and generate evidence sufficient to guide changes in the programme policy.

## Structure for operational research under RNTCP

National OR Committee

- Zonal OR Committee
- State OR Committee
- Medical colleges

# Priority Areas of Research includes the following

- 1. Strengthening surveillance and tuberculosis notification
- 2. Improvement of TB disease burden estimation
- 3. Understanding TB transmission and how best to interrupt it
- 4. Demand generation, prevention, systematic screening of high-risk groups, and early case finding
- 5. Improving the cascade of care in public and private sector care
- 6. Socio-economic impact and poverty alleviation
- 7. Strengthening RNTCP management
- 8. Integration with State Insurance and UHC initiatives Research Priorities

Status of Operational Research proposals submitted and approved by different levels of OR Committee for FY 2016-17.

Table: 9.1. Summary of Zonal OR Proposals

Activity	East	North East	North	South 1	South 2	West	Total
Number of State OR Committee meetings held	6	12	7	3	7	9	44
Number of OR projects received by the State OR Committee	8	11	40	49	19	42	169
Number of OR proposals approved by the State OR Committee	7	6	34	21	10	23	101
Number of OR proposals reviewed by the State OR Committee and forwarded to the Zonal OR Committee for approval	2	5	1	2	0	0	10
Number of OR proposals approved by the Zonal OR Committee	1	4	0	1	0	0	6
Number of thesis proposals received by the State OR Committee	8	5	23	34	4	44	118
Number of thesis Proposals approved	8	6	20	33	2	31	100
Number of thesis initiated with RNTCP as a topic in the Zone	8	6	24	33	2	30	103

# **Summary of National Operational Research proposals**

National Research committee meets twice in a year and Status of operational Research

proposals submitted and approved by National Operational Research Committee Meeting for FY 2017-18 are as follows.

Date of Meeting	NO. of Proposals presented	No. of proposals Approved	No. of proposals Initiated
23 <sup>rd</sup> Feb 2017	13	7	1
6th July 2017	7	5	1



North -East Zonal Operational Research Workshop of RNTCP 23-25 October 2017

Consultative Meeting on Operational Research was held on 6th July 2017 at Taj Mahal Hotel, New Delhi in which Zonal Operational Research (ZOR) Workshops have been planned. As per the

plan two ZOR workshops have been conducted in North East from 23 to 25 October 2017 and in West Zone from 10-12 October 2017.



West Zone Operational Research Workshop of RNTCP 10th to 12th Oct 2017

Table: 9.2. Self -Funded studies under RNTCP in FY2017-18

S. No.	Study Title	Principal Investigator
1	Protocol for survey to determine direct and indirect costs due to TB and to estimate proportion of TB-affected households experiencing catastrophic costs due to TB in INDIA-2017	
2	Integrated chronic disease management using the primary healthcare infrastructure in India- A feasibility study	
3	End-line KAP survey about Tuberculosis across 30 districts in India under Project Axshya	Dr. Karuna Sagili, The Union South East Asia Office New Delhi

Table: 9.3. Status of OR projects under RNTCP in FY 2017-18

S. No.	Study Title	PI	Status	<b>Total Duration</b>
1	Multi-centric Cohort Study of recurrence of Tuberculosis among newly diagnosed sputum positive pulmonary Tuberculosis patients treated under RNTCP.	Dr Mohan Natarajan	Completed	3 Yrs
2	Evaluation of gene xpert as compared to conventional methods of genital TB among infertile Women.		On going	3 Yrs
3	A Randomized controlled trial of either Discontinuation at 6 months or continuation till 9 months after initial response to RNTCP Category I treatment	· ·	Completed	4 yrs
4	Operational Feasibility and performance of TrueNat MTB Rif assays in field settings under the Revised National Tuberculosis Control Program	Tripathi, NIRT	On going	3 Months
5	Evaluation of gene xpert as compared to conventional methods of genital TB among infertile Women.		On going	3 Yrs

## **Developments in RNTCP Research**

Research Consortium for Tuberculosis: ICMR with the programme division has established a Tuberculosis Research Consortium for streamlining all research related to TB within the country. This will include participation of Department of Biotechnology (DBT), Council of Scientific and Industrial Research (CSIR), Departments of Science and Technology (DST) and other academic/research institutions.

The consortium will drive the development of a pioneer national TB Research Strategy in line with the WHO End-TB Strategy and create a scientific network and develop a country specific prioritized research agenda that will allow India to be a model country for TB research. This forum will have strong financial and technical commitment from all stakeholders, including representatives from the private sector.


National Institutes (NIRT, JALMA, NITRD & NTI) are exclusively focusing on TB research. ICMR & its basic science institutes, Department of Health Research (ICMR), DST, DBT, CSIR and Indian Institute of Science (IISc) India are also leaders in basic, clinical, translational and operational research.

In addition various technical partners like WHO, The Union support in capacity building and implementation of researches under RNTCP. Funding through various institutes could be harnessed to promote integrated research.

National Research Committee provides technical guidance to Central TB Division in identification of priority areas for Operation Research under RNTCP and helps the programme in taking evidence based policy decisions.

### **TrueNat Study**

TrueNat, a new indigenous diagnostic tool for use in peripheral settings that has been validated by ICMR. The aim of the study was to evaluate the operational feasibility and performance of TrueNat MTB Rif assays in field settings under RNTCP. Results of the study was evaluated by Expert Committee and the committee recommended that TrueNat can be used as a point of care test for detection of TB and Rifampicin resistance TB at peripheral centres i.e. DMCs. Also, in the view of the satisfactory performance of the TrueNat in the feasibility study and other factors such as cost effectiveness, ease of performance, transportability, and placement at the peripheral level, it can be used as a part of the diagnostic algorithm for TB at the DMCs.





V

भारत में immunization 30-35 साल से चल रहा है। बावजूद इसके 2014 तक हम संपूर्ण कवरेज का लक्ष्य प्राप्त नहीं कर पाए थे। जिस रफ्तार से immunization का दायरा बढ़ रहा था, अगर वैसे ही चलता रहता तो भारत को संपूर्ण कवरेज तक पहुंचने में 40 साल और लग जाते: PM

11:51 AM - Mar 13, 2018

 $\bigcirc$  1,744  $\bigcirc$  535 people are talking about this

θ

www.tbcindia.gov.in www.nikshay.gov.in www.nikshayaushadhi.in

# Chapter 10

### **Introduction:**

easuring, monitoring, and evaluating TB outcomes is central to the success of RNTCP programme. Regular central and state programme evaluation will continue as is being done based on new interventions and strategies. One of the key objectives of M&E is to monitor the performance of TB control activities by using available data to inform appropriate interventions to upgrade the districts, state and national TB plans.

Surveillance is another important component in the control and elimination of TB and provides information on the epidemiology of the disease, the evolution of trends and the description of those groups in the population at increased risk of TB and unfavourable prognosis. It is an essential element in monitoring the effectiveness of interventions aimed at elimination of the disease.

The following M&E activities are undertaken at the National level under RNTCP:

- National RNTP Review meeting with State Tuberculosis Officer from 12th to 14th of September 2017 at Chandigarh.
- Regional PMDT, TB-HIV & PPM review meeting for North zone
- Assessment of Daily Regimen implementation visits to states
- Central Internal Evaluations
- Review of nationwide implementation of FDC by Secretary, AS&MD and JS of HFM
- Regular programme review by CTD officials

### through ECHO platform

- Joint international assessment of the tuberculosis diagnostic network of India
- NRL and IRL visits by CTD officials
- National Task Force Meeting
- Zonal Task Force Meeting
- World Bank Mission
- Global Fund Mission

## Table: 10.1. List of Monitoring & Evaluation for the FY 2016-17

S. No	Activities	Numbers
1	National Review meeting: 12th to 14th of September 2017 at Chandigarh	1
2	Video Conference	3
3	Daily regimen Preparedness Assessment Visit to states	20
4	Central Internal Evaluations	3
5	Regional PMDT & TB HIV review meeting	1
6	Zonal Task Force meeting	6
7	National Task Force meeting	1
8	Joint Assessment of TB Diagnostic Network of India	1
9	NRL Coordination committee meeting	1

### **National Review Meeting:**

To review the progress, achievements and constraints being faced by the State/UTs in implementation of the Revised National Tuberculosis Control Programme (RNTCP), the Central Tuberculosis Division (CTD), Dte.GHS, MOHFW and the World Health Organization (WHO) organized a National programme review meeting with State Tuberculosis Officer and State RNTCP Consultants. Review meeting was conducted from 12<sup>th</sup> to 14<sup>th</sup> September 2017 at Hotel Hyatt Regency in Chandigarh.

Meeting was inaugurated by Mr. Bramha Mohan, Hon'ble Health Minister; Government of Punjab. Meeting was attended Dr Sunil Khaparde DDG TB, Mr Arun Kumar Jha Economic Advisor Ministry of Health and Family Welfare Government of India.

### **Central Internal Evaluation:**

Monitoring and evaluation help an organization to extract relevant information from past and ongoing activities that can be used as the basis for programmatic fine-tuning, reorientation, future planning and advocacy, to ensure universal access to quality care for all TB patients.

As part of the Supervision and Monitoring, the Central level evaluations is to review the programme performance in selected districts of the state and it helps to review and monitor the overall programme performance of the state. The Central Internal Evaluation (CIE) envisages the programmatic challenges and address support actions for improving quality of RNTCP implementation.

To achieve the goal of eliminating TB by 2025, Central TB Division prioritized the central level monitoring and evaluation of the programme. As per the strategy of eliminating TB by 2025, CIE for 3 States i.e. Andhra Pradesh, Karnataka and Madhya Pradesh was conducted in September, October, November 2017 respectively and further evaluation of other states is planned in 2018.

During field visits of CIE in the selected districts and health institutes the salient observations and recommendations of the team members were briefed to the Principal Secretary-Health, NHM officials and District Magistrate of the respective districts for compliance and necessary actions.

### Joint International Assessment of the Tuberculosis Diagnostic Network of India

A comprehensive, high-quality TB diagnostic network is essential to accurately and rapidly diagnose TB and link confirmed TB cases to appropriate and timely treatment. Revised National Tuberculosis Control Program (RNTCP) has a vast country wide TB diagnostic network of Designated Microscopy Centres (DMCs), CBNAAT (Xpert) labs, Intermediate Reference Laboratories (IRLs) and National Reference Laboratories (NRLs) equipped with newer rapid TB diagnostics.

National Strategic Plan for TB Elimination (2017-25), envisage for "Early identification of presumptive TB cases, at the first point of care be it private or public sectors, and prompt diagnosis using high sensitivity diagnostic tests to provide universal access to quality TB diagnosis including drug resistant TB in the country". As the program is aiming towards an early and increased case

detection, upfront drug susceptibility testing, extended drug susceptibility testing, tapping into private sector diagnostic capacity, newer drugs and treatment regimens; TB prevalence survey, and surveillance, a Comprehensive Assessment of the TB Diagnostic Network was conducted in October – November 2017

# Daily regimen Preparedness Assessment Visit

Revised National TB Control Programme has introduced daily regimen in 5 states in January – February 2017. It was expanded to all states by October 2017. For smooth and timely roll out of daily regimen in all other states, a team comprising CTD Official, representative of National Institutes, state/ district program

managers and WHO Consultants undertook appraisal for preparedness. The team visited randomly selected two districts. On first two days district visit was done and on third day state level institutions were visited. District and state visit concluded with appraisal to DM, Principal Secretaries Health. The visits were conducted between June to September 2017.

### **ECHO Video Conference:**

RNTCP always incorporates latest strategies in program. Last year program first time used the ECHO- Zoom platform to review the program. By using Video conference program can reach program managers with minimal resources and with more efficient use of available time. In year 2017 following meetings were conducted using VC

Table: 10.2. List of VC held by MoHFW & Central TB Division

S. No	Month	Agenda	Meeting chaired by	Participants
1	October 2017	Review of RNTCP and Launch of Daily regimen	Secretary Health & Family welfare	PS Health, MD NHM, STO and RNTCP consultant
2	October 2017	RNTCP review	AS & MD	PS Health, MD NHM,
3	October 2017	Review Daily Regimen Implementation Status	DDG TB	STO's and RNTCP consultant
4	July 2017	Review Active case finding Phase II preparatory activities	DDG TB	STO's and RNTCP consultant
5	May 2017	Review preparatory steps towards implementation of daily regimen	DDG TB	STO's and RNTCP consultant
6	January 2017	Review preparatory steps towards implementation of daily regimen	DDG TB	STO's and RNTCP consultant
7	January 2017	Review Active case finding Phase II preparatory activities	DDG TB	STO's and RNTCP consultant


### Regional PMDT & TB HIV review meeting

The PMDT meeting was conducted for the North Zone states (Himachal Pradesh, Punjab, Chandigarh, Haryana, Delhi, J&K, Uttrakhand & Uttar Pradesh) at Shimla from 21-23 November 2017 under the Chairpersonship of Dr. S.D. Khaparde, DDG-TB and Dr. V.S. Salhotra, ADDG-TB. Sh. Prabodh Saxena, PS (H), Govt.

of HP graced the inaugural session. Objectives of the meeting was to give update on recent developments in PMDT, sensitize on revised PMDT Guidelines, review the progress and challenges in scaling up of PMDT services, update the status on implementation of universal DST and to review TB-HIV collaborative activities in these states.



Dr. V. S. Salhotra, ADDG-TB, addressing the gathering of review meeting



Hon'ble Prime Minister Shri Narendra Modi with Dr. Rajitha Senaratne, Hon'ble Minister of Health and Indigenous Medicine, Sri Lanka



# PMO India OPMOIndia



साथियों, पहले हमारा immunisation coverage सिर्फ 1% की रफ्तार से बढ़ रहा था। सिर्फ तीन-साढ़े तीन साल में अब ये 6% प्रतिवर्ष से ज्यादा हो गया है और अगले एक वर्ष में हम 90 प्रतिशत immunisation coverage का लक्ष्य हासिल करने जा रहे हैं: PM 11:52 AM - Mar 13, 2018

 $\bigcirc$  2,256  $\bigcirc$  677 people are talking about this

A

www.tbcindia.gov.in www.nikshay.gov.in www.nikshayaushadhi.in

# Chapter 11

RNTCP programme. An adequately staffed, trained & motivated health workforce is a prerequisite to achieve the ambitious goal of eliminating TB by 2025. One of the main elements of HR is training which builds adequate workforce to cater to complex and demanding multiple new task for MDR/ XDR TB and comorbidities care. The training programmes need to cover more than 20 lakh trainees which will require a multi layered cascade system of training. This is a huge task and hence will be optimized for reach and quality by developing e-modules using different types of ICT system.

Since the last formal release of training material 2012, RNTCP has undergone a series of changes. These changes have increased the size and complexity of training needs and the base training material is due for a significant update. The size and complexity necessitates a more focused training delivery, relevant to the particular trainee category, without generating multiple versions of the same instruction. New instruction need to integrate easily and penetrate quickly to the periphery, while maintaining quality standards and efficiently utilizing training resources. The development of E-learning methods gives us the opportunity to achieve all the above.

On 24th March 2017, the Union Health Minister launched a first release of the E-learning platform christened Swasth-e-Gurukul. This new e-training system is expected to replace all primary training material in RNTCP using multimedia content. The training may be taken by the participant either in a self-paced manner on the e-learning platform or may further be augmented by using it in groups in classes. It

will also simultaneously incorporate evaluation and assessment of training.


from the modules Apart e-training simultaneously the STDCs are being further strengthened. The STDCs act as resource centers for translating the content to vernacular and adding relevant content as per local needs at the State level. The STDCs will also continue to act as centers for final certification of successful completion of training by interacting with the participants after culmination of e-learning and administering a post test questionnaire, if needed. These steps will not only help in rapidly filling the gap of untrained staff but will also prove to be an effective and sustainable way to keep-up with changing policy guidelines and percolating correct knowledge to every level of staff.

Human resource management and human resource development under RNTCP goes beyond 'training specific personnel for specific tasks'. It includes management of personnel, in addition to maintaining constant, high quality standards of training. Hence, the target is to achieve sustained professional competency in TB control activities that will benefit not just the States, but also the country at large.. Being under the overall umbrella of NHM, the HR policy and practice is mostly governed by the State NHM setup. The Central TB Division supplements this by provisioning contractual staff at strategic positions of the programme network, developing terms of reference for hiring of these staff and formulating standardized training material for creating a uniform knowledge base among workers.

Apart from general health system staff, RNTCP has provisioned dedicated programme staff at various levels. In the past one year, several new components like Daily Regimen, New Technical & Operational Guidelines, Nikshay enhancement, Pharmacovigilance, etc. have been added to RNTCP, creating an increased training need.

RNTCP has managed to meet with the enhanced

training requirements by conducting a series of training sessions in year 2017 to train the trainers on new Technical & Operational Guidelines (TOG). Cumulatively, trainers from across the country were trained at National Tuberculosis Institute, Bangalore and NITRD, New Delhi, who went on to train and sensitize State and District level staff and other stakeholders on the new TOG.



Hon'ble Prime Minister Shri Narendra Modi with Mr. Zahid Maleque, Hon'ble State Minister of Health and Family Welfare, Bangladesh





ऐसी ही नई अप्रोच के साथ हमारी सरकार स्वच्छ भारत मिशन के लिए भी काम कर रही है। इसी का नतीजा है कि 2014 में देश के ग्रामीण इलाकों में स्वच्छता का जो दायरा लगभग 40% था अब वो बढ़कर लगभग 80% तक पहुंच गया है। इतने कम समय में हमने दोगुनी कवरेज हासिल की है: PM

11:54 AM - Mar 13, 2018

 $\bigcirc$  3,276  $\bigcirc$  1,050 people are talking about this

www.tbcindia.gov.in www.nikshay.gov.in www.nikshayaushadhi.in

### **Success Stories**

### Assam

### 1 Efforts to increase monitoring

New forms of media have brought a paradigm shift in the health communication arena. RNTCP in Jorhat, Assam has started innovative way of supervision and monitoring through WhatsApp.

They have created a WhatsApp group for supervision and monitoring named "Let us fight against TB". This group helps the Jorhat District TB Cell feel united to stand against Tuberculosis and also helps them communicate messages regarding field level activities to District Magistrate (Deputy Commissioner), State TB officer and WHO consultants. The supervisory staffs like STS, STLS including LT feels motivated by the words of encouragement from their seniors and administrative heads.

The DTO who is the administrator of the group also asked staff to upload important information as well as photographs so that one can monitor the activities taking place in the field. The district has also been able to start a Random Active Case Detection program in a few high risk tribal villages and Tea Garden area of the district.



The use of WhatsApp groups has made communication much easier in many districts like Sivsagar, Kokrajhar, Lakhimpur etc. During the review meeting, Dr. N.J. Das, STO Assam encouraged all DTOs to use this ICT tool for communicating TB messages for saving lives.

### **Arunachal Pradesh**

# 2. Success of counselling - Counselling for TB helped in de-addiction too!

A patient Mr. Hangsik Kungkho from Laktong Village, Changlang, Arunachal Pradesh was diagnosed as new sputum positive and put on Cat I. He was a chronic alcoholic and an opium addict. During his treatment he missed few doses. Constant supervision was given by the staffs and ASHA of the village. Follow up sputum samples were negative and after6 months of treatment he was declared cured. After one year he again started developing signs& symptoms of TB. On being brought to the hospital by our STS, he was found to have relapsed and again suffering from sputum positive tuberculosis. During his treatment counselling was given to him several times for proper adherence to treatment and also for opium &alcohol de-addiction. Our staff, especially STS, took great effort to give regular medication & build the patient's self-confidence. Today we are

proud to say that he has been declared cured from TB and has been de-addicted from opium after taking it for 20-27 years. This is a result of regular monitoring & supervision and good counselling given to the patient by the staff that today he has developed self-confidence &lives a happy life with his family.

### Gujarat

### 3. Case Finding Efforts in high risk groups

It is well known that tuberculosis can spread rapidly in crowded settings. Prisons are one of such settings where people come in close contact making it a suitable place for spreading TB infection. A lot of prisoners are also undernourished, addicted to drugs and may even be suffering from diseases that may render them immunocompromised, thus, susceptible to developing TB disease. Hence, it is crucial to not only make police staff aware of TB, but also conduct regular screening of prisoners. Junagadh District TB Cell successfully worked alongside the Police Department to conduct ACSM activities to





increase awareness among staff and prisoners, they also conducted screening camps in the prisons and screened 1091 prisoners of which 1 person was diagnosed with microbiologically confirmed TB.

### 4. Reaching out to the Women

### **International Woman's Day Celebration**

The Junagadh district officials found a great opportunity in the fact that both World TB Day and World Woman's Day are placed in the same month. It was decided that TB awareness should reach all women too, who generally assume the caretaker role in the family. Hence, a combined event was held on 08 March 2017, which provided information about TB among women and HIV-related people. This was supported by the Vihaan project.

Sensitization workshop was also held on March 21, 2017, in Junagadh TU Urban 1, Uma Mahila Mandal. Dr. K.B. Nimavat gave information about tuberculosis and encouraged the ladies to spread the message of TB through their association. The program was organized by



Sensitization of women's group on the occasion of International Women's Day

Junagadh Urban 1 TB Supervisor P.J. Dadhaniya and TBHV Bamrotiya while Thanksgiving was done by DPPMC Ramesh Baku.

### Tamil Nadu

### 5. Private Sector Engagement

Together we can eliminate TB – starting with small changes.

RNTCP is now providing diagnostic and treatment along with patient support services even to patients who seek care in the private sector. After several TB sensitization programmes to medico societies of Salem District, Tamil Nadu, TB notification and CBNAAT referrals from private sector has improved.

AVM Hospital is one of the many private hospitals in Salem where all medical and paramedical staff has been sensitized on TB through RNTCP PPM activities and the hospital regularly notifies TB patients.

Mr. Senthil from Dhadhagapatty was found sputum smear positive at AVM hospital. He was started on ATT in January 2017 and was counselled by the doctor and staff nurse for regular adherence. In spite of the counselling, Senthil stopped visiting the hospital as after two months of treatment when his symptoms had subsided. Even when the staff nurse called him over phone, he did not respond. The Medical Officer at AVM Hospital, Dr. Jayapal, then instructed the nurse to contact RNTCP staff through the PPM Coordinator, who in turn arranged a home visit to the patient's house by the STS. Mr. Senthil and his family were counselled for treatment and though very adamant initially, Senthil later understood

the importance of completing the entire course of treatment and agreed to resume his ATT from a nearby Govt. PHI. Throughout his treatment, he was regularly counselled by the RNTCP staff and he successfully completed his treatment on 05/11/2017.

It was only through a good liaison between the public and private sectors in Salem district that a patient, who would have otherwise been lost to follow up and probably developed resistance, was counselled and brought back to treatment.

### 6. TB-Tobacco

### From one awareness to another



Mrs. Shanthi from Kovilpatti, Thoothukudi district, Tamil Nadu runs a grocery store near her home. She was diagnosed with TB and started treatment on 28.08.2017. She was regularly counselled by RNTCP personnel on the various ways in which someone can get infected with TB and how this infection progresses to a serious disease. This awareness about TB compelled her

India TB Report 2018

to make a choice that she might not have taken otherwise. Shanthi decided to stop selling any tobacco products in her grocery store!

Shanthi says, "Even though I may suffer some losses in my sales, I cannot turn a blind eye to this menace which is tobacco! The loss doesn't matter to me. Hereafter, I will never sell any tobacco related products for the welfare of General Public."

# CSR Engagement - The Joy of collaboration!

It was raining heavily when on my way home from work in the evening, I (DPPMC) saw a huge crowd, almost blocking the whole road. On enquiring I was told that it was the opening function of a famous jewellery brand in Villupuram (Tamil Nadu).

Seeing that huge crowd I could very well understand how influential this brand's marketing was in the public. No doubt I had seen their hoardings and advertisements everywhere. This gave me an idea! I could try to contact the brand managers and get a sponsorship for combining their advertisement with RNTCP messages! When I discussed it with my DTO, he encouraged me to follow it through since it was an effective way of making our message reach further into the community. It took us a long while to get an appointment with the branch head of that jewellery branch. When we finally met him after 3 months, we had a sample board ready with messages on TB along with logo of both RNTCP as well as the jewellery brand. The branch head found it impressive and readily agreed to sponsor such boards at every block PHC in Villupuram. The sample board was released by the district Collector. Top officials of the jewellery company from Trissur also attended the event and pledged their support to RNTCP in the End TB Strategy.



Villuppuram Collector, DTO & Joyalukkas Manager releasing the IEC board.



IEC Board Displayed at Pudupettai PHC by STS/STLS in Villupuram District Tamilnadu


### West Bengal

### 8. Sale of drugs - Regulating sale of antituberculosis medicines

As per a 2015 GOI notification (Schedule H1) TB drugs can be sold in retail only on prescription by a registered medical practitioner and details of the prescriber as well as the patient are to be recorded in a register by the chemists/ pharmacists. With increasing collaboration with the private sector, RNTCP is aiming to provide diagnostic,



treatment and patient support services even to patients in the private sector. To extend public sector services to all such patients, the district officials Bengal of South 24 Parganas (West) contacted the Assistant Director, Directorate of Drug Control to strengthen this implementation and to share details of all listed patients with the TB department. A notice has also been issued to ensure implementation of Schedule H1 and submission of a quarterly report in this regard.



# 9. Peer support - Encouraging adherence to treatment through peer support

Aminur Islam, a 20 years old orphan, was diagnosed with MDR TB at the age of 17 years and got more than 12 months treatment without fail. Follow up cultures in intensive phase were negative and patient was shifted from IP to CP after 6 months. Follow up cultures in continuation phase was also negative up to 12 months. But unfortunately there was reversion in subsequent follow up cultures in continuation phase. Resistance was detected on 2nd line DST of his samples, and then he was diagnosed as an XDR TB patient. After receiving the recommendation

from DOT Plus site we initiated Category V treatment. At the time of counselling by DTO and other concerned medical officers of Dakshin Dinajpur District Hospital DRTB committee, he never got frustrated but assured that he will continue his full course of treatment. He has now completed 13 months treatment and all the sample results are found negative and his weight is also increasing gradually. Even though his treatment is ongoing, he has started playing an important role in MDR TB patient provider meetings. He is an inspiration to many and encourages his peer group to continue



Aminur Islam talking in a Patient Provider Meeting

their treatment course without missing a single dose. He cites his own journey and hardships and boosts the morale of his friends who may be going through difficulties in adhering to treatment.

### 10. Community engagement

Even though a large section of society continues to seek care from non-qualified private practitioners (quacks), not sufficient efforts go into increasing their awareness so that may also contribute by referring patients to RNTCP. Keeping this in mind, Malda district decided to conduct a community meeting to inform and educate them and in turn increase notification of TB patients who can be referred to RNTCP for correct and quality assured diagnostics, treatment and patient support.





Community meeting with Non qualified private practitioners (Quack) at Malda.

### Annexures





www.tbcindia.gov.in www.nikshay.gov.in www.nikshayaushadhi.in

### **Annexures**

Ar	nex No.	litle	Page No.
1.	TB	Notification – 2017	
	a)	State wise	108
	b)	District wise	109
2.	St	ate wise TB Treatment Outcome of cases notified in 2016 from public sector	
	a)	Microbiologically confirmed	
		i) New Cases	137
		ii) Previously Treated Cases	138
	b)	Clinically Diagnosed	
		i) New Cases	139
		ii) Previously Treated Cases	140
	c)	HIV Co-infected TB Cases	
		i) New Cases	141
		ii) Previously Treated Cases	142
3.	Int	ensified TB Case Finding in ICTC & ART Centre	
	a)	ICTC	143
	b)	ART	144
4.		tte wise performance in Programmatic Management of Drug Resistant TB MDT)	
	a)	Notification of DRTB cases-2017	145
	b)	12-month Culture conversion	146
	c)	Treatment Outcome	147
5.	RN	TTCP Programme Infrastructure	
	a)	Human Resources	148
	b)	CBNAAT Laboratories	154
	c)	Cartified Ch-DST Laboratories	155

India TB Report 2018

Annexure 1a): State wise TB Case Notification 2017

1 Total 3 ation (akh/ r)		1	3	6	<u>.</u>	3	r)	r.	1	0	8	4	2	9		8	3			7	6		9	9	∞	6	4	3	6	7	6	4		0	1	0	33
Annual Total TB Notification Rate (/Lakh/ year)	92	191	203	119	82	523	145	225	151	360	128	224	145	226	74	118	123	29	70	167	159	76	116	186	148	159	114	153	139	197	119	107	44	140	151	100	138.33
Total TB patients Notified	292	83118	3154	40174	96489	5930	41272	963	457	65893	1935	149061	40751	16451	10476	44128	81187	22754	46	134333	192458	2805	3961	2245	3013	71131	1604	45313	105953	1271	93327	39223	1693	311041	16760	97297	1827959
Annual TB Notification Rate Private Sector	9	31	1	10	35	23	37	16	25	28	25	59	24	10	8	19	18	24	0	21	26	37	18	4	36	6	0	21	28	9	24	20	0	30	34	16	29
TB patients notified from Private Sector	22	16044	15	3454	41494	566	10679	70	9/	5121	372	39639	6647	736	1056	7267	11988	8232	0	16750	67558	1114	809	44	729	3969	3	9829	21179	36	12061	7395	8	29699	3748	15088	383784
Annual Notification Rate (Public)	22	130	202	109	47	200	107	209	126	332	103	164	121	216	29	66	105	43	20	146	103	22	86	183	112	150	113	131	111	191	95	87	44	110	117	85	%29
% HIV Positive among Known Status	1%	10%	%0	1%	1%	2%	1%	%0	%0	1%	3%	3%	1%	%0	1%	%0	%8	1%	%0	1%	2%	2%	1%	2%	14%	2%	4%	1%	1%	%0	2%	%9	1%	1%	%0	1%	3%
% known HIV status among treated	82%	94%	38%	45%	41%	%89	%86	%16	%76	41%	%06	95%	%99	83%	45%	%19	%92	36%	%0	23%	21.6	47%	25%	%44	26%	28%	%62	%69	%98	%92	71%	74%	22%	26%	47%	28%	%29
% Paediatric TB	2%	3%	19%	2%	%8	%6	2%	%9	%9	14%	4%	%9	%9	%9	%2	4%	2%	2%	17%	%6	%9	4%	%2	12%	%8	2%	3%	%9	4%	%9	3%	3%	2%	%9	2%	4%	%9
% Clinically Diagnosed	25%	34%	46%	45%	35%	48%	46%	22%	%99	22%	45%	38%	32%	33%	43%	36%	36%	35%	42%	47%	43%	%9€	46%	%59	45%	%8E	32%	38%	44%	45%	34%	33%	41%	36%	44%	%EE	39%
% Micro- biologically confirmed	48%	%99	54%	25%	%59	52%	54%	45%	34%	43%	22%	62%	%89	%29	22%	64%	64%	%59	28%	53%	22%	64%	54%	35%	22%	62%	%89	62%	26%	25%	%99	%29	26%	%4%	26%	%29	%19
% Previously Treated TB Patients	13%	16%	12%	11%	10%	12%	10%	%6	10%	14%	12%	19%	17%	17%	14%	11%	15%	%8	3%	12%	14%	13%	10%	%6	16%	12%	13%	17%	22%	10%	15%	19%	11%	14%	22%	12%	15%
% New TB Patients	87%	84%	%88	%68	%06	%88	%06	91%	%06	%98	%88	81%	83%	83%	%98	%68	85%	%76	%26	%88	%98	%28	%06	%16	84%	%88	%28	83%	%82	%06	85%	81%	%68	%98	%82	%88	85%
% Extra Pulmonary TB	34%	11%	34%	19%	%4	36%	13%	36%	16%	42%	31%	16%	20%	24%	30%	%9	16%	73%	762	14%	24%	22%	762	43%	22%	20%	28%	24%	16%	34%	17%	14%	18%	14%	20%	21%	18%
% Pulmonary TB	%99	%68	%99	81%	%26	%19	%28	64%	84%	28%	%69	84%	%08	%92	%02	94%	84%	77%	71%	%98	%92	%82	71%	22%	28%	%08	72%	%92	84%	%99	83%	%98	82%	%98	%08	%62	82%
% Initiated on Treatment	100%	%86	%62	%98	72%	%6€	%86	26%	%//6	%/8	%12	%2%	84%	54%	%92	%68	22%	72%	83%	84%	74%	%12	%89	%62	%98	%76	%98	%44	%83%	%19	%12	72%	%£8	74%	%98	%16	%62
Treatment	270	62282	2468	31518	39689	2231	28473	503	370	53027	1115	92844	28594	8487	7143	32756	39106	10411	38	98449	92131	1198	2294	1741	1967	62968	1376	29901	70073	754	52989	22897	1396	180082	11209	75105	1147855
TB patients notified from Public sector	270	67074	3139	36720	54995	5664	30593	893	381	60772	1563	109422	34104	15715	9420	36861	66169	14522	46	117583	124900	1691	3353	2201	2284	67162	1601	38977	84774	1232	74256	31828	1685	244074	13012	82209	1444175
Population in Lakhs	4	515	16	338	1178	11	285	4	3	183	15	999	281	73	141	373	099	341	1	804	1213	30	34	12	20	449	14	297	761	9	783	368	39	2215	111	971	13215
State Name	Andaman and Nicobar	Andhra Pradesh	Arunachal Pradesh	Assam	Bihar	Chandigarh	Chhattisgarh	Dadra and Nagar Haveli	Daman and Diu	Delhi	Goa	Gujarat	Haryana	Himachal Pradesh	Jammu and Kashmir	Jharkhand	Karnataka	Kerala	Lakshadweep	Madhya Pradesh	Maharashtra	Manipur	Meghalaya	Mizoram	Nagaland	Odisha	Puducherry	Punjab	Rajasthan	Sikkim	Tamil Nadu	Telangana	Tripura	Uttar Pradesh	Uttarakhand	West bengal	Grand Total

# Annexure 1b): District wise TB Case Notification 2017

al  -  -   n																		
Annual Total Notifi- cation Rate	147	145	203	135	183	142	189	150	199	120	166	166	164	68	171	22	83	132
Total Notifi- cation	6270	9679	9109	7229	9340	9899	7981	4635	7023	3378	7411	4047	8129	96	64	133	138	92
Private Sector Notifi- cation Rate	25	41	57	19	42	26	46	24	41	6	36	13	17	0	0	6	0	0
Private Sector Notifi- cation	1070	1796	1726	1036	2166	1239	1921	737	1437	245	1629	325	717	0	0	22	0	0
Notifi- cation Rate (Public)	122	103	146	115	141	115	144	126	158	111	129	152	146	68	171	46	83	132
HIV Status Positive % (of Known)	%6	%8	%6	11%	12%	13%	%8	%8	12%	%8	%8	%9	13%	1%	%0	1%	%0	%0
HIV Status Known %	%26	%26	%28	94%	%68	%66	%96	%66	%26	%66	%96	%66	%98	%68	%62	84%	79%	72%
Paedi- atric TB %	2%	7%	3%	4%	3%	2%	2%	2%	3%	3%	2%	2%	7%	%8	3%	2%	%9	%6
Clin- ically Diag- nosed	35%	%61	24%	31%	32%	38%	37%	31%	43%	32%	36%	42%	%0E	23%	%09	20%	30%	17%
Micro- biolog- ically Con- firmed %	%59	81%	%92	%69	%89	62%	%89	%69	22%	%89	64%	28%	%02	47%	40%	20%	%02	83%
Previ- ously Treat- ed %	16%	15%	17%	12%	16%	15%	15%	19%	18%	12%	12%	14%	20%	18%	11%	%9	15%	13%
% New TB Patients	84%	%28	83%	%88	84%	85%	85%	81%	82%	%88	%88	%98	%08	82%	%68	94%	85%	%88
Extra Pul- mo- nary TB %	10%	12%	10%	14%	14%	16%	10%	%6	10%	%8	21%	17%	%8	25%	40%	39%	18%	%9
Pul- mo- nary TB %	%06	%88	%06	%98	%98	84%	%06	91%	%06	%76	%62	83%	%76	75%	%09	61%	82%	94%
Treat- ment Initiat- ed %	95%	%66	92%	93%	%56	%66	%66	%86	%26	%26	%98	%66	%02	100%	100%	100%	%88	78%
Treat- ment Initiat- ed	4781	4460	4047	5775	6785	5382	5983	3829	5399	2982	4980	3702	4177	92	49	111	121	72
Public Sector Notifi- cation	5200	4499	4379	6193	7174	5447	0909	3898	5586	3133	5782	3722	6001	92	29	111	138	92
Total Pop- ulation	4257381	4348249	3007487	5371152	5097651	4722074	4219102	3092522	3537393	2814545	4470909	2442741	4102516	107329	37444	241618	166228	69585
District Name	Anantapur	Chittoor	Cuddapah	East Godavari	Guntur	Krishna	Kurnool	Nellore	Prakasam	Srikakulam	Visakhapatnam	Vizianagaram	West Godavari	Nicobars	North & Middle Andaman	South Andaman	Changlang	Dibang Valley
State Name	Andhra Pradesh	Andaman and Nicobar	Andaman and Nicobar	Andaman and Nicobar	Arunachal Pradesh	Arunachal Pradesh												

State Name	District Name	Total Pop- ulation	Public Sector Notifi- cation	Treat- ment Initiat- ed	Treat- ment Initiat- ed %	Pul- mo- nary TB %	Extra Pul- mo- nary TB %	% New TB Patients	Previ- ously Treat- ed %	Micro- biolog- ically Con- firmed	Clin- ically Diag- nosed	Paedi- atric TB %	HIV Status Known %	HIV Status Positive % (of Known)	Notifi- cation Rate (Public)	Private Sector Notifi- cation	Private Sector Notifi- cation Rate	Total Notifi- cation	Annual Total Notifi- cation Rate
Arunachal Pradesh	East Kameng	88100	380	354	%86	%59	35%	%06	10%	29%	71%	39%	51%	%0	431	0	0	380	431
Arunachal Pradesh	East Siang	111251	203	165	81%	81%	19%	82%	18%	%29	33%	11%	28%	%0	182	0	0	203	182
Arunachal Pradesh	Kurung Kumey	100800	59	28	%86	%82	22%	84%	16%	53%	47%	29%	%0		59	0	0	59	59
Arunachal Pradesh	Lohit	187211	09	43	72%	%88	12%	%02	30%	77%	23%	2%	%0		32	0	0	09	32
Arunachal Pradesh	Lower Subansiri	93072	06	63	%02	%89	37%	95%	%8	26%	44%	21%	48%	%0	26	0	0	06	26
Arunachal Pradesh	Papumpare	198175	1461	1020	%02	%09	40%	%88	12%	51%	49%	17%	31%	%0	737	15	∞	1476	745
Arunachal Pradesh	Tawang	56121	42	37	%88	%29	35%	%26	3%	22%	43%	14%	30%	%0	75	0	0	42	75
Arunachal Pradesh	Tirap	125832	310	287	%86	21%	49%	%26	3%	48%	52%	22%	63%	%0	246	0	0	310	246
Arunachal Pradesh	Upper Siang	39648	11	0	%0										28	0	0	11	28
Arunachal Pradesh	Upper Subansiri	93484	72	20	%69	72%	28%	%08	20%	%29	38%	11%	%0		77	0	0	72	73
Arunachal Pradesh	West Kameng	97762	62	75	%26	%62	21%	84%	16%	71%	29%	16%	27%	%0	81	0	0	79	81
Arunachal Pradesh	West Siang	126141	142	123	%28	72%	28%	%28	13%	81%	19%	15%	28%	%0	113	0	0	142	113
Assam	Baksa	1004991	795	315	40%	84%	16%	%88	12%	61%	39%	3%	0%		62	1	0	962	79
Assam	Barpeta	1764727	820	530	%29	95%	%8	%62	21%	%92	24%	3%	%0		46	22	1	842	48
Assam	Bongaigaon	26296	823	633	77%	84%	16%	%88	12%	%16	%6	2%	84%	%0	107	113	15	936	122
Assam	Cachar	1880342	2221	2067	93%	%02	30%	%46	%9	40%	%09	2%	44%	2%	118	71	4	2292	122
Assam	Chirang	533863	377	325	%98	%68	11%	%76	%8	%09	40%	3%	24%	%0	71	42	8	419	78
Assam	Darrang	983451	229	594	%88	82%	18%	%06	10%	20%	20%	3%	88%	%0	69	101	10	2778	26
Assam	Dhemaji	745198	800	772	%26	74%	79%	%76	%8	27%	43%	2%	62%	%0	107	106	14	906	122
Assam	Dhubri	2110256	2290	2172	%26	%26	3%	%88	12%	54%	46%	3%	29%	%0	109	17	1	2307	109
Assam	Dibrugarh	1437899	2922	2769	%26	%89	32%	%16	%6	51%	46%	%8	32%	1%	203	377	26	3299	229
Assam	Goalpara	1092682	1275	1217	%26	%98	14%	%28	13%	72%	28%	3%	24%	%0	117	217	20	1492	137
Assam	Golaghat	1146518	1487	1446	%26	%82	22%	94%	%9	44%	%95	2%	61%	%0	130	61	5	1548	135
Assam	Hailakandi	713992	499	457	%76	%82	22%	%28	13%	23%	47%	2%	%89	3%	70	1	0	200	20

Jornat         1181844         1203         1149         96%         75%         25%           Kamrup         1663218         991         334         34%         84%         16%           Kamrup         1663218         991         334         34%         84%         16%           Kamrup Metro         1358877         1026         587         57%         85%         15%           Karingani         1045382         1266         1097         87%         85%         15%           Kokrajhar         975459         1786         1085         98%         81%         19%           Lakhimpur         1126944         1108         1085         98%         81%         19%           Marigaon         1037339         1060         449         42%         8%         17%           Nadagon         1037339         1060         449         42%         8%         17%           Nadagon         10460         878         833         17%         17%           Nagaon         1245690         1314         1125         86%         17%           Sibsagar         1245690         1314         1125         88%         17%	Patients Treat-ed %	ed % firmed %	Con- Diag- iirmed nosed %	atric TB %	Status Known %	Positive % (of Known)	cation Rate (Public)	Sector Notifi- cation	Sector Notifi- cation Rate	Total Notifi- cation	Total Notifi- cation Rate
1 165218         991         334         34%         84%         16%           2 1358877         1026         587         57%         85%         15%           3 1045382         1266         1097         87%         55%         15%           4 1045382         1266         1097         87%         55%         15%           5 1317972         971         920         95%         78%         22%           6 112694         1786         1647         92%         87%         13%           1 112694         1786         1647         92%         87%         13%           1 112694         1786         1647         92%         87%         13%           1 112694         1786         449         42%         87%         13%           1 112694         1786         88%         81%         17%           1 12604         2673         2304         86%         17%           1 1426204         2575         2299         89%         83%         17%           1 1426204         2575         2299         89%         14%         14%           1 1426204         2575         2299         88% <td< td=""><td>90% 10</td><td>10% 48%</td><td>25%</td><td>%2</td><td>83%</td><td>%0</td><td>102</td><td>82</td><td>4</td><td>1281</td><td>108</td></td<>	90% 10	10% 48%	25%	%2	83%	%0	102	82	4	1281	108
0         1358877         1026         587         57%         85%         15%           2         1045382         1266         1097         87%         95%         5%           3         1045382         1266         1097         87%         95%         5%           4         1317972         971         920         95%         78%         22%           1126994         1108         1085         98%         81%         19%           1126994         1108         1085         98%         81%         19%           1126994         1108         1085         98%         81%         19%           1126994         1108         1085         98%         81%         19%           1126994         1108         449         42%         82%         17%           1126909         1106         449         42%         82%         17%           112690         878         833         17%         88%         17%           1146204         2575         2299         89%         87%         14%           1146204         2575         2299         89%         17%         28%	78%   22	22%   52%	48%	3%	3%	%0	09	13	1	1004	09
1045382         1266         1097         87%         95%         5%           1317972         971         920         95%         78%         22%           1317972         971         920         95%         78%         22%           1126994         1786         1647         92%         87%         13%           1126994         1108         1085         98%         81%         19%           1037339         1060         449         42%         92%         8%           1037339         1060         449         42%         92%         8%           1124560         1314         1125         86%         8%         17%           2085721         3369         2995         89%         87%         17%           1426204         2575         2299         89%         87%         17%           1426204         2575         2299         89%         87%         17%           1426204         2575         2299         89%         17%         3%           11         2848804         87         58%         17%         3%           10         23588         29         24%	76% 24	24% 57%	43%	%2	36%	%0	9/	358	56	1384	102
1317972         971         920         95%         78%         22%           975459         1786         1647         92%         87%         13%           112694         1108         1085         98%         81%         13%           112694         1108         1085         98%         81%         13%           1037339         1060         449         42%         92%         8%           112600         878         833         95%         8%         11%           915100         878         833         95%         8%         11%           1245690         1314         1125         86%         75%         25%           142604         2575         2299         89%         77%         28%           142604         2575         2299         89%         77%         28%           117         1037         93%         86%         14%           142604         2795         88%         17%         3%           1426204         2575         2299         89%         17%         3%           11         2383         179         88%         17%         3%      <	90% 10	10% 56%	44%	3%	2%	4%	121	54	rc	1320	126
975459         1786         1647         92%         87%         13%           1126994         1108         1085         98%         81%         19%           1126994         1108         1085         98%         81%         19%           1126994         1108         1085         98%         81%         19%           1126903         2673         2304         86%         89%         11%           915100         878         833         95%         8%         17%           1245690         1314         1125         86%         75%         25%           2085721         3369         2995         89%         72%         28%           1426204         2575         2299         89%         72%         28%           11426204         2575         2299         89%         72%         28%           11426204         2575         2299         89%         72%         28%           11426204         2575         2299         89%         17%         3%           11         2848804         87         52%         28%         18%           12         2848804         87         58	6 %16	%47%	23%	2%	41%	7%	74	0	0	126	74
1126994         1108         1085         98%         81%         19%           1037339         1060         449         42%         92%         8%           3060366         2673         2304         86%         89%         11%           915100         878         833         95%         8%         17%           231309         397         360         91%         78%         23%           1245690         1314         1125         86%         75%         25%           2085721         3369         2995         89%         87%         14%           1426204         2575         2299         89%         87%         14%           101885         1117         1037         93%         86%         14%           101885         1117         1037         93%         86%         14%           11         2848804         877         559         64%         99%         17%           123598         297         258         87%         97%         3%           13351493         1646         1369         83%         17%         444916           1937184         650         166 <td>6 %16</td> <td>9% 45%</td> <td>25%</td> <td>3%</td> <td>%99</td> <td>1%</td> <td>183</td> <td>61</td> <td>9</td> <td>1847</td> <td>189</td>	6 %16	9% 45%	25%	3%	%99	1%	183	61	9	1847	189
1037339         1060         449         42%         92%         8%           3060366         2673         2304         86%         89%         11%           3060366         2673         2304         86%         89%         11%           1245690         1314         1125         86%         75%         25%           1245690         1314         1125         86%         75%         25%           1426204         2575         2299         89%         77%         25%           1426204         2575         2299         89%         77%         28%           1426204         2575         2299         89%         77%         28%           1426204         2575         2299         89%         77%         28%           1426204         2575         2299         89%         77%         28%           1426204         2575         2299         88%         14%           1428804         877         559         64%         99%         1%           2302123         994         540         58%         1%         1%           3439818         2797         2405         86%	87% 13	13% 53%	47%	4%	43%	%0	86	250	22	1358	120
3060366         2673         2304         86%         89%         11%           915100         878         833         95%         83%         17%           231309         397         360         91%         78%         23%           1245690         1314         1125         86%         75%         25%           2085721         3369         2995         89%         77%         28%           1426204         2575         2299         89%         77%         28%           1426204         2575         2299         89%         77%         28%           1426204         2575         2299         89%         77%         28%           1117         1037         93%         86%         14%           12848804         877         559         64%         97%         3%           12848804         877         559         64%         97%         3%           13351493         1646         1369         83%         17%         3%           1937184         650         196         30%         94%         6%           4449162         376         569         15%         4%	84% 16	16% 49%	21%	3%	16%	%0	102	0	0	1060	102
915100         878         833         95%         83%         17%           231309         397         360         91%         78%         23%           1245690         1314         1125         86%         75%         25%           2085721         3369         2995         89%         83%         17%           1426204         2575         2299         89%         72%         25%           901885         1117         1037         93%         86%         14%           1426204         2575         2299         89%         72%         28%           1117         1037         93%         86%         14%           11         2848804         877         559         64%         99%         17%           1232183         1646         1369         83%         17%         8%         2%           1125284         877         559         64%         99%         17%         3%           11         2848804         877         559         64%         98%         17%         3%           1232184         1646         1369         83%         17%         8%         2% <td< td=""><td>87% 13</td><td>13% 58%</td><td>45%</td><td>4%</td><td>%79</td><td>%0</td><td>87</td><td>394</td><td>13</td><td>3067</td><td>100</td></td<>	87% 13	13% 58%	45%	4%	%79	%0	87	394	13	3067	100
231309         397         360         91%         78%         23%           1245690         1314         1125         86%         75%         25%           2085721         3369         2995         89%         77%         25%           1426204         2575         2299         89%         72%         28%           1426204         2575         2299         89%         72%         28%           3183409         2039         1796         88%         97%         3%           11         2848804         877         559         64%         99%         1%           2302123         994         540         54%         98%         2%           3351493         1646         1369         88%         9%         1%           3439818         2797         2405         86%         8%         2%           4449162         3760         569         15%         94%         6%           4968060         2977         2824         95%         4%         6%           2901888         1451         1315         91%         96%         4%           1992130         1404         1152	90% 10	10% 66%	34%	4%	64%	%0	96	114	12	992	108
1245690         1314         1125         86%         75%         25%           2085721         3369         2995         89%         83%         17%           1426204         2575         2299         89%         72%         28%           1426204         2575         2299         89%         72%         28%           1117         1037         93%         86%         14%           3183409         2039         1796         88%         97%         3%           ad-BI         2848804         877         559         64%         99%         1%           r         3351493         1646         1369         88%         92%         8%           r         3351493         1646         1369         88%         1%         1%           r         3439818         2797         2405         86%         8%         2%           ga         1937184         650         196         30%         96%         4%           ga         4449162         3760         569         1%         6%         4%           gi         2901888         1451         135         96%         4%         6%<	86% 14	14% 65%	35%	%8	37%	%0	172	4	2	401	173
2085721         3369         2995         89%         83%         17%           1426204         2575         2299         89%         72%         28%           901885         1117         1037         93%         86%         14%           3183409         2039         1796         88%         97%         3%           ad-BI         793598         297         258         87%         97%         3%           ad-BI         2848804         877         559         64%         99%         1%           i         2302123         994         540         54%         98%         2%           i         3351493         1646         1369         83%         17%         8%           i         3439818         2797         2405         86%         8%         2%           ga         4449162         3760         569         15%         94%         6%           i         2901888         1451         1315         91%         92%         8%           i         2901888         646         641         99%         96%         4%           i         1925288         646         96% <td>88% 12</td> <td>12% 50%</td> <td>20%</td> <td>%9</td> <td>36%</td> <td>%0</td> <td>105</td> <td>35</td> <td>3</td> <td>1349</td> <td>108</td>	88% 12	12% 50%	20%	%9	36%	%0	105	35	3	1349	108
1426204         2575         2299         89%         72%         28%           901885         1117         1037         93%         86%         14%           3183409         2039         1796         88%         97%         3%           ad-BI         793598         297         258         87%         97%         3%           ad-BI         2848804         877         559         64%         99%         1%           r         332123         994         540         54%         99%         1%           r         3439818         2797         2405         86%         8%         2%           r         3439818         2797         2405         86%         8%         2%           ga         1937184         650         196         30%         98%         2%           ga         4449162         3760         569         15%         94%         6%           gi         2901888         1451         1315         91%         96%         4%           d         1992130         1404         1152         82%         96%         4%           d         125288         646	87% 13	13% 68%	32%	%9	35%	%0	162	282	14	3651	175
ad-BI 284804 2039 1796 88% 97% 3% ad-BI 2848804 877 559 64% 99% 1% 2302123 994 540 54% 98% 2% 1% 2302123 994 540 54% 98% 2% 1% 3351493 1646 1369 83% 92% 8% 17% 3439818 2797 2405 86% 83% 17% 38 1937184 650 196 30% 98% 2% 1937184 650 196 30% 98% 2% 1937184 650 196 30% 98% 2% 1937184 650 196 30% 98% 2% 1937184 650 196 30% 98% 2% 1937184 650 196 30% 98% 2% 1937184 650 196 30% 98% 2% 1449162 3760 569 15% 94% 6% 1992130 1404 1152 82% 96% 4% 1% 1275288 646 641 99% 95% 5% 5% 1845588 993 934 94% 95% 5% 5%	89% 11	11% 51%	46%	%8	%69	%0	181	829	46	3233	227
3183409         2039         1796         88%         97%         3%           bad-BI         2848804         877         559         64%         97%         3%           bad-BI         2848804         877         559         64%         99%         1%           ii         2302123         994         540         54%         98%         2%           ir         3351493         1646         1369         83%         92%         8%           ir         3439818         2797         2405         86%         8%         2%           ga         1937184         650         196         30%         98%         2%           ga         4449162         3760         569         15%         94%         6%           ij         2901888         1451         1315         91%         92%         8%           d         1992130         1404         1152         82%         96%         4%           d         1275288         646         641         99%         95%         5%           d         1845588         933         934         94%         95%         5%	92% 8	8% 42%	28%	4%	19%	%0	124	24	3	1141	127
bad-BI         793598         297         258         87%         97%         3%           bad-BI         2848804         877         559         64%         99%         1%           ii         2302123         994         540         54%         99%         1%           ir         3439818         1646         1369         88%         2%         8%           ir         3439818         2797         2405         86%         83%         17%           ga         1937184         650         196         30%         98%         2%           ga         4449162         3760         569         15%         94%         6%           nj         2901888         1451         1315         91%         92%         4%           d         1992130         1404         1152         82%         96%         4%           d         1275288         646         641         99%         95%         5%           d         1275288         93         934         94%         95%         5%	82 %26	3% 45%	22%	21%	%0		64	1050	33	3089	26
bad-BI         2848804         877         559         64%         99%         1%           i         3351493         1646         1369         83%         92%         2%           ir         3439818         2797         2405         86%         83%         17%           ga         1937184         650         196         30%         94%         6%           ga         4449162         3760         569         15%         94%         6%           ij         2901888         1451         1315         91%         95%         4%           d         1992130         1404         1152         82%         96%         4%           d         1275288         646         641         99%         95%         5%           d         1275288         93         934         94%         95%         5%	90% 10	10% 60%	40%	%2	75%	%0	37	87	11	384	48
ii         2302123         994         540         54%         98%         2%           ii         3351493         1646         1369         83%         92%         8%           ir         3439818         2797         2405         86%         83%         17%           ga         1937184         650         196         30%         98%         2%           ga         4449162         3760         569         15%         94%         6%           ij         2901888         1451         1315         91%         92%         4%           d         1992130         1404         1152         82%         96%         4%           d         1275288         646         641         99%         95%         5%           1845588         993         934         94%         95%         5%	77% 23	23%   93%	%2	4%	64%	1%	31	438	15	1315	46
ii 3351493 1646 1369 83% 92% 8% 8% 8% 17% 2405 86% 83% 17% 2405 86% 83% 17% 2405 86% 83% 17% 2405 86% 83% 17% 2405 86% 83% 17% 2405 86% 2449162 3760 569 15% 94% 6% 1449162 3760 569 15% 94% 6% 1449162 277 2824 95% 96% 4% 1152 2901888 1451 1315 91% 92% 8% 4% 4% 1152288 646 641 99% 95% 5% 5% 1845588 993 934 94% 95% 5% 5%	82% 18	18% 52%	48%	%9	%97	1%	43	64	3	1058	46
Ir         3439818         2797         2405         86%         83%         17%           3085798         1173         838         71%         98%         2%           ga         1937184         650         196         30%         98%         2%           ga         4449162         3760         569         15%         94%         6%           nj         2901888         1451         1315         91%         92%         4%           d         1992130         1404         1152         82%         96%         4%           d         1275288         646         641         99%         95%         5%           1845588         993         934         94%         95%         5%	89% 11	11% 52%	48%	11%	71%	1%	49	336	10	1982	26
ga     1085798     1173     838     71%     98%     2%       ga     4449162     3760     569     15%     94%     6%       ri     2901888     1451     1152     95%     96%     4%       ri     2901888     1451     1152     82%     96%     4%       d     1275288     646     641     99%     95%     5%       1845588     993     934     94%     95%     5%	92% 8	8% 53%	47%	14%	%29	%0	81	1045	30	3842	112
nga 4449162 3760 569 15% 94% 6% 2% 1449162 3760 569 15% 94% 6% 15% 201888 1451 1315 91% 95% 4% 192130 1404 1152 82% 96% 4% ad 1275288 646 641 99% 95% 5% 1845588 993 934 94% 95% 5% 5%	93% 7	%68   %2	11%	%2	23%	2%	38	287	56	1960	64
aga     4449162     3760     569     15%     94%     6%       nij     2968060     2977     2824     95%     96%     4%       nij     2901888     1451     1315     91%     92%     8%       ad     1275288     646     641     99%     95%     5%       1845588     993     934     94%     95%     5%	79% 21	21%   96%	4%	%9	%0		34	1	0	651	34
mj     2968060     2977     2824     95%     96%     4%       mj     2901888     1451     1315     91%     92%     8%       n     1992130     1404     1152     82%     96%     4%       ad     1275288     646     641     99%     95%     5%       1845588     993     934     94%     95%     5%	84% 16	16% 86%	14%	10%	%28	%0	85	268	20	4657	105
nrj     2901888     1451     1315     91%     92%     8%       1992130     1404     1152     82%     96%     4%       ad     12/5288     646     641     99%     95%     5%       1845588     993     934     94%     95%     5%	93% 7	26%	44%	%8	41%	1%	09	1969	40	4946	100
ad 1275288 646 641 99% 95% 5% 182 1845588 993 934 94% 95% 5%	8 %76	%29 %8	33%	%2	%88	%0	50	1274	44	2725	94
ad 1275288 646 641 99% 95% 5% 1845588 993 934 94% 95% 5%	94% 6	6% 61%	39%	2%	1%	%0	20	116	9	1520	92
1845588 993 934 94% 95% 5%	6 %16	%99 %6	34%	%8	%2	2%	51	218	17	864	89
	89% 11	11% 63%	37%	%9	1%	%0	54	102	9	1095	59
Katihar 3480570 2122 1834 86% 96% 4%	88% 12	12% 84%	16%	%9	%44	2%	61	116	3	2238	64

District Name	Total Pop- ulation	Public Sector Notifi- cation	Treat- ment Initiat- ed	Treat- ment Initiat- ed %	Pul- mo- nary TB %	Extra Pul- mo- nary TB %	% New TB Patients	Previ- ously Treat- ed %	Micro- biolog- ically Con- firmed	Clin- ically Diag- nosed	Paedi- atric TB %	HIV Status Known %	HIV Status Positive % (of Known)	Notifi- cation Rate (Public)	Private Sector Notifi- cation	Private Sector Notifi- cation Rate	Total Notifi- cation	Annual Total Notifi- cation Rate
Khagaria	1880413	794	628	%62	%86	%2	%76	%8	%82	22%	%6	48%	%0	42	536	29	1330	71
Kishanganj	1918245	603	160	27%	%76	%8	94%	%9	72%	28%	2%	12%	11%	31	536	28	1139	59
Lakhisarai	1135233	493	464	94%	%88	12%	84%	16%	36%	61%	%9	%8	%0	43	140	12	633	26
Madhepura	2262735	726	544	75%	%26	3%	82%	18%	84%	16%	2%	%99	%0	32	115	5	841	37
Madhubani	5077714	623	149	24%	%16	%6	%68	11%	74%	79%	4%	76%	3%	12	8	0	631	12
Munger	1541738	1360	1304	%96	%28	13%	%06	10%	21%	46%	%6	26%	%0	88	165	11	1525	66
Muzaffarpur	5420951	1695	1294	%92	%46	%9	%86	2%	%89	37%	%9	%29	%0	31	449	8	2144	40
Nalanda	3258648	1209	1143	%26	%76	%8	95%	%8	72%	28%	2%	54%	1%	37	332	10	1541	47
Nawada	2514615	1186	362	81%	%86	7%	%88	12%	81%	19%	4%	48%	%0	47	1268	20	2454	86
Pashchim Cham- paran	4450080	1673	264	16%	%96	4%	83%	17%	82%	18%	2%	42%	%0	38	575	13	2248	51
	6548784	2222	1110	20%	%98	14%	85%	15%	25%	45%	10%	%6	2%	34	19015	290	21237	324
Purba Cham- paran	5766107	1970	1328	%29	94%	%9	%86	2%	%09	40%	2%	20%	1%	34	1075	19	3045	53
Purnia	3713101	2447	2250	%76	%46	%9	%26	2%	%02	30%	%2	23%	%0	99	179	2	2626	71
Rohtas	3360825	1499	1328	%68	%86	2%	84%	16%	%92	24%	2%	%0		45	249	7	1748	52
Saharsa	2152110	510	431	85%	%66	1%	93%	%/	74%	%97	2%	35%	%0	24	260	56	1070	20
Samastipur	4826710	2655	1990	75%	85%	15%	%76	%8	64%	36%	%6	4%	1%	55	1981	41	4636	96
	4473129	3050	2211	72%	%68	11%	%28	13%	%67	21%	%9	%44	%0	89	1803	40	4853	108
Sheikhpura	720274	280	174	%29	%86	%2	83%	17%	23%	47%	%9	2%	%0	39	221	31	501	70
Sheohar	745219	275	230	84%	%06	10%	82%	18%	71%	762	4%	%68	%0	37	2	0	277	37
Sitamarhi	3879288	2212	1517	%69	%86	%2	%46	%9	%83%	17%	%2	73%	1%	57	568	15	2780	72
Siwan	3764205	2118	1922	91%	%96	4%	83%	17%	64%	%98	2%	14%	1%	26	1881	95	3999	106
Supaul	2527938	764	099	%98	%26	3%	%16	%6	73%	27%	2%	%09	%0	30	214	8	8/6	39
Vaishali	0805968	805	396	46%	%56	2%	83%	17%	74%	%97	%9	23%	%0	20	1122	28	1927	49
Chandigarh	1133639	5664	2231	36%	%19	39%	%88	12%	25%	48%	%6	%89	2%	200	266	23	5930	523
Balarampur	798881	886	937	%26	%26	2%	95%	%8	38%	%29	4%	%26	%0	124	25	3	1013	127
Balod	976668	1961	937	%86	%28	15%	%16	%6	36%	61%	3%	81%	%0	107	91	10	1052	117
Baloda Bazar	1557466	1679	1605	%96	%06	10%	%16	%6	21%	46%	%9	%66	1%	108	319	20	1998	128
Bastar	821806	1206	868	74%	%22	23%	%88	12%	51%	46%	4%	93%	%0	133	133	15	1339	147
Bemetara	508998	969	969	100%	%68	11%	%28	13%	23%	47%	2%	%66	1%	80	60	7	756	87
Chhattisgarh Bijapur	263143	1051	1050	100%	%06	10%	%98	14%	53%	47%	%9	%88	13%	399	18	7	1069	406

Annual Total Notifi- cation Rate	66	.1	00	92	7	os.	2	9	31	9;	35	- 8 8	1,5	83	33	<u>0</u>	12	6	30	6	34	.55	7.	ıc	74		4
7	239	171	190	146	117	88	85	98	131	126	135	108	132	153	183	140	112	109	130	69	134	225	177	25	274	297	454
Total Notifi- cation	5550	1441	3560	1043	2116	800	863	544	1723	873	1533	006	201	2474	4725	2353	1029	319	335	298	1065	896	421	36	1659	1802	3209
Private Sector Notifi- cation Rate	86	62	28	4	28	0	6	1	35	24	20	13	0	18	107	35	41	10	3	1	15	16	32	0	7	4	54
Private Sector Notifi- cation	2274	520	1471	31	206	0	88	9	461	164	224	109	0	292	2763	581	378	30	6	8	118	70	92	0	43	25	379
Notifi- cation Rate (Public)	141	109	111	142	68	88	76	85	96	103	116	95	132	135	92	105	71	66	126	89	119	209	145	55	267	293	400
HIV Status Positive % (of Known)	1%	1%	4%	%0	%0	%0	2%	%0	1%	1%	%0	1%	%0	%0	1%	3%	%0	1%	%0	%0	%0	%0	%0	%0	1%	1%	1%
HIV Status Known %	%26	%68	%76	%86	85%	93%	%66	%08	%76	%06	94%	%86	94%	%26	%76	%26	%44	100%	%26	87%	%96	%16	%26	36%	%82	48%	22%
Paedi- atric TB %	%9	3%	%/	2%	4%	3%	4%	4%	%9	%9	%9	3%	2%	2%	4%	4%	2%	3%	%9	2%	3%	%9	2%	14%	11%	14%	12%
Clin- ically Diag- nosed	51%	51%	47%	47%	54%	%95	39%	43%	47%	49%	79%	41%	51%	42%	40%	29%	22%	54%	44%	64%	43%	55%	%89	48%	51%	39%	62%
Micro- biolog- ically Con- firmed %	49%	%67	23%	23%	46%	44%	61%	22%	23%	21%	74%	%69	46%	28%	%09	71%	43%	46%	%95	36%	22%	45%	32%	52%	46%	61%	38%
Previ- ously Treat- ed %	%8	%8	12%	12%	%6	%8	12%	%6	%6	11%	11%	%9	%8	%6	15%	12%	12%	10%	17%	11%	%6	%6	%6	21%	16%	13%	13%
% New TB Patients	%76	%76	%88	%88	91%	%76	%88	%16	%16	%68	%68	%56	%76	91%	%28	%88	%88	%06	83%	%68	91%	91%	%16	%62	84%	%28	%28
Extra Pul- mo- nary TB %	17%	11%	25%	%9	14%	2%	4%	%8	17%	%8	%8	15%	18%	%8	21%	16%	2%	13%	11%	2%	10%	%98	16%	21%	41%	35%	44%
Pul- mo- nary TB %	83%	%68	75%	%76	%98	%26	%96	%76	%83%	%76	%76	%28	%78	%76	%62	84%	%26	%28	%68	%26	%06	64%	84%	%62	%69	%29	%95
Treat- ment Initiat- ed %	%26	%86	87%	%66	%68	%22	%86	%58	%76	%26	%86	%66	71%	%26	91%	%66	91%	100%	%99	88%	94%	%95	%86	95%	%88	%82	94%
Treat- ment Initiat- ed	3186	905	1813	1004	1434	618	757	458	1166	069	1287	782	143	2081	1784	1748	290	289	215	517	887	503	337	33	1416	1393	2672
Public Sector Notifi- cation	3276	921	5089	1012	1610	800	775	538	1262	602	1309	791	201	2182	1962	1772	651	289	326	290	947	893	345	36	1616	1777	2830
Total Pop- ulation	2321989	842053	1875683	713089	1805574	904163	1015686	630022	1316447	690437	1132020	830490	152190	1618528	2578242	1682318	919028	292267	257913	863470	797258	427881	238187	64966	605962	605962	706956
District Name	Bilaspur-CG	Dhamtari	Durg	Gariyaband	Janjgir	Jashpur	Kabirdham (Kawardha)	Kondagaon	Korba	Koriya	Chhattisgarh Mahasamund	Mungeli	Narayanpur	Raigarh-CG	Raipur	Rajnandgaon	Sarguja	South Bastar Dantewada	Sukma	Surajpur	Uttar Bastar Kanker	Dadra & Nagar Haveli	Daman	Diu	Bijwasan	BJRM Chest Clinic	BSA Chest Clinic
State Name	Chhattisgarh Bilaspur-CG	Chhattisgarh Dhamtari	Chhattisgarh	Chhattisgarh	Chhattisgarh	Chhattisgarh	Chhattisgarh	Chhattisgarh	Chhattisgarh	Chhattisgarh	Chhattisgarh	Chhattisgarh Mungeli	Chhattisgarh Narayanpur	Chhattisgarh Raigarh-CG	Chhattisgarh Raipur	Chhattisgarh Rajnandgaon	Chhattisgarh	Chhattisgarh	Chhattisgarh	Chhattisgarh	Chhattisgarh	Dadra and Dadra Nagar Haveli Haveli	Daman and Diu	Daman and Diu	Delhi	Delhi	Delhi

Annual Total Notifi- cation Rate	309	263	375	569	289	332	526	279	512	469	378	340	296	477	351	306	429	290	347	484	257	443	155	94	268	290	119
Total Notifi- cation	2187	3314	2462	950	876	1342	4253	2256	1809	3549	2862	3781	2090	4821	5310	4018	1516	2048	2452	2931	1038	3358	1313	622	4352	17838	1967
Private Sector Notifi- cation Rate	16	12	5	13	9	27	55	6	85	108	40	28	0	18	19	12	258	15	3	23	6	15	26	22	48	64	30
Private Sector Notifi- cation	116	150	30	47	19	108	445	69	300	815	301	311	2	177	294	159	911	105	20	142	36	117	225	147	771	3949	501
Notifi- cation Rate (Public)	293	251	370	255	283	305	471	271	427	361	338	312	295	460	331	294	171	275	344	460	248	428	128	71	221	226	88
HIV Status Positive % (of Known)	1%	%0	1%	2%	%0	1%	3%	2%	2%	2%	1%	1%	1%	1%	2%	%0	1%	2%	1%		3%	1%	4%	2%	4%	4%	2%
HIV Status Known %	25%	28%	71%	84%	1%	77%	12%	27%	%69	72%	26%	44%	84%	%02	1%	18%	53%	26%	21%	%0	%89	19%	%76	%98	93%	%76	%26
Paedi- atric TB %	14%	14%	13%	12%	11%	14%	15%	12%	12%	%6	12%	14%	12%	15%	14%	15%	12%	10%	15%	14%	13%	18%	4%	4%	%/	2%	2%
Clin- ically Diag- nosed	25%	27%	61%	53%	41%	52%	%89	22%	51%	39%	54%	61%	53%	53%	64%	61%	38%	48%	%29	64%	29%	%89	47%	41%	45%	50%	28%
Micro- biolog- ically Con- firmed %	45%	43%	39%	47%	26%	48%	37%	43%	49%	61%	46%	39%	47%	47%	36%	39%	%59	52%	33%	36%	41%	37%	23%	29%	25%	%09	72%
Previ- ously Treat- ed %	15%	16%	14%	14%	15%	21%	12%	11%	20%	18%	13%	13%	12%	16%	13%	12%	20%	15%	11%	15%	20%	19%	12%	12%	17%	18%	15%
% New TB Patients	85%	84%	%98	%98	%28	%62	%88	%68	%08	82%	%28	%28	%88	84%	%28	%88	%08	85%	%68	85%	%08	81%	%88	%88	83%	82%	%28
Extra Pul- mo- nary TB %	39%	48%	40%	44%	45%	42%	47%	38%	42%	32%	39%	41%	34%	41%	44%	43%	34%	37%	43%	43%	41%	25%	33%	28%	21%	29%	13%
Pul- mo- nary TB %	%19	25%	%09	%95	25%	%89	23%	%29	%89	%89	61%	%69	%99	26%	%95	22%	%99	%89	27%	22%	26%	45%	%29	72%	%62	71%	87%
Treat- ment Initiat- ed %	%56	62%	%26	%96	%26	%26	%66	85%	61%	81%	93%	100%	%26	22%	94%	%98	%86	%26	73%	%26	%66	%26	%99	84%	64%	72%	%68
Treat- ment Initiat- ed	1975	1963	2363	867	835	1172	3756	1865	920	2208	2375	3459	2030	2632	4736	3335	592	1841	1777	2712	995	3138	714	401	2288	9935	1309
Public Sector Notifi- cation	2071	3164	2432	903	857	1234	3808	2187	1509	2734	2561	3470	2088	4644	5016	3859	605	1943	2432	2789	1002	3241	1088	475	3581	13889	1466
Total Pop- ulation	706956	1262422	626459	353478	302981	403975	807950	807950	353478	757453	757453	1110931	206956	1009937	1514906	1312918	353478	706956	706956	605962	403975	757453	849085	664476	1621214	6157606	1658844
District Name	CD Chest Clinic	DDU Chest Clinic	GTB Chest Clinic	Gulabi Bagh	Hedgewar Chest Clinic	Jhandewalan	Karawal Nagar	Kingsway	LN Chest Clinic	LRS	MNCH Chest Clinic	Moti Nagar	Narela	NDMC	Nehru Nagar	Patparganj	RK Mission	RTRM Chest Clinic	SGM Chest Clinic	Shahadra	SPM Marg	SPMH Chest Clinic	North Goa	South Goa	Ahmadabad	Ahmadabad MC	Amreli
State Name	Delhi	Delhi	Delhi	Delhi	Delhi	Delhi	Delhi	Delhi	Delhi	Delhi	Delhi	Delhi	Delhi	Delhi	Delhi	Delhi	Delhi	Delhi	Delhi	Delhi	Delhi	Delhi	Goa	Goa	Gujarat	Gujarat	Gujarat

State Name	District Name	Total Pop- ulation	Public Sector Notifi- cation	Treat- ment Initiat- ed	Treat- ment Initiat- ed %	Pul- mo- nary TB %	Extra Pul- mo- nary TB %	% New TB Patients	Previ- 14 ously Treat- ed % 1	Micro- biolog- ically Con- firmed	Clin- ically Diag- nosed	Paedi- atric TB %	HIV Status Known %	HIV Status Positive % (of Known)	Notifi- cation Rate (Public)	Private Sector Notifi- cation	Private Sector Notifi- cation Rate	Total Notifi- cation	Annual Total Notifi- cation Rate
Gujarat	Anand	2307087	3570	3174	%68	%88	12%	%62	21%	%69	31%	3%	%88	1%	155	1237	54	4807	208
Gujarat	Arvalli	1125210	2005	1786	%68	%86	2%	%82	22%	%59	35%	3%	%96	2%	178	899	80	2904	258
Gujarat	Banaskantha	3440113	5486	4331	%64	%76	%8	82%	18%	28%	45%	4%	%76	3%	159	1945	22	7431	216
Gujarat	Bharuch	1709877	2646	2313	%28	%98	14%	%83%	17%	%69	31%	4%	%26	2%	155	775	45	3421	200
Gujarat	Bhavnagar	2659228	3455	2878	83%	85%	15%	%92	24%	%92	24%	%9	%88	3%	130	1376	52	4831	182
Gujarat	Botad	711278	612	574	94%	%28	13%	%82	22%	%89	32%	4%	91%	1%	98	196	28	808	114
Gujarat	Chhota Udepur	1181609	1434	1328	%86	%26	3%	%62	21%	%28	13%	2%	%28	1%	121	253	21	1687	143
Gujarat	Dahod	2344945	5748	5139	%68	%16	%6	%62	21%	64%	%9£	%6	%98	2%	245	1711	73	7459	318
Gujarat	Devbhumi dwarka	829555	544	531	98%	%76	%8	%92	24%	71%	29%	3%	%66	2%	66	122	15	999	80
Gujarat	Gandhinagar	1524770	2592	2073	%08	%62	21%	84%	16%	%09	20%	%9	93%	%9	170	1262	83	3854	253
Gujarat	Gir Somnath	1334756	1501	1478	%86	%88	12%	81%	19%	%99	34%	2%	%96	%0	112	481	36	1982	148
Gujarat	Jamnagar	1528196	2031	1813	%68	%82	22%	%08	20%	%99	34%	%9	%26	1%	133	494	32	2525	165
Gujarat	Junagadh	1679696	1578	1449	%76	%62	21%	83%	17%	%89	37%	2%	%16	%9	94	647	39	2225	132
Gujarat	Kachchh	2306675	3020	2959	%86	%£8	17%	82%	18%	%09	40%	2%	%66	2%	131	1023	44	4043	175
Gujarat	Kheda	2264119	3238	2846	%88	%£6	%2	%62	21%	%02	30%	3%	%26	1%	143	1580	70	4818	213
Gujarat	Mahesana	2253026	4740	3966	84%	%28	13%	%82	22%	%98	64%	4%	%02	2%	210	3703	164	8443	375
Gujarat	Mahisagar	1096495	2219	2124	%96	%96	4%	%92	24%	%82	22%	2%	%86	1%	202	914	83	3133	286
Gujarat	Morbi	1064143	927	844	91%	%28	13%	%82	22%	%44	23%	2%	%86	1%	87	900	85	1827	172
Gujarat	Narmada	650756	1055	924	88%	%76	%8	82%	18%	73%	27%	3%	%66	%0	162	634	97	1689	260
Gujarat	Navsari	1465859	1890	1821	%96	%82	22%	%28	18%	%79	38%	4%	%86	2%	129	429	29	2319	158
Gujarat	Panch Mahals	1810471	3702	3536	%96	%86	2%	73%	27%	74%	76%	%9	%66	2%	204	1207	67	4906	271
Gujarat	Patan	1481361	2607	2043	%82	%88	12%	%92	24%	%19	36%	3%	%96	%8	176	1772	120	4379	296
Gujarat	Porbandar	644590	699	648	%26	85%	15%	83%	17%	22%	43%	2%	%66	%9	104	286	44	955	148
Gujarat	Rajkot	3336968	4512	3828	85%	%82	22%	83%	17%	26%	41%	2%	%26	4%	135	2023	61	6535	196
Gujarat	Sabarkantha	1552119	2448	2072	85%	%16	%6	%08	20%	26%	41%	3%	%26	2%	158	1452	94	3900	251
Gujarat	Surat	1778785	4655	4079	%88	%62	21%	83%	17%	%89	37%	2%	94%	2%	262	795	45	5450	306
Gujarat	Surat Municipal Corp	4925395	6547	5822	%68	74%	26%	83%	17%	27%	43%	2%	%86	3%	133	2933	60	9480	192
Gujarat	Surendranagar	1752873	2561	2271	%68	91%	%6	22%	23%	74%	%97	4%	%26	%9	146	901	51	3462	198
Gujarat	The Dangs	251673	318	289	91%	82%	18%	84%	16%	%09	40%	%8	%86	%0	126	0	0	318	126
Gujarat	Vadodara	1478815	4726	3947	84%	%98	14%	%28	13%	26%	44%	%8	%98	2%	320	140	6	4866	329

				_																								
Annual Total Notifi- cation Rate	278	158	163	187	161	228	139	108	129	140	137	113	162	147	122	114	119	176	166	112	128	147	140	127	146	224	186	256
Total Notifi- cation	5368	2964	1446	2360	2908	4547	1455	1810	2493	1489	8707	1350	2706	1572	1248	1376	1377	1094	2217	1115	1499	2107	2293	1707	263	1235	668	4094
Private Sector Notifi- cation Rate	85	34	7	29	48	62	18	43	23	3	20	16	21	21	14	1	6	3	12	25	17	31	16	11	4	1	5	8
Private Sector Notifi- cation	1636	631	61	363	863	1242	191	717	451	27	596	187	357	222	141	13	104	16	164	244	203	448	255	143	15	5	22	127
Notifi- cation Rate (Public)	193	124	156	158	113	166	121	99	106	138	117	86	141	126	108	113	110	174	154	88	110	115	124	116	142	223	182	248
HIV Status Positive % (of Known)	4%	4%	2%	1%	1%	1%	1%	%0	%0	%0	%0	1%	%0	1%	3%	%0	1%	%0	1%	%0	1%	1%	1%	%0	1%	1%	1%	%0
HIV Status Known %	%28	%76	91%	20%	71%	33%	81%	%89	%08	36%	71%	%69	81%	%76	84%	23%	%88	93%	84%	%88	82%	71%	23%	%86	%86	72%	%26	%88
Paedi- atric TB %	%9	2%	3%	2%	4%	11%	2%	%/	4%	2%	2%	4%	%9	4%	4%	10%	%8	2%	%6	2%	%9	2%	%8	2%	%9	%2	2%	2%
Clin- ically Diag- nosed	35%	37%	42%	24%	21%	%89	23%	44%	22%	29%	32%	22%	23%	23%	32%	41%	18%	46%	24%	39%	23%	32%	41%	29%	29%	30%	26%	35%
Micro- biolog- ically Con- firmed %	%59	%89	28%	%9/	%62	42%	%44	%99	%82	71%	%89	%8/	%44	%44	%89	%69	%78	54%	%92	%19	77%	%89	%69	71%	%12	%02	74%	%29
Previ- ously Treat- ed %	20%	14%	18%	17%	24%	15%	26%	14%	23%	20%	25%	20%	14%	19%	19%	21%	13%	2%	10%	12%	19%	18%	17%	17%	16%	20%	19%	16%
% New TB Patients	%08	%98	82%	83%	%92	85%	74%	%98	%44	%08	75%	%08	%98	81%	81%	%62	%28	%26	%06	%88	81%	82%	83%	83%	84%	%08	81%	84%
Extra Pul- mo- nary TB %	18%	18%	18%	25%	11%	40%	%8	21%	13%	17%	18%	12%	11%	16%	13%	19%	23%	36%	15%	%67	21%	11%	16%	24%	22%	27%	22%	25%
Pul- mo- nary TB %	%78	%78	%28	75%	%68	%09	%76	%62	%28	83%	82%	%88	%68	84%	%28	81%	%22	64%	85%	71%	%62	%68	84%	%92	%82	73%	%82	75%
Treat- ment Initiat- ed %	85%	%28	%68	71%	61%	91%	%62	41%	84%	%88	%28	%88	83%	83%	%76	%68	%76	%16	%06	%98	%28	83%	%76	%76	%86	28%	%89	62%
Treat- ment Initiat- ed	3162	2033	1231	1426	1255	3024	962	453	1707	1292	1508	1028	1948	1122	1018	1217	1174	983	1842	753	1127	1383	1869	1470	535	719	556	2467
Public Sector Notifi- cation	3732	2333	1385	1997	2045	3305	1264	1093	2042	1462	1732	1163	2349	1350	1107	1363	1273	1078	2053	871	1296	1659	2038	1564	578	1230	877	3967
Total Pop- ulation	1931851	1880376	889678	1261609	1807995	1996489	1044907	1680340	1934186	1061981	1478308	1190667	1671726	1070109	1022886	1209029	1154745	620229	1334887	994529	1174932	1437325	1642601	1347484	405867	551179	482605	1601156
District Name	Vadodara Corp	Valsad	Vyara (Surat)	Ambala	Bhiwani	Faridabad	Fatehabad	Gurgaon	Hisar	Jhajjar	Jind	Kaithal	Karnal	Kurukshetra	Mahendragarh	Mewat	Palwal	Panchkula	Panipat	Rewari	Rohtak	Sirsa	Sonipat	Yamunanagar	Bilaspur-HP	Chamba	Hamirpur-HP	Kangra
State Name	Gujarat	Gujarat	Gujarat	Haryana	Haryana	Haryana	Haryana	Haryana	Haryana	Haryana	Haryana ]	Haryana	Haryana	Haryana	Haryana ]	Haryana	Haryana	Haryana	Haryana	Haryana	Haryana ]	Haryana	Haryana	Haryana	Himachal Pradesh	Himachal Pradesh	Himachal Pradesh	Himachal Pradesh

al - 1				1				1											
Annual Total Notifi- cation Rate	115	194	191	201	326	202	279	138	42	27	31	73	142	82	94	48	133	41	2/9
Total Notifi- cation	103	903	64	2131	2821	1139	1707	762	202	223	489	752	2949	132	646	475	219	382	407
Private Sector Notifi- cation Rate	0	41	0	12	5	1	31	2	2	0	1	9	12	0	2	2	1	0	5
Private Sector Notifi- cation	0	189	0	129	44	8	188	6	27	3	20	61	239	0	17	18	1	3	26
Notifi- cation Rate (Public)	115	154	191	189	321	201	248	136	41	27	30	29	131	82	16	47	132	40	71
HIV Status Positive % (of Known)	%0	1%	%0	%0	%0	%0	%0	1%	%0	%0	%0		2%			%0	%0	%0	%0
HIV Status Known %	77%	73%	3%	%82	64%	85%	83%	93%	72%	%96	72%	%0	52%	%0	%0	95%	1%	24%	%76
Paedi- atric TB %	3%	%9	2%	2%	%9	%/_	3%	3%	18%	%8	11%	10%	2%	%6	7%	2%	2%	4%	13%
Clin- ically Diag- nosed	22%	32%	53%	41%	35%	40%	26%	29%	52%	49%	27%	46%	40%	64%	38%	43%	35%	49%	49%
Microbiolog- ically Confirmed	%82	%89	47%	29%	%59	%09	74%	71%	48%	51%	73%	54%	%09	36%	%59	22%	%59	51%	51%
Previ- ously Treat- ed %	15%	26%	14%	20%	13%	16%	12%	18%	%9	10%	%9	11%	21%	15%	21%	2%	15%	12%	2%
% New TB Patients	85%	74%	%98	%08	%28	84%	%88	82%	94%	%06	94%	%68	%62	85%	%62	%86	85%	%88	%26
Extra Pul- mo- nary TB %	15%	21%	39%	30%	31%	21%	16%	21%	34%	39%	24%	38%	22%	21%	13%	36%	31%	35%	33%
Pul- mo- nary TB %	85%	%62	%19	%02	%69	%62	84%	%62	%99	61%	%92	%79	%82	%62	%28	64%	%69	%59	%29
Treat- ment Initiat- ed %	71%	%89	100%	46%	16%	74%	43%	%06	94%	85%	%06	%88	%89	51%	25%	94%	27%	91%	%06
Treat- ment Initiat- ed	73	486	64	984	442	839	648	674	641	188	423	209	1694	29	348	430	124	346	342
Public Sector Notifi- cation	103	714	49	2002	2777	1131	1519	753	089	220	469	169	2710	132	629	457	218	379	381
Total Pop- ulation	89552	464738	33493	1061810	864076	563205	612609	553530	1675067	825515	1571475	1036645	2070109	160881	690828	982383	165051	938014	534992
District Name	Kinnaur	Kullu	Lahul & Spiti	Mandi	Shimla	Sirmaur	Solan	Una	Anantnag	Badgam	Baramula	Doda	Jammu	Kargil	Kathua	Kupwara	Leh	Poonch	Pulwama
State Name	Himachal Pradesh	Jammu and Kashmir																	

	. Treat- Pul- ment mo-		Previ- %— ously	Micro- vi- biolog- ly ically	- Clin-	Paedi-	HIIV	HIIV	Notifi- cation	Private Sector	Private Sector	Total	Annual Total
		mo- nary P. TB %	New TB Treat- Patients Created & ed %			atric TB %	Known %	Positive % (of Known)	Rate (Public)	Notifi- cation	Notifi- cation Rate	Notifi- cation	Notifi- cation Rate
694817 511 427 84%	%95	44%	86% 14%	%   57%	43%	%9	%0		74	0	0	511	74
1757898 781 535 69%	22%	43%	93% 7%	, 49%	21%	%6	16%	%0	44	640	36	1421	81
976220 1162 971 84%	75%	25%	80% 20%	%   93%	37%	2%	64%	%0	119	1	0	1163	119
2333310 2152 1381 64%	%28	13%	85% 15%	% 54%	46%	4%	45%	%0	92	1009	43	3161	135
1179493 946 870 92%	%86	2%	87%   13%	% 27%	43%	3%	%09	%0	80	41	3	286	84
1688241 1075 990 92%	%26	3%	95% 5%	%98 9	14%	3%	94%	%0	64	136	8	1211	72
3035756 2197 2152 98%	94%	%9	%16	95%	2%	%9	74%	%0	72	571	19	2768	91
1494980 2126 1909 90%	%86	2%	90% 10%	%65 %	41%	3%	%52	%0	142	501	34	2627	176
1496441 1437 1256 87%	%86	2%	8% 8%	%89 9	32%	4%	23%	%0	96	12	1	1449	- 62
2767043 1962 1842 94%	%26	2%	88%   12%	% 23%	27%	2%	17%	%0	7.1	424	15	2386	98
1483987   1385   1298   94%	%26	3%	89% 11%	% 25%	45%	3%	%22	%0	93	172	12	1557	105
1160654 918 897 98%	%16	%6	90% 10%	% 89 %	37%	%9	71%	%0	62	20	2	826	81
1962236   1468   1435   98%	%86	3/ %/	90%   10%	% 22%	43%	2%	%08	1%	75	149	8	1617	82
894215 924 878 95%	%26	3%	84% 16%	%   71%	76%	3%	28%	%0	103	78	6	1002	112
600097 564 548 97%	%86	%2	90% 10%	% 65%	38%	3%	%68	%0	94	2	0	999	94
811563 305 284 93%	%96	4%	85%   15%	%85   %	45%	7%	22%	2%	38	8	1	313	39
821187 761 756 99%	%26	2%	%8 8%	%89 9	32%	%9	45%	%0	93	0	0	761	93
522512 477 460 96%	%68	11%	%6   %16	, 74%	%97	%9	12%	%0	91	19	4	496	95
1017554 1642 1525 93%	%26	3%	84% 16%	%99 %	34%	1%	20%	%0	161	0	0	1642	161
2191179 2425 2251 93%	%66	1%	93% 7%	, 72%	78%	2%	%52	%0	111	3	0	2428	111
1699263 2926 2376 81%	%56	2%	93% 7%	, 48%	52%	3%	84%	%0	172	42	2	2968	175
2592580 3076 2838 92%	91%	3 %6	86% 14%	% 25%	45%	4%	%09	1%	119	292	23	3668	141
1074088 757 591 78%	91%	%6	81% 19%	% 74%	76%	4%	34%	%0	70	111	10	898	81
3295305 2959 2196 74%	%28	13%	88% 12%	%25 %	45%	4%	48%	%0	06	2638	80	5597	170
1301407 1607 1439 90%	94%	%9	90% 10%	% 48%	25%	2%	%28	%0	123	206	54	2313	178
1203431 2052 1988 97%	%26	3%	89% 11%	%   62%	38%	2%	48%	%0	171	31	3	2083	173
678761 720 596 83%		,0,	7000	òòò	210/	/00	54%	%0	106	,	c	722	106

State Name	District Name	Total Pop-	Public Sector	Treat- ment	Treat- ment	Pul- mo-	Extra Pul-			1.00	Clin- ically		HIV	HIV Status Positive	Notifi- cation	Private Sector	Private Sector Notifi-	Total Notifi-	Annual Total Notifi-
		ulation	Notifi- cation	Initiat- ed	Initiat- ed %	nary TB %		Patients	Treat- ed %	Con- firmed %	Diag- nosed	TB %	Known %	% (of Known)	Rate (Public)	Notifi- cation	cation Rate	cation	cation Rate
Karnataka	Bagalkot	2042890	2243	1708	%92	%06	10%	%5%	18%	46%	21%	3%	%89	30%	110	495	24	2738	134
Karnataka	Bangalore City	7977252	7947	2495	31%	73%	27%	82%	18%	%99	34%	2%	54%	4%	100	2414	30	10361	130
Karnataka	Bangalore Rural	1066654	926	505	23%	83%	17%	%98	14%	74%	79%	3%	72%	4%	06	38	4	994	93
Karnataka	Bangalore Urban	2382816	4835	2900	%09	75%	25%	%98	14%	%89	37%	2%	%16	4%	203	099	28	5495	231
Karnataka	Belgaum	5162730	6117	4557	74%	%68	11%	%16	%6	46%	21%	%6	%88	15%	118	558	11	6675	129
Karnataka	Bellary	2736042	3187	1215	38%	84%	16%	82%	18%	%29	33%	4%	75%	%6	116	287	21	3774	138
Karnataka	Bidar	1836737	1835	251	14%	%28	13%	84%	16%	25%	45%	4%	%92	1%	100	253	14	2088	114
Karnataka	Bijapur	2350028	1410	572	41%	%16	%6	94%	%9	%02	30%	%2	%44	%9	09	807	34	2217	94
Karnataka	Chamarajanagar	1103070	1069	773	72%	85%	15%	85%	15%	73%	27%	3%	91%	10%	26	42	4	1111	101
Karnataka	Chikkaballapur	1355256	1978	1522	%22	85%	15%	85%	15%	72%	78%	3%	83%	%9	146	105	∞	2083	154
Karnataka	Chikmagalur	1229253	930	751	81%	%62	21%	84%	16%	%29	35%	%8	84%	3%	9/	101	8	1031	84
Karnataka	Chitradurga	1793909	2322	1512	%59	%68	11%	%98	14%	%89	32%	3%	83%	2%	129	357	20	2679	149
Karnataka	Dakshina Kan- nada	2251194	2205	882	40%	%98	14%	84%	16%	%02	30%	4%	%84	3%	86	239	11	2444	109
Karnataka	Davanagere	2103479	2215	868	41%	81%	19%	%83%	17%	64%	36%	4%	25%	2%	105	156	7	2371	113
Karnataka	Dharwad	1995532	2140	1440	%29	%82	23%	%28	15%	%89	32%	2%	72%	11%	107	715	98	2855	143
Karnataka	Gadag	1150903	1638	1112	%89	82%	18%	%16	%6	%99	34%	%8	63%	%6	142	345	30	1983	172
Karnataka	Gulbarga	2771165	2081	1522	73%	%88	17%	83%	17%	26%	41%	4%	%89	3%	75	484	17	2565	93
Karnataka	Hassan	1919068	1095	618	%95	%08	20%	81%	19%	22%	23%	3%	83%	%9	57	155	8	1250	65
Karnataka	Haveri	1727061	1758	1356	77%	%98	14%	84%	16%	%29	35%	2%	51%	1%	102	172	10	1930	112
Karnataka	Kodagu	599377	295	120	41%	%92	24%	83%	18%	71%	762	3%	54%	%9	49	22	4	317	53
Karnataka	Kolar	1664099	1771	1544	87%	%08	20%	%68	11%	%89	32%	3%	74%	%9	106	54	3	1825	110
Karnataka	Koppal	1503182	1675	906	54%	%16	%6	%62	21%	71%	762	3%	%09	2%	111	261	17	1936	129
Karnataka	Mandya	1954137	1406	688	%89	%98	14%	82%	18%	27%	23%	2%	%44	2%	72	226	12	1632	84
Karnataka	Mysore	3235587	3383	1078	32%	85%	18%	83%	17%	%02	30%	3%	%69	4%	105	219	4	3602	111
Karnataka	Raichur	2079567	3041	1660	25%	94%	%9	81%	19%	%02	30%	2%	%44	11%	146	290	28	3631	175
Karnataka	Ramanagara	1169815	1110	819	74%	81%	19%	%08	20%	74%	79%	3%	%44	2%	95	09	2	1170	100
Karnataka	Shimoga	1896694	1716	828	20%	%58	15%	%28	15%	72%	78%	4%	%62	3%	90	335	18	2051	108
Karnataka	Tumkur	2897096	9608	2124	%69	22%	23%	%98	14%	62%	38%	4%	%62	%9	107	101	3	3197	110
Karnataka	Udupi	1272638	1004	436	43%	%28	15%	%82	22%	73%	27%	2%	%28	11%	79	888	20	1892	149
Karnataka	Uttara Kannada	1552401	928	575	%09	83%	17%	%28	15%	64%	%98	2%	77%	4%	62	165	11	1123	72

																	r	-		r	r			
Annual Total Notifi- cation Rate	171	64	75	29	64	92	81	51	54	30	92	36	22	111	84	20	66	122	131	180	186	163	172	121
Total Notifi- cation	2167	1395	2524	671	1639	1217	2178	1040	1697	1274	1859	440	2585	3538	269	46	553	286	1085	1684	3501	2509	3002	2288
Private Sector Notifi- cation Rate	30	14	31	13	34	27	23	12	34	8	13	14	35	39	40	0	0	0	0	0	21	36	23	3
Private Sector Notifi- cation	384	305	1028	144	998	365	611	247	1061	338	363	175	1167	1232	330	0	0	0	0	1	397	559	408	63
Notifi- cation Rate (Public)	141	50	45	47	30	64	28	39	20	22	52	22	42	73	44	70	66	122	131	180	165	127	149	118
HIV Status Positive % (of Known)	11%	%0	2%	%0	%0	%0	2%	1%	%0	%0	2%	%0	1%	1%	%0		%0	%0	%0	%0	1%	1%	1%	%0
HIV Status Known %	%26	42%	35%	46%	45%	%19	%89	13%	11%	20%	23%	34%	31%	16%	24%	%0	100%	%82	93%	21%	22%	20%	27%	4%
Paedi- atric TB %	2%	4%	4%	2%	%9	2%	2%	%€	%2	11%	2%	4%	3%	%9	%6	17%	%6	%/_	3%	%9	3%	10%	%8	%6
Clin- ically Diag- nosed	34%	32%	32%	36%	47%	37%	34%	33%	44%	44%	35%	32%	36%	33%	31%	42%	20%	32%	34%	51%	51%	43%	61%	54%
Micro- biolog- ically Con- firmed %	%99	%89	%89	64%	23%	%89	%99	%29	%99	%99	%59	%89	64%	%29	%69	28%	20%	%89	%99	49%	49%	27%	39%	46%
Previ- ously Treat- ed %	19%	%9	13%	2%	%9	14%	%2	%6	%9	%2	2%	10%	%8	%2	4%	3%	33%	12%	%8	3%	%9	11%	%8	14%
% New TB Patients	81%	94%	%28	%26	94%	%98	%86	%16	%46	%86	93%	%06	%76	%86	%96	%26	%29	%88	%76	%26	94%	%68	%76	%98
Extra Pul- mo- nary TB %	10%	21%	16%	31%	31%	27%	20%	15%	32%	%67	25%	13%	24%	25%	18%	29%	17%	10%	4%	3%	3%	17%	18%	%6
Pul- mo- nary TB %	%06	%62	84%	%69	%69	73%	%08	%28	%89	71%	75%	%28	%92	75%	%2%	71%	83%	%06	%96	%26	%26	83%	82%	91%
Treat- ment Initiat- ed %	85%	%22	%88	83%	28%	29%	%59	71%	20%	%99	%69	%08	73%	%76	25%	83%	3%	%96	%06	87%	81%	95%	95%	45%
Treat- ment Initiat- ed	1508	844	1310	437	449	244	1025	564	316	621	1035	212	1029	2122	203	38	19	949	226	1456	2522	1790	2396	1006
Public Sector Notifi- cation	1783	1090	1496	527	773	852	1567	793	989	986	1496	265	1418	2306	367	46	553	286	1085	1683	3104	1950	2594	2225
Total Pop- ulation	1267319	2166634	3348938	1130777	2578830	1330034	2685088	2021072	3154613	4197538	2870093	1220717	3376940	3175834	833756	62929	558522	807315	830409	936168	1884743	1535197	1745246	1887408
District Name	Yadgiri	Alappuzha	Ernakulam	Idukki	Kannur	Kasaragod	Kollam	Kottayam	Kozhikode	Malappuram	Palakkad	Pathanamthitta	Thiruvanantha- puram	Thrissur	Wayanad	Lakshadweep	Agar Malwa	Alirajpur	Anuppur	Ashoknagar	Balaghat	Barwani	Betul	Bhind
State Name	Karnataka	Kerala	Kerala	Kerala	Kerala	Kerala	Kerala	Kerala	Kerala	Kerala	Kerala	Kerala	Kerala	Kerala	Kerala	Lakshad- weep	Madhya Pradesh							

le																			
Annual Total Notifi- cation Rate	265	191	152	171	217	199	177	206	161	144	360	158	154	258	176	120	133	109	170
Total Notifi- cation	6943	1600	2963	3951	3039	1738	8408	4667	1253	1985	8808	666	2112	9355	4801	1362	1909	1584	3518
Private Sector Notifi- cation Rate	09	29	3	14	4	2	22	62	0	35	106	55	2	40	18	0	18	14	29
Private Sector Notifi- cation	1567	241	52	318	09	19	379	1498	0	482	2390	346	31	1446	504	0	263	206	592
Notifi- cation Rate (Public)	205	162	149	157	213	197	156	145	161	109	253	103	151	218	158	120	115	95	141
HIV Status Positive % (of Known)	2%	2%	%0	1%	%0	%0	2%	2%	1%	%0	%0	1%	7%	2%	1%	1%	%0	%0	2%
HIV Status Known %	36%	%89	38%	64%	48%	78%	64%	%19	%09	13%	%89	73%	64%	%29	21%	36%	%29	44%	%29
Paedi- atric TB %	12%	%6	2%	4%	2%	14%	13%	11%	%8	%8	%8	15%	16%	20%	%2	%6	%9	2%	16%
Clin- ically Diag- nosed	52%	45%	35%	38%	34%	%95	54%	25%	37%	%89	41%	51%	%29	25%	48%	45%	52%	47%	38%
Micro- biolog- ically Con- firmed %	48%	25%	%59	%29	%99	44%	46%	45%	63%	32%	29%	46%	38%	45%	52%	55%	48%	53%	62%
Previ- ously Treat- ed %	13%	3%	11%	14%	21%	19%	%6	%2	%6	12%	18%	2%	%8	13%	16%	%8	%6	%9	10%
% New TB Patients	%28	%26	%68	%98	%62	81%	%16	%86	%16	%88	82%	%56	%76	%28	84%	%26	91%	94%	%06
Extra Pul- mo- nary TB %	27%	11%	4%	10%	16%	15%	19%	10%	4%	11%	16%	10%	16%	25%	17%	%9	5%	10%	18%
Pul- mo- nary TB %	%82	%68	%96	%06	84%	%58	81%	%06	%96	%68	84%	%06	84%	%52	%£8	94%	%56	%06	82%
Treat- ment Initiat- ed %	82%	48%	%86	82%	54%	%68	%96	%98	82%	%69	%98	82%	%06	94%	%08	%29	%06	%26	%76
Treat- ment Initiat- ed	4418	648	2701	2964	1622	1529	2598	3022	1028	1044	4915	538	1882	7415	3439	913	1480	1331	2705
Public Sector Notifi- cation	5376	1359	2911	3633	2979	1719	2694	3499	1253	1503	2698	653	2081	2909	4297	1362	1646	1378	2926
Total Pop- ulation	2623712	838687	1953103	2315889	1400080	871240	1731796	2420439	780217	1374859	2249677	631848	1374900	3625481	2726271	1134610	1431081	1450756	2074481
District Name	Bhopal	Burhanpur	Chhatarpur	Chhindwara	Damoh	Datia	Dewas	Dhar	Dindori	Guna	Gwalior	Harda	Hoshangabad	Indore	Jabalpur	Jhabua	Katni	Khandwa	Khargone
State Name	Madhya Pradesh																		

-	1		ı				1										1		
Annual Total Notifi- cation Rate	169	182	126	159	212	142	114	120	148	140	139	175	142	119	128	129	183	159	131
Total Notifi- cation	1970	2708	2752	1920	1936	1602	1677	2051	2381	3665	3665	4316	2057	1819	1516	1440	1395	3049	1635
Private Sector Notifi- cation Rate	0	37	18	26	63	0	7	5	13	0	10	15	13	9	30	7	0	9	11
Private Sector Notifi- cation	0	553	386	319	574	0	102	85	211	0	592	375	195	86	351	82	1	122	137
Notifi- cation Rate (Public)	169	145	109	132	149	142	107	115	135	140	129	160	128	113	66	122	183	153	120
HIV Status Positive % (of Known)	%0	3%	1%	1%	3%	%0	%0	1%	3%	1%	%0	%0	1%	2%	%0	1%	%0	%0	%0
HIV Status Known %	17%	%69	39%	73%	82%	41%	21%	%29	%08	%62	19%	54%	%28	36%	30%	%06	%08	3%	%69
Paedi- atric TB %	%8	%6	2%	2%	%9	13%	%9	11%	%8	%6	%8	%8	10%	2%	%9	16%	10%	3%	%9
Clin- ically Diag- nosed	20%	43%	29%	38%	44%	34%	46%	47%	46%	53%	48%	54%	47%	41%	20%	48%	28%	14%	44%
Micro- biolog- ically Con- firmed %	20%	22%	71%	%29	26%	%99	54%	53%	54%	47%	52%	46%	53%	29%	20%	52%	72%	%98	26%
Previ- ously Treat- ed %	%9	23%	19%	20%	17%	15%	15%	16%	18%	11%	%6	4%	%6	13%	12%	11%	20%	22%	16%
% New TB Patients	94%	%44	81%	%08	83%	%28	85%	84%	82%	%68	%16	%96	%16	%28	%88	%68	%08	%82	84%
Extra Pul- mo- nary TB %	11%	12%	10%	18%	11%	2%	11%	%6	15%	18%	14%	18%	11%	11%	3%	21%	2%	2%	%8
Pul- mo- nary TB %	%68	%88	%06	82%	%68	%86	%68	%16	%58	82%	%98	82%	%68	%68	%26	%62	%86	%86	95%
Treat- ment Initiat- ed %	%86	%06	75%	%82	84%	%26	91%	91%	%06	85%	84%	%06	%96	%62	%89	85%	%96	75%	80%
Treat- ment Initiat- ed	1830	1936	1776	1250	1145	1523	1430	1790	1944	3115	2866	3533	1779	1360	262	1158	1337	2198	1198
Public Sector Notifi- cation	1970	2155	2366	1601	1362	1602	1575	1966	2170	3665	3399	3941	1862	1721	1165	1358	1394	2927	1498
Total Pop- ulation	1167217	1484425	2177212	1210004	915095	1125677	1475414	1713441	1611449	2618837	2634958	2469129	1452490	1527683	1179922	1117043	762195	1912066	1248087
District Name	Mandla	Mandsaur	Morena	Narsinghpur	Neemuch	Panna	Raisen	Rajgarh	Ratlam	Rewa	Sagar	Satna	Sehore	Seoni	Shahdol	Shajapur	Sheopur	Shivpuri	Sidhi
State Name	Madhya Pradesh																		

Annual Total Notifi- cation Rate	82	141	145	132	146	86	147	26	255	113	207	325	444	147	88	473	347	237	94	287	69	223	108	457	827	119	492
Total Notifi- cation	1131	2257	3202	944	2366	4444	561	1187	1155	2751	1453	2981	3507	1840	2318	2499	2284	904	1228	2215	1939	1295	2971	2283	2621	2829	2284
Private Sector Notifi- cation Rate	rc	.C	24	0	25	2	50	3	173	19	111	196	208	52	16	258	66	134	21	1	21	145	49	254	199	24	301
Private Sector Notifi- cation	62	75	520	ε	411	108	191	38	783	463	782	1794	1643	649	413	1362	651	513	275	8	582	841	1329	1271	629	583	1394
Notifi- cation Rate (Public)	82	136	122	132	121	95	26	92	82	94	96	130	236	95	72	215	248	102	73	286	49	78	09	203	629	94	192
HIV Status Positive % (of Known)	%0	%0	1%	%0	1%	3%	4%	4%	%9	2%	2%	%8	2%	2%	4%	3%	3%	4%	4%	3%	10%	4%	3%	%9	2%	%6	3%
HIV Status Known %	2%	48%	%99	%68	71%	%26	72%	%62	%08	%76	94%	82%	%28	73%	74%	%29	46%	72%	84%	16%	%79	%4%	72%	%88	21%	%88	43%
Paedi- atric TB %	%9	%9	10%	2%	2%	4%	4%	2%	4%	4%	2%	%8	10%	%2	4%	10%	12%	%8	%9	13%	%9	%8	3%	%9	10%	4%	%8
Clin- ically Diag- nosed	44%	51%	21%	51%	52%	42%	%95	30%	36%	32%	46%	22%	45%	41%	78%	%62	%/9	41%	41%	%69	%89	48%	35%	46%	47%	45%	41%
Micro- biolog- ically Con- firmed %	26%	49%	49%	49%	48%	28%	44%	%02	61%	%89	54%	43%	22%	26%	72%	21%	33%	26%	29%	31%	37%	52%	%59	54%	23%	28%	29%
Previ- ously Treat- ed %	10%	12%	20%	%8	13%	%6	15%	15%	19%	15%	17%	14%	12%	14%	15%	22%	20%	10%	16%	15%	10%	14%	16%	17%	22%	12%	19%
% New TB Patients	%06	%88	%08	92%	%88	91%	85%	85%	81%	85%	83%	%98	%88	%98	85%	%82	%08	%06	84%	85%	%06	%98	84%	83%	%82	%88	81%
Extra Pul- mo- nary TB %	16%	12%	19%	%9	13%	17%	26%	19%	29%	18%	31%	40%	34%	30%	14%	41%	30%	31%	24%	27%	31%	29%	18%	42%	36%	25%	33%
Pul- mo- nary TB %	84%	%88	81%	94%	%28	83%	74%	81%	71%	82%	%69	%09	%99	%02	%98	%69	%02	%69	%92	73%	%69	71%	82%	28%	64%	%52	%29
Treat- ment Initiat- ed %	%26	85%	27%	%26	94%	77%	53%	91%	%26	%86	84%	%92	22%	%89	64%	46%	54%	82%	%98	%82	71%	%26	%86	26%	45%	%28	54%
Treat- ment Initiat- ed	1037	1850	1537	915	1840	3333	197	1051	341	2231	561	868	1065	750	1222	525	885	320	821	1711	962	430	1531	571	835	1949	483
Public Sector Notifi- cation	1069	2182	2682	941	1955	4336	370	1149	372	2288	671	1187	1864	1191	1905	1137	1633	391	953	2207	1357	454	1642	1012	1992	2246	890
Total Pop- ulation	1305274	1600854	2200988	713033	1615580	4550731	380830	1510136	452514	2434468	701960	916557	789013	1255630	2646271	528418	992829	381975	1301045	771992	2795786	580925	2740193	499440	316868	2381391	463844
District Name	Singrauli	Tikamgarh	Ujjain	Umaria	Vidisha	Ahmadnagar	Ahmednagar MC	Akola	Akola MC	Amravati	Amravati MC	Andheri East	Andheri West	Aurangabad MC	Aurangabad-MH	Bail Bazar Road	Bandra East	Bandra West	Bhandara	Bhiwandi Ni- zampur	Bid	Borivali	Buldana	Byculla	Centenary	Chandrapur	Chembur
State Name	Madhya Pradesh	Madhya Pradesh	Madhya Pradesh	Madhya Pradesh	Madhya Pradesh	Maharashtra	Maharashtra	Maharashtra	Maharashtra	Maharashtra	Maharashtra	Maharashtra	Maharashtra	Maharashtra	Maharashtra	Maharashtra	Maharashtra	Maharashtra	Maharashtra	Maharashtra	Maharashtra	Maharashtra	Maharashtra	Maharashtra	Maharashtra	Maharashtra	Maharashtra

	_				_																				_				
Annual Total Notifi- cation Rate	403	1144	263	115	432	135	490	126	271	671	373	88	102	189	66	120	284	81	304	393	26	353	241	161	447	106	177	107	241
Total Notifi- cation	1794	7683	1082	2082	1748	1501	3426	1803	1345	3006	1587	1132	4173	946	2113	1627	1871	2915	1814	1383	2580	3128	1418	1421	1676	2525	4623	3247	1381
Private Sector Notifi- cation Rate	211	896	151	8	157	7	360	48	113	342	314	20	47	87	28	38	66	14	197	212	26	134	71	30	291	17	62	13	174
Private Sector Notifi- cation	626	6498	621	139	633	81	2516	684	562	1532	1333	256	1904	433	909	516	651	522	1175	748	969	1189	418	267	1092	395	2056	394	866
Notifi- cation Rate (Public)	192	177	112	107	276	127	130	2/8	158	329	09	89	56	103	71	82	185	99	107	180	71	219	170	131	156	06	86	94	29
HIV Status Positive % (of Known)	2%	2%	4%	4%	3%	1%	2%	3%	2%	3%	%8	4%	%6	15%	2%	3%	3%	%6	12%	7%	%/	4%	4%	4%	%9	2%	%/	2%	2%
HIV Status Known %	93%	%88	%76	74%	%96	85%	%82	%28	%28	38%	%08	%69	54%	%66	85%	%28	%28	%66	%26	%89	%5/	%96	75%	%66	%44	%66	%82	64%	42%
Paedi- atric TB %	4%	%8	%/	%9	%8	3%	10%	3%	%9	10%	2%	4%	3%	%9	4%	4%	10%	4%	%/	10%	2%	%8	14%	%/	12%	4%	%9	2%	10%
Clin- ically Diag- nosed	23%	47%	22%	24%	35%	33%	40%	34%	46%	73%	42%	37%	34%	23%	42%	%95	39%	32%	46%	%44	40%	46%	46%	35%	%95	33%	38%	45%	21%
Micro- biolog- ically Con- firmed %	47%	23%	43%	%92	%29	%29	%09	%99	51%	27%	28%	%89	%99	%24	28%	44%	61%	%89	54%	%27	%09	54%	51%	%29	44%	%29	%29	25%	49%
Previ- ously Treat- ed %	19%	20%	18%	10%	13%	12%	13%	14%	17%	15%	19%	16%	14%	13%	12%	%97	12%	11%	13%	%0E	%£1	%91	%9	12%	13%	%£1	16%	13%	15%
% New TB Patients	81%	%08	82%	%06	%28	%88	%28	%98	83%	85%	81%	84%	%98	%28	%88	74%	%88	%68	%28	%02	%28	84%	%56	%88	%28	%28	84%	%28	85%
Extra Pul- mo- nary TB %	34%	27%	32%	12%	16%	14%	31%	19%	22%	31%	26%	15%	11%	27%	17%	31%	39%	19%	34%	39%	22%	33%	31%	31%	34%	21%	35%	21%	39%
Pul- mo- nary TB %	%99	73%	%89	%88	84%	%98	%69	%18	%8/	%69	74%	85%	%68	%£4	83%	%69	61%	81%	%99	%19	%8/	%29	%69	%69	%99	%62	%29	%62	61%
Treat- ment Initiat- ed %	%88	%89	%26	%98	44%	77%	%69	81%	%68	52%	100%	%26	%69	%76	%29	71%	29%	%26	84%	51%	%28	87%	%69	85%	91%	%46	%59	%89	%89
Treat- ment Initiat- ed	750	750	447	1676	496	1100	625	902	693	892	253	852	1572	471	1010	793	723	2324	535	325	1638	1689	692	983	529	1999	1672	1799	261
Public Sector Notifi- cation	855	1185	461	1943	1115	1420	910	1119	783	1474	254	928	5269	513	1508	1111	1220	2393	639	635	1885	1939	1000	1154	584	2130	2567	2853	383
Total Pop- ulation	444904	671321	411940	1815335	404246	1114514	686869	1435100	496614	447840	425069	1279517	4084967	499737	2125503	1353383	659210	3608266	596126	352279	2664953	886549	589274	884129	375288	2379603	2610555	3045298	574191
District Name	Colaba	Dadar	Dahisar	Dhule	Dhule MC	Gadchiroli	Ghatkopar	Gondiya	Goregaon	Govandi	Grant Road	Hingoli	Jalgaon	Jalgaon MC	Jalna	Kalyan Dombivli MC	Kandivali	Kolhapur	Kolhapur MC	Kurla	Latur	Malad	Malegoan Cor- poration	Mira Bhayander	Mulund	Nagpur	Nagpur MC	Nanded	Nanded Waghela MC
State Name	Maharashtra	Maharashtra	Maharashtra Kolhapur	Maharashtra	Maharashtra	Maharashtra	Maharashtra	Maharashtra	Maharashtra	Maharashtra	Maharashtra	Maharashtra	Maharashtra	Maharashtra															

Annual Total Notifi- cation Rate	173	165	127	48	22	42	80	13	133	203	105	115	72	155	333	143	118	108	80	29	82	92	394	155	203	146	102	54	63	29	0
Total Notifi- cation	514	822	720	189	34	195	160	47	1266	920	313	189	536	069	1487	198	108	140	136	26	54	99	1541	118	564	92	202	139	62	49	1
Private Sector Notifi- cation Rate	100	78	29	0	0	5	13	0	27	58	5	0	0	17	10	0	0	0	0	0	0	0	147	0	26	0	0	0	0	0	0
Private Sector Notifi- cation	298	386	376	0	0	24	27	0	253	263	15	0	0	77	44	0	0	0	0	0	0	0	574	0	155	0	0	0	0	0	0
Notifi- cation Rate (Public)	72	88	61	48	22	37	99	13	106	145	100	115	72	137	323	143	118	108	80	59	87	92	247	155	147	146	102	54	63	29	0
HIV Status Positive % (of Known)	%0	13%	2%	100%		2%	%2		1%	7%	2%	%0	%0	1%	%8	4%	22%	%0	%0	2%	%0	%0	17%	%0	16%	%0	%0		14%	%0	
HIV Status Known %	41%	71%	43%	1%	%0	46%	%76	%0	46%	%89	%95	2%	81%	44%	%08	%98	48%	46%	84%	84%	%69	%26	%82	2%	47%	%29	3%	%0	72%	29%	
Paedi- atric TB %	%9	3%	3%	3%	%0	2%	2%	%0	%9	%6	2%	%9	2%	10%	14%	12%	%8	10%	4%	11%	%6	79%	2%	12%	%6	11%	2%	12%	%8	%9	
Clin- ically Diag- nosed	79%	34%	32%	47%	792	43%	44%	40%	%09	20%	39%	762	32%	54%	%69	20%	48%	34%	26%	47%	83%	%29	21%	20%	21%	29%	19%	20%	39%	11%	
Microbiolog- biolog- ically Con- firmed %	74%	%99	%89	23%	74%	22%	%95	%09	40%	20%	61%	71%	%89	46%	31%	20%	52%	%99	41%	23%	17%	38%	46%	20%	46%	71%	81%	20%	%19	%68	
Previ- ously Treat- ed %	19%	10%	11%	23%	11%	10%	11%	10%	14%	13%	10%	%6	%6	%9	%8	%/	11%	%2	11%	22%	11%	10%	20%	14%	15%	16%	12%	13%	2%	11%	
% New TB Patients	81%	%06	%68	%22	%68	%06	%68	%06	%98	%28	%06	%16	%16	94%	%76	%86	%68	%86	%68	%82	%68	%06	%08	%98	85%	84%	%88	%28	%86	%68	
Extra Pul- mo- nary TB %	17%	23%	20%	30%	11%	21%	34%	%0	35%	33%	25%	10%	15%	41%	46%	32%	31%	37%	28%	45%	20%	28%	17%	18%	38%	24%	22%	17%	20%	%2	
Pul- mo- nary TB %	83%	22%	%08	%02	%68	%62	%99	100%	%59	%29	75%	%06	%28	26%	54%	%89	%69	%89	72%	25%	20%	72%	83%	82%	%29	%92	%82	83%	%08	%86	
Treat- ment Initiat- ed %	%88	33%	%08	84%	%99	85%	%86	43%	33%	%06	71%	%66	75%	%06	%86	14%	%68	74%	45%	%88	%29	44%	%76	100%	%76	%66	36%	72%	%86	%26	%0
Treat- ment Initiat- ed	190	145	276	159	19	145	131	20	332	591	211	187	401	552	1338	28	96	104	61	49	36	29	606	118	375	75	73	100	61	45	0
Public Sector Notifi- cation	216	436	344	189	34	171	133	47	1013	657	298	189	536	613	1443	198	108	140	136	56	54	99	296	118	409	92	202	139	62	49	1
Total Pop- ulation	297963	497196	565320	968688	153931	461890	201131	367284	952917	454282	298783	164868	743456	445897	446066	138406	91690	129655	170116	94674	62227	71620	391210	76263	278199	52117	198990	258223	97814	168213	202730
District Name	Churachandpur	Imphal East	Imphal West	Senapati	Tamenglong	Thoubal	Ukhrul	East Garo Hills	East Khasi Hills	Jaintia Hills	Ri Bhoi	South Garo Hills	West Garo Hills	West Khasi Hills	Aizawl	Champhai	Kolasib	Lawngtlai	Lunglei	Mamit	Saiha	Serchhip	Dimapur	Kiphire	Kohima	Longleng	Mokokchung	Mon	Peren	Phek	Tuensang
State Name	Manipur	Manipur	Manipur	Manipur	Manipur	Manipur	Manipur	Meghalaya	Meghalaya	Meghalaya	Meghalaya	Meghalaya	Meghalaya	Meghalaya	Mizoram	Mizoram	Mizoram	Mizoram	Mizoram	Mizoram	Mizoram	Mizoram	Nagaland	Nagaland	Nagaland	Nagaland	Nagaland	Nagaland	Nagaland	Nagaland	Nagaland

Annual Total Notifi- cation Rate	29	101	162	118	124	127	108	82	223	121	126	147	275	195	70	131	164	143	203	72	185	112	210	255	268	121	141	173	06	236
Total Notifi- cation	115	146	2203	2077	3065	2009	202	1377	2002	3383	419	1873	1695	7359	845	2561	1019	2398	1591	1115	3269	1690	3086	1668	7195	1574	1456	1123	1634	2424
Private Sector Notifi- cation Rate	0	0	4	4	4	1	0	11	68	16	0	3	16	15	4	2	0	8	2	0	1	14	2	0	19	7	0	4	10	0
Private Sector Notifi- cation	0	0	57	65	108	21	0	172	809	455	0	37	66	552	44	45	0	138	14	0	23	210	36	0	499	96	0	26	181	0
Notifi- cation Rate (Public)	29	101	158	114	119	126	108	75	156	105	126	144	259	181	99	129	164	134	201	72	184	86	207	255	249	113	141	169	80	236
HIV Status Positive % (of Known)	3%	%0	2%	1%	1%	7%	1%	2%	3%	1%	%0	%0	1%	4%	3%	1%	1%	1%	%0	1%	%0	1%	1%	%0	1%	1%	1%	%0	2%	1%
HIV Status Known %	%99	%28	%28	22%	2%	28%	%29	%62	%68	75%	25%	27%	%95	%02	%96	41%	71%	%08	%89	21%	47%	46%	64%	1%	74%	15%	74%	47%	46%	48%
Paedi- atric TB %	%9	14%	4%	2%	4%	3%	3%	3%	12%	%9	%9	4%	%8	%9	2%	4%	7%	3%	%/	3%	4%	4%	%/	4%	3%	4%	4%	2%	%8	2%
Clin- ically Diag- nosed	11%	37%	29%	47%	28%	46%	38%	36%	43%	48%	17%	24%	40%	43%	41%	46%	36%	29%	38%	%67	32%	33%	%98	762	41%	34%	33%	22%	44%	34%
Micro- biolog- ically Con- firmed	%68	%89	71%	53%	72%	54%	62%	64%	22%	52%	83%	%92	%09	22%	29%	54%	61%	71%	%79	%12	%89	%29	64%	71%	26%	%99	%29	%8/	26%	%99
Previ- ously Treat- ed %	3%	2%	16%	2%	15%	%6	12%	15%	14%	10%	10%	13%	10%	13%	10%	11%	16%	12%	%6	11%	14%	19%	11%	10%	%8	2%	16%	%2	17%	10%
% New TB Patients	%26	%26	84%	%26	85%	%16	%88	85%	%98	%06	%06	%28	%06	%28	%06	%68	84%	%88	%16	%68	%98	81%	%68	%06	%76	%86	84%	%86	83%	%06
Extra Pul- mo- nary TB %	18%	18%	15%	24%	18%	27%	19%	792	37%	33%	%9	20%	16%	28%	31%	27%	21%	13%	24%	19%	14%	25%	16%	%2	14%	%9	18%	10%	24%	12%
Pul- mo- nary TB %	82%	82%	85%	%92	82%	73%	81%	74%	63%	%29	94%	%08	84%	72%	%69	73%	%62	87%	%92	81%	%98	75%	84%	93%	%98	94%	82%	%06	%92	%88
Treat- ment Initiat- ed %	%66	%99	%66	%26	%26	94%	%66	%9/	92%	%58	%66	%66	%86	%26	%66	%56	%96	94%	%46	%£6	%76	%46	%96	%86	%26	82%	91%	84%	84%	%86
Treat- ment Initiat- ed	114	26	2120	1959	2857	1872	504	910	1288	2488	414	1818	1491	6619	792	2392	786	2123	1528	1035	3258	1430	2913	1555	6377	1216	1320	921	1226	2383
Public Sector Notifi- cation	115	146	2146	2012	2957	1988	202	1205	1394	2928	419	1836	1596	2089	801	2516	1019	2260	1577	1115	3546	1480	3020	1668	9699	1478	1456	1097	1453	2424
Total Pop- ulation	171247	145262	1360078	1763139	2478464	1581602	470488	1611215	895954	2800691	333857	1275850	615900	3764778	1215590	1953189	619770	1682371	782818	1539954	1928058	1506493	1472622	655308	2688594	1303458	1029083	648637	1815982	1028809
District Name	Wokha	Zunheboto	Anugul	Balangir	Baleshwar	Bargarh	Baudh	Bhadrak	Bhubaneshwar MC	Cuttack	Debagarh	Dhenkanal	Gajapati	Ganjam	Jagatsinghapur	Jajapur	Jharsuguda	Kalahandi	Kandhamal	Kendrapara	Kendujhar	Khordha	Koraput	Malkangiri	Mayurbhanj	Nabarangapur	Nayagarh	Nuapada	Puri	Rayagada
State Name	Nagaland	Nagaland	Odisha	Odisha	Odisha	Odisha	Odisha	Odisha	Odisha	Odisha	Odisha	Odisha	Odisha	Odisha	Odisha	Odisha	Odisha	Odisha	Odisha	Odisha	Odisha	Odisha	Odisha	Odisha	Odisha	Odisha	Odisha	Odisha	Odisha	Odisha

Annual Total Notifi- cation Rate	195	119	234	114	176	111	144	227	88	145	157	108	150	182	103	193	66	115	205	139	88	115	238	136	121	77	160	131	166	185	92
Total Notifi- cation	2174	828	5212	1604	4700	711	2143	1460	583	1611	1666	1918	2539	4265	901	7202	1053	1218	1944	1149	581	772	4827	966	2147	927	4583	5354	3390	2511	1887
Private Sector Notifi- cation Rate	25	0	6	0	31	3	10	9	4	4	8	16	37	54	3	44	8	6	43	11	8	31	14	5	3	0	20	47	6	32	5
Private Sector Notifi- cation	275	0	208	3	828	21	153	39	27	49	80	283	624	1254	23	1655	84	26	408	92	52	206	278	37	45	1	699	1896	183	436	131
Notifi- cation Rate (Public)	170	119	225	113	145	108	134	221	84	140	150	92	113	129	100	148	91	106	162	128	80	84	224	131	118	77	140	82	157	153	61
HIV Status Positive % (of Known)	1%	%0	1%	4%	1%	1%	1%	1%	1%	2%	3%	%0	%0	2%	%0	1%	1%	1%	1%	%0	%0	%0	1%	2%	%0	2%	1%	1%	1%	%0	1%
HIV Status Known	44%	%28	22%	%62	%22	%96	75%	%46	82%	%6	25%	84%	83%	%92	%66	%92	%68	%62	54%	30%	71%	%09	20%	71%	%62	47%	74%	%06	%96	%26	22%
Paedi- atric TB %	4%	3%	3%	3%	%8	%9	%9	%9	2%	2%	%2	2%	4%	%9	%9	%6	4%	2%	%9	%2	4%	2%	4%	4%	2%	2%	%2	4%	3%	4%	3%
Clin- ically Diag- nosed	45%	48%	44%	32%	49%	41%	762	44%	33%	39%	30%	38%	33%	34%	41%	43%	45%	78%	36%	44%	31%	%0£	%98	37%	41%	20%	22%	%99	72%	37%	41%
Micro- biolog- ically Con- firmed %	%89	52%	%95	%89	21%	26%	71%	%95	%29	61%	%02	%79	%29	%99	26%	22%	25%	72%	64%	%95	%69	%02	%29	%89	26%	%08	43%	44%	75%	%89	26%
Previ- ously Treat- ed %	13%	10%	11%	13%	13%	16%	19%	19%	15%	20%	21%	18%	18%	18%	16%	14%	18%	18%	16%	16%	15%	14%	20%	18%	15%	24%	24%	12%	16%	21%	17%
% New TB Patients	%28	%06	%68	%28	%28	84%	81%	81%	85%	%08	%62	82%	85%	82%	84%	%98	82%	82%	84%	84%	%28	%98	%08	82%	%28	%92	%92	%88	84%	%62	83%
Extra Pul- mo- nary TB %	22%	23%	16%	28%	34%	27%	20%	22%	28%	16%	19%	21%	15%	25%	20%	30%	24%	19%	30%	22%	23%	13%	24%	22%	25%	14%	79%	20%	%9	16%	11%
Pul- mo- nary TB %	%82	%22	84%	72%	%99	73%	%08	%82	72%	84%	%18	%62	%28	%52	%08	%02	%92	81%	%02	%82	%22	%28	%92	%82	75%	%98	74%	%08	94%	84%	%68
Treat- ment Initiat- ed %	%88	83%	%96	%98	82%	94%	77%	%88	%96	%26	%68	%26	%29	%82	22%	%88	81%	91%	94%	85%	75%	%88	79%	75%	%88	40%	95%	%88	%59	%26	93%
Treat- ment Initiat- ed	1669	689	4819	1376	3191	647	1539	1256	535	1519	1406	1587	1289	2361	497	4894	783	1025	1437	903	395	496	1200	721	1852	368	3680	3037	2086	1907	1629
Public Sector Notifi- cation	1899	828	5004	1601	3872	069	1990	1421	556	1562	1586	1635	1915	3011	878	5547	696	1121	1536	1057	529	999	4549	626	2102	926	4014	3458	3207	2075	1756
Total Pop- ulation	1116990	697424	2225256	1412191	2671290	639578	1489674	643353	662867	1114192	1059764	1778685	1697685	2340123	877021	3741062	1064318	1057729	945993	824615	658957	671443	2029640	732952	1774499	1201374	2868271	4074524	2036344	1358087	2889953
District Name	Sambalpur	Sonapur	Sundargarh	Puducherry	Amritsar	Barnala	Bathinda	Faridkot	Fatehgarh Sahib	Fazilka	Firozpur	Gurdaspur	Hoshiarpur	Jalandhar	Kapurthala	Ludhiana	Mansa-PN	Moga	Mohali	Muktsar	Nawanshahr	Pathankot	Patiala	Rupnagar	Sangrur	Tarn Taran	Ajmer	Alwar	Banswara	Baran	Barmer
State Name	Odisha	Odisha	Odisha	Puducherry	Punjab	Punjab	Punjab	Punjab	Punjab	Punjab	Punjab	Punjab	Punjab	Punjab	Punjab	Punjab	Punjab	Punjab	Punjab	Punjab	Punjab	Punjab	Punjab	Punjab	Punjab	Punjab	Rajasthan	Rajasthan	Rajasthan	Rajasthan	Rajasthan

2828556 2828556 2674694 2627297 1235812 11339636 1339636 1339636 1339636 1339636 1339636 1341158 1541158 2030772 156037 156037 1564304 20374207 2164304 2261997 2261997	2292 3737 1207 1330 1978 11767 1112 1893	ea %	nary TB %	mo- nary TB %	% New TB Patients	ously Treated %	ically Con- firmed %	ically Diag- nosed	Paedi- atric TB %	HIV Status Known %	Status Positive % (of Known)	cation Rate (Public)	Sector Notifi- cation	Sector Notifi- cation Rate	I otal Notifi- cation	Total Notifi- cation Rate
rr 2674694 rr 2627297 rr 1235812 rrgarh 1692585 rpur 1339636 rrpur 1341051 ragar 1541158 ragar 1341051 rer 745674 rer 745674 rer 746637 rar 1566037 rr 1618335 rr 3671992 rr 3671992 rr 3671992 rr 3671992 rr 3671992 rr 3671992		%96	%28	13%	%28	18%	46%	24%	4%	82%	1%	84	962	34	3352	119
rr 2627297  urgarh 1692585  1235812  1235812  2264925  1816699  pur 1339636  rrpur 1541158  nangarh 1974735  DTC II 3410251  ner 745674  rer 745674  rer 745674  rer 1566037  unun 2374207  ur 4089705  ii 1618335  ii 1618335  ii 954207  garh 954207		84%	84%	16%	71%	29%	%89	37%	3%	84%	3%	166	1527	57	5955	223
rrgarh 1692585  rrgarh 1692585  pur 1816699  pur 1339636  ripur 1541158  nangar 1541158  nangarh 1974735  DTC II 3410251  ner 745674  rer 74689705  rer 9374207  rer 9374207  rer 9374207  rer 9374207  rer 9374207  rer 93825  rer 9		40%	%£/	27%	75%	25%	%95	44%	4%	%68	1%	114	299	22	3575	136
urgarh 162585  1816699  pur 1339636  ripur 1541158  nagar 1541158  nangarh 1974735  DTC II 3410251  ner 745674  ner 745674  rar 1566037  unun 2374207  ar 1566037  ar 1564304  ar 3671992  r 3671992  garh 954207		%88	%88	12%	%44	23%	20%	20%	2%	%62	1%	122	395	32	1899	154
pur 1339636 ripur 1339636 ripur 1341158 ragar 185419 rangarh 1974735 rer 745674 rer 745674 rer 745674 rer 745672 rar 1566037 rar 1566037 rar 2030772 rar 4089705 rar 4089705 rar 3671992 rar 3671992 rar 3671992 rar 3671992 rar 3671992		83%	84%	16%	71%	29%	%89	32%	3%	%06	3%	140	569	16	2640	156
rrpur 1339636  rrpur 1339636  ragar 1339636  nangarh 1974735  DTC II 3410251  ner 745674  rer 745674  rer 1566037  unun 2374207  rr 4089705  li 1618335  li 1618335  rr 3671992  rr 3671997  garh 954207		%88	82%	18%	73%	27%	%29	35%	4%	%88	%0	68	258	11	2271	100
nagar 1339636 nangarh 1541158 nangarh 1974735 DTC II 3410251 ner 745674 ar 1566037 ar 1566037 ar 4089705 di 1618335 di 2164304 ar 3671992 ar 3671992 garh 954207		81%	%28	13%	%22	23%	42%	%89	4%	%19	1%	92	62	3	1440	79
nangarh 1974/35 nangarh 1974/35 nangarh 1974/35 DTC II 3410251 ner 7456/4 ner 7456/4 ner 7460/37 ar 15660/37 ar 15660/37 ar 4089/05 li 1618335 li 1618335 ar 3671992 ar 3671992 garh 954207		%28	%68	11%	%92	24%	29%	41%	4%	%96	1%	163	964	72	3149	235
nangar 2185419 nangarh 1974735 DTC II 3410251 ner 745674 ar 1566037 ar 1566037 ar 4089705 ii 1618335 ii 3671992 ar 3671997 garh 954207	2119	84%	%86	%2	%28	15%	%89	37%	3%	85%	2%	163	40	3	2555	166
nangarh 1974735  3984225  DTC II 3410251  ner 745674  2030772  ar 1566037  Li 4089705  li 1618335  li 1618335  ar 3671992  ar 3671997  garh 954207	2321	81%	85%	15%	%82	22%	62%	38%	4%	%68	1%	130	838	38	3688	169
DTC II 3410251  ner 745674  ar 2030772  ar 1566037  ar 4089705  ii 1618335  ii 1618335  ir 3671992  ar 3671992  garh 954207	2497	%62	%68	11%	%92	24%	%89	32%	%9	83%	1%	161	358	18	3531	179
C II 3410251 745674 2030772 156037 un 2374207 4089705 1618335 2164304 3671992 dh 954207	3723	75%	%5/	25%	%82	22%	20%	20%	%9	%06	1%	125	2041	51	7035	177
2030772 1566037 1566037 2374207 4089705 1618335 2164304 3671992 10 954207 th 954207	4424	95%	%8/	22%	%62	21%	22%	45%	2%	%98	1%	141	1176	34	5994	176
2030772 un 2374207 4089705 1618335 1618335 2164304 3671992 3671992 th 954207	235	%69	%28	13%	%92	24%	%29	35%	4%	%28	1%	46	31	4	371	50
un 2374207 4089705 1618335 2164304 3671992 2261997 th 954207	1662	%44	%96	4%	%82	22%	22%	43%	2%	%06	2%	106	974	48	3120	154
2374207 4089705 1618335 164304 2164304 3671992 2261997 arh 954207	1391	83%	84%	16%	%62	21%	25%	45%	3%	%68	1%	106	182	12	1848	118
4089705 1618335 2164304 3671992 2261997 arh 954207	11112	%08	%28	13%	%52	25%	%09	40%	3%	81%	1%	29	337	14	1733	73
1618335 2164304 3671992 2261997 arh 954207	3244	85%	%62	21%	%22	23%	43%	22%	4%	%28	2%	94	694	17	4524	111
2164304 3671992 2261997 arh 954207	1436	95%	%06	10%	%02	30%	53%	47%	3%	%06	%0	96	218	13	1771	109
3671992 2261997 arh 954207	1797	%62	72%	28%	%62	21%	45%	25%	2%	%06	1%	105	692	32	2958	137
2261997 apgarh 954207	1581	94%	84%	16%	%52	25%	43%	22%	3%	%29	4%	46	732	20	2407	99
954207	1916	%26	%88	12%	%82	22%	25%	45%	2%	%86	2%	68	120	5	2140	62
1.000.01	2276	95%	94%	%9	%08	20%	%99	34%	3%	83%	1%	259	0	0	2475	259
Kajsamand   1283234   1416	1237	%28	84%	16%	%82	22%	%29	33%	2%	%08	1%	110	315	25	1731	135
Sawai Madhopur   1484798   1766	1545	87%	84%	16%	%4/	23%	28%	45%	4%	%82	%0	119	286	39	2352	158
Sikar 2971271 2188	1676	%22	%£8	17%	%92	24%	62%	38%	3%	85%	2%	74	1521	51	3709	125
Sirohi 1150881 1214	608	%29	%68	11%	%92	24%	%29	33%	4%	%98	2%	105	482	42	1696	147
Tonk 1577559 1983	1703	%98	%58	15%	%82	22%	%89	42%	3%	62%	%0	126	235	15	2218	141
Udaipur 3393085 4703	3714	%62	%98	14%	83%	17%	%09	40%	4%	%26	1%	139	1388	41	6091	180
East District 200309 527	160	30%	64%	36%	%06	10%	54%	46%	%9	29%	%0	263	36	18	563	281
North District 45257 81	72	%68	%29	33%	%06	10%	%89	32%	10%	%66	%0	179	0	0	81	179

	_		I		1				ı		ı —										_				ı —				_	
Annual Total Notifi- cation Rate	198	159	128	107	134	64	123	161	135	106	88	116	110	201	129	118	84	02	96	109	136	65	126	83	51	142	149	133	137	130
Total Notifi- cation	200	243	184	3712	5044	1821	1999	3789	3318	3889	1785	1360	2256	9635	2259	2212	1534	1005	1680	1582	5132	1346	2512	2161	405	1916	3707	1837	2577	3831
Private Sector Notifi- cation Rate	0	2	0	27	52	3	15	15	16	14	8	24	27	63	11	18	8	4	5	27	37	22	62	11	3	13	3	6	34	38
Private Sector Notifi- cation	0	3	0	940	1948	78	239	353	403	206	163	278	545	2067	191	338	146	63	93	396	1409	316	1575	294	23	171	83	119	648	1133
Notifi- cation Rate (Public)	198	157	128	08	82	62	108	146	119	92	08	93	28	138	118	100	9/	99	06	82	66	71	47	72	48	129	146	125	102	92
HIV Status Positive % (of Known)	%0	%0	%0	1%	4%	%0	%6	2%	%9	7%	2%	%6	%6	%9	3%	%/	2%	%8	2%	2%	%8	%/	1%	2%	2%	%8	3%	2%	3%	%8
HIV Status Known %	%82	%88	%96	%59	84%	10%	94%	%09	73%	83%	%76	75%	%28	26%	85%	%88	%44	%96	81%	%02	%98	46%	61%	%08	84%	%59	83%	%62	%76	34%
Paedi- atric TB %	%9	%8	%9	3%	2%	2%	3%	4%	1%	3%	1%	7%	3%	3%	4%	2%	4%	3%	2%	2%	3%	3%	2%	2%	3%	2%	2%	3%	4%	3%
Clin- ically Diag- nosed	20%	47%	44%	39%	%98	41%	38%	37%	31%	40%	79%	32%	38%	32%	24%	25%	45%	38%	30%	18%	27%	32%	44%	39%	44%	31%	29%	22%	24%	33%
Micro- biolog- ically Con- firmed %	20%	23%	26%	61%	64%	29%	%29	%89	%69	%09	74%	%89	%29	%89	%92	75%	%89	%29	%02	82%	73%	%89	%99	61%	%99	%69	71%	%82	%92	%29
Previ- ously Treat- ed %	15%	%2	10%	14%	15%	18%	16%	12%	21%	20%	15%	16%	17%	18%	15%	14%	16%	16%	12%	11%	13%	14%	18%	17%	%6	14%	15%	19%	12%	11%
% New TB Patients	%28	93%	%06	%98	85%	82%	84%	%88	%62	%08	85%	84%	83%	82%	85%	%98	84%	84%	%88	%68	%28	%98	82%	83%	91%	%98	85%	81%	%88	%68
Extra Pul- mo- nary TB %	25%	36%	40%	25%	20%	18%	18%	14%	10%	24%	13%	13%	20%	15%	12%	11%	25%	21%	10%	%6	14%	15%	79%	13%	28%	14%	17%	11%	13%	20%
Pul- mo- nary TB %	75%	64%	%09	75%	%08	85%	%28	%98	%06	%92	%28	%28	%08	%28	%88	%68	%52	%62	%06	91%	%98	%28	74%	%28	72%	%98	83%	%68	%28	%08
Treat- ment Initiat- ed %	%98	%92	95%	%62	84%	85%	83%	62%	%62	46%	52%	%02	%28	%29	84%	72%	%62	%29	29%	%02	71%	%22	%86	%62	77%	29%	83%	73%	81%	84%
Treat- ment Initiat- ed	171	182	169	2195	2589	1475	1457	2129	2309	1657	848	759	1490	2830	1728	1344	1096	582	939	836	2639	794	873	1476	295	1023	2997	1254	1554	2275
Public Sector Notifi- cation	200	240	184	2772	9608	1743	1760	3436	2915	2383	1622	1082	1711	8924	2068	1874	1388	942	1587	1186	3723	1030	486	1867	382	1745	3624	1718	1929	8692
Total Pop- ulation	100970	153183	144091	3464170	3769541	2823299	1631423	2346200	2452842	3681916	2022507	1168654	2044821	3301098	1752099	1868369	1832655	1429617	1757153	1451944	3777607	1455949	1992251	2608259	797932	1350040	2486898	1376537	1887036	2945938
District Name	Singtam	South District	West District	Centeral Chennai	Coimbatore	Cuddalore	Dharmapuri	Dindigul	Erode	Kancheepuram	Kanniyakumari	Karur	Krishnagiri	Madurai	Nagapattinam	Namakkal	North Chennai	Perambalur	Pudukkottai	Ramanathapu- ram	Salem	Sivaganga	South Chennai	Thanjavur	The Nilgiris	Theni	Thiruvallur	Thiruvarur	Thoothukudi	Tiruchirappalli
State Name	Sikkim	Sikkim	Sikkim	Tamil Nadu	Tamil Nadu	Tamil Nadu	Tamil Nadu	Tamil Nadu	Tamil Nadu	Tamil Nadu	Tamil Nadu	Tamil Nadu	Tamil Nadu	Tamil Nadu	Tamil Nadu	Tamil Nadu	Tamil Nadu	Tamil Nadu	Tamil Nadu	Tamil Nadu	Tamil Nadu	Tamil Nadu	Tamil Nadu	Tamil Nadu	Tamil Nadu	Tamil Nadu	Tamil Nadu	Tamil Nadu	Tamil Nadu	Tamil Nadu

Tirunelveli         3335663         3040         1660         55%           Tirunpur         2682553         2064         1475         71%           Tirunpur         2682553         2064         1475         71%           Vellore         4264025         4535         4227         93%           Viluppuram         3759453         3255         2463         76%           Adilabad         697326         1304         885         68%           Bhadrachalam         875249         1761         1362         77%           Gadwal         810546         605         508         84%           Jayashankar         670456         838         671         80%           Kamareddy         988368         733         630         86%           Krhammam         2042249         896         370         41%           Mahabubnagar         1655752         1024         618         60%		84% 1 84% 1	%	firmed nosed %	TB %	% %	% (of Known)	(Public)	canon	Rate	cation	cation Rate
radai         2682553         2064         1475           nualai         2680103         1831         750           nu         4264025         4535         4227           gar         2109494         2745         971           gar         2109494         2745         971           lam         875249         1761         1362           lam         875249         1771         1008           lam         670456         838         671           gar         123041         659         407           lad         141803         161         73           lad         2410021         2504         2144           col         1665091         918         632			16% 72%	% 28%	4%	22%	2%	91	1165	35	4205	126
nalai         2680103         1831         750           n         4264025         4535         4277           n         3759453         3255         2463           gar         2109494         2745         971           gar         2109494         2745         971           e97326         1304         885         1           lam         875249         1761         1362           lam         875249         1761         1593           lam         875494         422         1608           lam         173444         422         1608           lam         1734041         659         407           lam         1734041         659         407           lam         17320         1614         162           lam         17320         162         164		_	16% 61%	%68 %	2%	%59	3%	77	278	10	2342	87
n         4264025         4335         4227           n         3759453         3255         2463           gar         2109494         2745         971           lam         697326         1304         885           lam         875249         1761         1362           lam         875249         1761         1362           lam         875249         1761         1362           lam         875249         1761         1593           lam         875249         1761         1593           lam         870456         838         671           lam         670456         838         671           lam         1166690         1127         1008           lam         732376         575         501           gar         165752         1024         618           lam         2410021         2504         2144           col         1035300         865         671           lam         1665091         918         632           lam         1665091         918         633           lam         1672496         873         693		-	15% 65%	% 35%	1%	%96	3%	89	123	5	1954	73
nn         3759453         3255         2463           gar         2109494         2745         971           gar         2109494         2745         971           lam         697326         1304         885           lam         875249         1761         1362           lam         875249         1771         1008           lam         670456         838         671           ga         732376         575         501           gar         165952         1024         618           gar         165752         1024         2144           col         1065091         918         632           lam         1665091         918         632           lam         1672496         873         693           lam         1672496         873         693		89% 1	11% 60%	% 40%	2%	%02	2%	106	1808	42	6343	149
gar         2109494         2745         971           697326         1304         885           lam         875249         1761         1362           lam         875249         1761         1362           lam         810546         605         508           lam         810546         605         508           lam         810546         605         508           lam         4181189         3771         1593           lam         670456         838         671           lam         670456         838         671           lam         6704249         896         370           lam         732376         575         501           gar         1655752         1024         618           lam         921596         1127         922           lam         1655091         918         632           lam         1665091         918         632           lam         1665091         918         632           lam         1665091         918         632           lam         1672496         873         693           lam		85% 1	15% 52%	% 48%	3%	25%	4%	87	434	12	3689	86
lam 875249 1304 885  224376 438 358  1 810546 605 508  1 1166690 1127 1008  1 1166690 1127 1008  1 1166690 1127 1008  1 1234041 659 407  1 2042249 896 370  1 2042249 896 370  1 2042249 896 370  2 2042249 896 370  1 2042249 896 370  2 2042249 896 370  2 2042249 896 370  1 165575 1024 618  1 165091 127 922  2 410021 2504 2144  ool 1033300 865 671  1 1652496 873 693  1 1672496 873 693  1 1672496 873 693  1 1672496 873 693  1 1672496 873 693  1 1672496 873 693  1 1672496 873 1086		87% 1	13% 80%	% 20%	2%	82%	3%	130	745	35	3490	165
lam 875249 1761 1362  1 810546 605 508  1 4181189 3771 1593  1 166690 1127 1008  1 166690 1127 1008  1 1234041 659 407  1 2042249 896 370  1 2042249 896 370  1 2042249 896 370  2 2042249 896 370  1 2042249 896 370  2 2042249 896 370  1 1655752 1024 618  2 1 1655752 1024 618  1 165752 1024 618  2 1 165752 1024 618  2 1 1033300 865 671  2 2 1 1035300 865 671  2 2 1 1035300 865 631  2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		81% 1	19% 26%	% 44%	2%	74%	2%	187	2	0	1306	187
lam 875249 1761 1362  8 10546 605 508  1 4181189 3771 1593  1 1166690 1127 1008  1 553875 484 422  1 553875 484 422  1 2042249 896 671  1 2042249 896 370  bad 732376 575 501  1 921596 1127 922  1 921596 1127 922  1 1655752 1024 618  1 1655752 1024 618  1 1655754 1024 618  1 165780 865 671  2 410021 2504 2144  col 1035300 865 671  1 1652991 918 632  1 1652991 771  2 2301596 873 693  ii 2301596 873 1086		89% 1	11% 61%	%68 %	3%	64%	%0	28	5	1	443	84
810546         605         508           1         4181189         3771         1593           1166690         1127         1008           1166690         1127         1008           1         553875         484         422           1         670456         838         671           y         98368         733         630           r         1234041         659         407           r         1234041         659         407           gar         1625752         1024         618           gar         1655752         1024         618           ool         1655752         1024         2144           ool         1033300         865         671           1665091         918         632           1         1665091         918         632           1         1672496         873         693           1         1672496         873         693           1         12301596         1320         1086           1         1065760         851         712		78% 2	22% 76%	% 24%	2%	%29	%6	201	298	89	2359	270
1181189 3771 1593   1166690 1127 1008   1166690 1127 1008   1166690 1127 1008   1166690 1127 1008   1167 1008   1167 1008   1167 1009		84% 1	16% 58%	% 42%	3%	72%	%9	75	9	1	611	75
nr 670456 1127 1008  rr 670456 838 671  y 988368 733 630  rr 1234041 659 407  t 2042249 896 370  bad 732376 575 501  gar 1655752 1024 618  1 921596 1127 922  1 921596 1127 922  1 1655091 918 632  1 1655091 918 632  1 1655091 918 632  1 1655091 918 632  1 1652496 873 693  i 1672496 873 693  i 1672496 873 693  i 1672496 873 693  i 1672496 873 1086	L	90% 1	10% 29%	% 41%	%9	%99	3%	06	423	10	4194	100
ur         670456         838         671           y         988368         733         671           r         988368         733         630           r         1234041         659         407           r         2042249         896         370           bad         732376         575         501           gar         1655752         1024         618           l         921596         1127         922           l         921596         1127         922           s         2410021         2504         2144           cool         1035300         865         671           d         1665091         918         632           d         1665091         918         632           d         1672496         873         693           d         925817         791         729           ii         2301596         1320         1086	91%   9%	84% 1	16% 66%	% 34%	2%	%82	10%	26	19	2	1146	86
r         670456         838         671           y         988368         733         630           r         1234041         659         407           r         2042249         896         370           bad         732376         575         501           gar         1655752         1024         618           l         921596         1127         922           gar         161803         161         73           s         2410021         2504         2144           cool         1035300         865         671           r         1665091         918         632           r         1665091         918         632           r         1672496         873         693           r         925817         791         729           r         2301596         1320         1086           r         1065760         851         712	94% 6%	€ %69	31% 67%	% 33%	1%	%9/	2%	87	62	11	546	66
y         988368         733         630           r         1234041         659         407           l         2042249         896         370           bad         732376         575         501           gar         1655752         1024         618           l         921596         1127         922           s         111803         161         73           sol         1035300         865         671           r         1665091         918         632           d         1672496         873         693           d         925817         791         729           i         2301596         1320         1086           i         2301596         851         712	93% 7%	71% 2	80% 80%	% 20%	1%	75%	3%	125	0	0	838	125
rr         1234041         659         407           l         2042249         896         370           bad         732376         575         501           gar         1655752         1024         618           l         921596         1127         922           s11803         161         73           col         1035300         865         671           l         1665091         918         632           l         1665091         918         633           l         1672496         873         693           l         225817         791         729           l         2301596         1320         1086           l         1065760         851         712	91% 8%	%86	%09   %2	% 40%	3%	%59	%8	74	104	11	837	85
pad         2042249         896         370           bad         732376         575         501           gar         1655752         1024         618           1         921596         1127         922           811803         161         73           2410021         2504         2144           col         1035300         865         671           1         1665091         918         632           1         1672496         873         693           1         2301596         1320         1086           1         2301596         851         712	87% 13%	82% 1	18%   79%	% 21%	7%	%£6	11%	53	305	25	964	28
bad         732376         575         501           gar         1655752         1024         618           1         921596         1127         922           811803         161         73           col         2410021         2504         2144           col         1035300         865         671           r         1665091         918         632           r         711145         696         543           r         1672496         873         693           r         925817         791         729           r         2301596         1320         1086           r         1065760         851         712	93% 2%	78%	22%   76%	6 24%	2%	%08	%8	44	1793	88	5689	132
gar         1655752         1024         618           1         921596         1127         922           811803         161         73         161           2410021         2504         2144         200           1035300         865         671         671           1665091         918         632         63           11145         696         543         63           1672496         873         693         63           25817         791         729           1065760         851         712	8% 8%	€   %0∠	%69   %08	%   31%	2%	%89	4%	62	0	0	575	62
1         921596         1127         922           811803         161         73           811803         161         73           2410021         2504         2144           ool         1035300         865         671           1665091         918         632         71145           711145         696         543         693           1 672496         873         693         693           1 2301596         1320         1086         729           1 065760         851         712         712	6%   6%	86% 1	14% 83%	%   17%	3%	%19	%9	62	46	3	1070	92
811803     161     73       2410021     2504     2144       cool     1035300     865     671       1665091     918     632       1     711145     696     543       1     1672496     873     693       925817     791     729       1     2301596     1320     1086       1     1065760     851     712	93% 7%	83% 1	17% 53%	% 47%	3%	51%	2%	122	15	2	1142	124
2410021     2504     2144       ool     1035300     865     671       1665091     918     632       711145     696     543       1 672496     873     693       925817     791     729       ii     2301596     1320     1086       1 005760     851     712	86% 14%	77% 2	23% 84%	6   16%	2%	93%	18%	20	3	0	164	20
ool 1035300 865 671 1665091 918 632 711145 696 543 1 1672496 873 693 i 2301596 1320 1086 1065760 851 712	70% 30%	83% 1	17%   59%	6 41%	%9	94%	%9	104	19	1	2523	105
1665091     918     632       711145     696     543       1     1672496     873     693       925817     791     729       1     2301596     1320     1086       1     1065760     851     712	93% 2%	82% 1	18% 20%	%08 9	2%	%79	7%	84	7	1	872	84
bad 1672496 873 693 alli 925817 791 729 cddi 2301596 1320 1086 t 1065760 851 712	85% 15%	81% 1	19%   76%	6 24%	4%	%29	%6	22	1122	29	2040	123
1672496     873     693       925817     791     729       2301596     1320     1086       1065760     851     712	8% 8%	85% 1	15%   53%	% 47%	7%	48%	%9	86	0	0	969	86
925817     791     729       2301596     1320     1086       1065760     851     712	87% 13%	%16	%8 %6	% 17%	3%	27%	4%	52	1076	64	1949	117
2301596 1320 1086 1065760 851 712	90% 10%	80% 2	20% 62%	%88 %	3%	%26	%2	85	8	1	266	98
1065760 851 712	79% 21%	85% 1	15% 64%	%98 9	4%	82%	%9	57	166	7	1486	92
	86% 14%	81% 1	19%   68%	% 32%	2%	%88	%9	80	0	0	851	80
Siricilla 647679 470 440 94%	98% 2%	76% 2	24% 65%	%28 %	3%	%99	%9	73	40	9	510	79
Sngareddy 1283558 1388 1152 83%	84% 16%	80% 2	20% 70%	%08 9	2%	%26	%6	108	6	1	1397	109

ual al ifi- on te	9	1	. ~	0	8	_									IC.	6	9			2		C		<u> </u>		0	4	1	7	
Annual Total Notifi- cation Rate	126	131	99	120	278	69	38	45	19	69	24	09	89	38	105	169	136	92	92	162	49	170	74	29	88	120	144	201	127	82
Total Notifi- cation	1379	1062	473	813	2889	009	152	206	64	303	124	274	199	371	5123	6894	9001	2457	1558	2459	2532	2462	2863	2380	2092	2386	5195	9266	3455	3367
Private Sector Notifi- cation Rate	34	0	0	27	94	4	0	0	0	0	0	0	0	1	24	12	20	26	18	28	4	6	27	11	10	34	17	52	14	37
Private Sector Notifi- cation	371	0	0	186	826	32	0	0	0	0	0	1	0	4	1190	203	1350	202	648	430	907	134	1025	406	249	699	622	2554	374	1495
Notifi- cation Rate (Public)	92	131	99	93	184	92	38	45	19	69	24	26	89	38	81	157	116	99	57	133	45	161	48	55	77	98	126	150	113	46
HIV Status Positive % (of Known)	%6	%9	2%	3%	%/	%6	%0	%0	%0	2%	%0	%0	1%	2%	%0	%0	1%	%0	%0	%0	%0	3%	%0	%0	%0	%0	%0	1%	%0	%0
HIV Status Known %	83%	%76	83%	%92	%89	%22	21%	76%	2%	%08	64%	44%	%76	%59	49%	%09	%09	39%	10%	16%	16%	21%	46%	64%	18%	%68	%89	%28	15%	71%
Paedi- atric TB %	3%	2%	3%	7%	3%	7%	3%	2%	%0	2%	%7	1%	4%	%7	%2	%2	%2	4%	4%	%9	%9	%9	%9	2%	2%	%9	%2	%9	%9	%9
Clin- ically Diag- nosed	32%	30%	33%	19%	30%	25%	62%	26%	22%	54%	38%	34%	45%	79%	38%	33%	35%	42%	41%	22%	22%	35%	22%	52%	46%	22%	31%	24%	25%	51%
Micro- biolog- ically Con- firmed %	%89	%02	%29	81%	%02	75%	38%	74%	43%	46%	%89	%99	22%	74%	%29	%29	%59	28%	26%	%82	43%	%59	%82	48%	54%	%82	%69	%92	%5/	46%
Previ- ously Treat- ed %	20%	20%	17%	34%	30%	22%	13%	10%	%6	%6	%6	10%	10%	15%	39%	12%	22%	13%	18%	14%	14%	18%	14%	12%	%6	79%	14%	15%	2%	16%
% New TB Patients	%08	%08	83%	%99	%02	%82	%28	%06	%16	91%	%16	%06	%06	%28	61%	%88	%82	%28	82%	%98	%98	82%	%98	%88	91%	74%	%98	%28	%26	84%
Extra Pul- mo- nary TB %	%8	15%	%2	%8	15%	12%	%6	18%	24%	20%	27%	13%	21%	19%	15%	15%	12%	12%	10%	%6	%6	22%	11%	10%	2%	15%	13%	10%	11%	23%
Pul- mo- nary TB %	%76	85%	93%	%76	85%	%88	%16	82%	%92	%08	73%	%28	%62	81%	85%	%28	%88	%88	%06	%16	%16	%82	%68	%06	%26	85%	%28	%06	%68	%22
Treat- ment Initiat- ed %	%86	%89	25%	%68	44%	%68	84%	72%	84%	%86	45%	%26	%96	%92	51%	74%	54%	95%	56%	94%	72%	91%	35%	81%	95%	75%	%76	58%	%06	47%
Treat- ment Initiat- ed	933	899	258	929	846	206	128	149	54	282	26	258	191	278	2018	4720	4141	1609	655	1905	1676	2117	645	1608	1688	1281	4230	4331	2785	889
Public Sector Notifi- cation	1008	1062	473	627	1911	268	152	206	64	303	124	273	199	364	3933	6391	7651	1755	1179	2029	2326	2328	1838	1974	1843	1717	4573	7422	3081	1872
Total Pop- ulation	1093246	810557	712906	676545	1039558	873814	397882	461524	343039	436038	508054	459599	291470	668896	4859518	4073723	9289099	2657226	2057541	1519892	5118003	1447516	3856596	3577432	2388401	1995504	3618790	4952572	2729601	4084063
District Name	Suryapet	Vikarabad	Wanaparthy	Warangal(Rural)	Wrangal(Urban)	Yadadri	Dhalai	Gomati	Khowai	North Tripura	Sepahijala	South Tripura	Unakoti	West Tripura	Agra	Aligarh	Allahabad	Ambedkar Nagar	Amethi	Auraiya	Azamgarh	Baghpat	Bahraich	Ballia	Balrampur	Banda	Barabanki	Bareilly	Basti	Bijnor
State Name	Telangana	Telangana	Telangana	Telangana	Telangana	Telangana	Tripura	Tripura (	Tripura	Tripura	Tripura 5	Tripura	Tripura	Tripura	Uttar Pradesh Agra	Uttar Pradesh Aligarh	Uttar Pradesh Allahabad	Uttar Pradesh Nagar	Uttar Pradesh Amethi	Uttar Pradesh Auraiya	Uttar Pradesh Azamgarh	Uttar Pradesh Baghpat	Uttar Pradesh Bahraich	Uttar Pradesh Ballia	Uttar Pradesh Balrampur	Uttar Pradesh Banda	Uttar Pradesh Barabanki	Uttar Pradesh Bareilly	Uttar Pradesh Basti	Uttar Pradesh Bijnor

_										_				1														1	
Annual Total Notifi- cation Rate	145	198	26	144	68	168	243	103	66	155	153	268	263	44	104	151	176	199	141	156	160	64	199	108	88	121	277	177	127
Total Notifi- cation	5028	2686	2110	1575	3042	3287	4249	2815	2088	4513	4234	4979	10289	1757	3969	7445	2148	2874	6414	2710	2967	3183	4432	2204	1622	2419	14081	2820	2246
Private Sector Notifi- cation Rate	14	26	12	23	32	47	47	18	20	33	39	28	30	4	22	49	52	51	12	36	42	4	29	26	2	13	105	71	9
Private Sector Notifi- cation	481	1022	592	250	1103	878	822	504	418	971	1093	517	1169	179	855	2393	631	731	533	628	786	188	1320	520	42	250	5323	1134	108
Notifi- cation Rate (Public)	131	172	85	121	26	121	196	84	80	121	113	240	233	39	82	103	124	148	130	120	118	09	140	83	98	109	173	106	121
HIV Status Positive % (of Known)	%0	%0	%0	%0	2%	%0	1%	%0	%0	%0	%0	%0	%0	3%	%0	1%	%0	%0	%0	1%	1%	%0	%0	%0	%0	%0	%0	%0	%0
HIV Status Known %	46%	48%	12%	%19	39%	%29	%44	1%	43%	%86	47%	49%	82%	54%	42%	%44	64%	22%	32%	64%	%02	16%	81%	29%	35%	%92	%82	30%	%44
Paedi- atric TB %	4%	2%	4%	%9	4%	%2	%/	%9	2%	%9	13%	12%	11%	2%	%/	%9	2%	%8	4%	%8	%9	2%	4%	4%	2%	4%	%2	2%	%9
Clin- ically Diag- nosed	%97	21%	30%	%97	34%	37%	32%	32%	35%	30%	46%	39%	%09	51%	44%	41%	34%	51%	25%	38%	36%	39%	78%	30%	29%	11%	36%	35%	32%
Micro- biolog- ically Con- firmed %	74%	46%	%02	74%	%99	%89	%89	%89	%59	%02	54%	61%	40%	49%	26%	29%	%99	46%	%52	%29	64%	61%	72%	%02	71%	%68	64%	%29	%89
Previ- ously Treat- ed %	12%	10%	12%	19%	18%	12%	16%	%2	13%	14%	79%	16%	16%	%9	11%	16%	13%	%6	%6	20%	16%	%6	22%	12%	15%	23%	20%	15%	%6
% New TB Patients	%88	%06	%88	81%	82%	%88	84%	%86	%28	%98	74%	84%	84%	94%	%68	84%	%28	%16	%16	%08	84%	%16	%82	%88	%28	%44	%08	85%	%16
Extra Pul- mo- nary TB %	2%	16%	%8	11%	%8	11%	19%	10%	%6	18%	21%	32%	34%	%8	11%	15%	%6	22%	4%	14%	7%	10%	%2	%8	18%	%2	18%	12%	2%
Pul- mo- nary TB %	%26	84%	%76	%68	%76	%68	81%	%06	%16	82%	%62	%89	%99	%76	%68	85%	%16	%82	%96	%98	%86	%06	%£6	%76	82%	%86	82%	%88	%86
Treat- ment Initiat- ed %	74%	%98	81%	85%	%29	91%	73%	84%	20%	85%	71%	83%	39%	95%	75%	61%	71%	%09	%06	%28	82%	%95	71%	%69	72%	82%	73%	61%	%82
Treat- ment Initiat- ed	3368	5708	1495	1123	1294	2147	2518	1952	832	2999	2244	3715	3581	1451	2344	3078	1082	1280	5287	1804	1786	1668	2197	1158	1130	1784	6414	1033	1676
Public Sector Notifi- cation	4547	6664	1844	1325	1939	2359	3427	2311	1670	3542	3141	4462	9120	1578	3114	5052	1517	2143	5881	2082	2181	2995	3112	1684	1580	2169	8758	1686	2138
Total Pop- ulation	3463699	3877275	2171274	1095976	3432681	1954147	1747359	2739941	2098898	2915711	2770959	1861092	3908293	4022026	3804899	4921554	1220049	1447516	4538996	1737019	1850753	4962912	2222971	2036862	1840413	1995504	5076645	1592268	1768037
District Name	Budaun	Bulandshahar	Chandauli	Chitrakoot	Deoria	Etah	Etawah	Faizabad	Farrukhabad	Fatehpur	Firozabad	Gautam Budh Nagar	Ghaziabad	Ghazipur	Gonda	Gorakhpur	Hamirpur-UP	Hapur	Hardoi	Hathras	Jalaun	Jaunpur	Jhansi	Jyotiba Phule Nagar	Kannauj	Kanpur Dehat	Kanpur Nagar	Kanshiram Nagar	Kaushambi
State Name	Uttar Pradesh Budaun	Uttar Pradesh Bulandshahar	Uttar Pradesh Chandauli	Uttar Pradesh Chitrakoot	Uttar Pradesh Deoria	Uttar Pradesh Etah	Uttar Pradesh Etawah	Uttar Pradesh Faizabad	Uttar Pradesh Farrukhabad	Uttar Pradesh Fatehpur	Uttar Pradesh Firozabad	Uttar Pradesh   Gautam Budh   Nagar	Uttar Pradesh Ghaziabad	Uttar Pradesh Ghazipur	Uttar Pradesh Gonda	Uttar Pradesh Gorakhpur	Uttar Pradesh Hamirpur-UP	Uttar Pradesh Hapur	Uttar Pradesh Hardoi	Uttar Pradesh Hathras	Uttar Pradesh Jalaun	Uttar Pradesh Jaunpur	Uttar Pradesh Jhansi	Uttar Pradesh   Jyotiba Phule   Nagar	Uttar Pradesh Kannauj	Uttar Pradesh Kanpur Dehat	Uttar Pradesh Kanpur Nagar	Uttar Pradesh Nagar	Uttar Pradesh Kaushambi

State Name	District Name	Total Pop- ulation	Public Sector Notifi- cation	Treat- ment Initiat- ed	Treat- ment Initiat- ed %	Pul- mo- nary TB %	Extra Pul- mo- nary TB %	% New TB Patients	Previ-   ously Treat- ed %	Microbiologically Confirmed	Clin- ically Diag- nosed	Paedi- atric TB %	HIV Status Known %	HIV Status Positive % (of Known)	Notifi- cation Rate (Public)	Private Sector Notifi- cation	Private Sector Notifi- cation Rate	Total Notifi- cation	Annual Total Notifi- cation Rate
Uttar Pradesh Kheri	Cheri	4456281	8009	5290	%88	%96	4%	%16	%6	%02	30%	4%	44%	%9	135	411	6	6419	144
Pradesh   k	Uttar Pradesh Kushinagar	3949651	2417	993	41%	%16	%6	%68	11%	48%	52%	%9	17%	2%	61	794	20	3211	81
Uttar Pradesh Lalitpur	alitpur	1354461	1376	296	%02	%76	%8	81%	19%	84%	16%	3%	%99	%0	102	208	25	2084	154
Uttar Pradesh Lucknow	ucknow	2086985	19201	9027	85%	81%	19%	84%	16%	%29	32%	%2	72%	1%	208	3283	59	13844	272
Pradesh N	Uttar Pradesh Maharajganj	2957068	2086	1811	87%	%76	%8	%06	10%	71%	29%	4%	71%	1%	71	344	12	2430	82
Uttar Pradesh Mahoba	Vahoba	971904	843	442	25%	94%	%9	84%	16%	%06	10%	3%	%9	%0	87	287	30	1130	116
Uttar Pradesh Mainpuri	Mainpuri	2047201	2292	1935	84%	%28	13%	%08	20%	74%	79%	2%	%02	%0	112	465	23	2757	135
Uttar Pradesh Mathura	Mathura	2822656	0968	3643	%76	84%	16%	%86	%2	%79	38%	%8	%08	%0	140	3276	116	7236	256
Uttar Pradesh Mau	Mau	2450438	1541	1373	%68	%76	%8	%06	10%	54%	46%	%9	%92	1%	63	1041	42	2582	105
Uttar Pradesh Meerut	Meerut	3825578	6945	4056	28%	%92	24%	%98	14%	25%	45%	2%	61%	1%	182	1792	47	8737	228
Uttar Pradesh Mirzapur	Mirzapur	2770959	3095	1021	33%	%26	3%	81%	19%	26%	41%	2%	39%	1%	112	223	8	3318	120
Pradesh N	Uttar Pradesh Moradabad	3525735	4252	3423	81%	82%	18%	%28	13%	24%	46%	%8	%88	1%	121	3687	105	7939	225
Pradesh N	Uttar Pradesh Muzaffarnagar	3122499	4458	3234	73%	72%	28%	%88	12%	64%	%98	2%	28%	%0	143	999	21	5123	164
Uttar Pradesh Pilibhit	ilibhit	2264328	2570	1574	61%	%16	%6	%28	15%	%02	30%	2%	46%	1%	113	1067	47	3637	161
Pradesh F	Uttar Pradesh Pratapgarh	3525735	7494	2158	%28	%16	%6	%88	12%	73%	27%	2%	%16	1%	71	634	18	3128	68
Uttar Pradesh Rae Bareli	Rae Bareli	3267250	6682	901	38%	%16	%6	%98	14%	61%	36%	%9	23%	%0	73	150	2	2549	78
Uttar Pradesh Rampur	kampur	2595189	4065	2961	73%	87%	13%	%06	10%	%69	31%	%9	%86	%0	157	924	36	4989	192
Pradesh S	Uttar Pradesh Saharanpur	3846257	6302	5489	87%	77%	23%	%28	15%	64%	36%	8%	82%	1%	164	1357	35	7659	199
Uttar Pradesh Sambhal	sambhal	2295347	1943	1431	74%	%16	%6	%88	12%	%82	22%	4%	%0		82	691	30	2634	115
Pradesh S	Uttar Pradesh Sant Kabir Nagar	1902450	1471	831	26%	%68	11%	%28	13%	%89	32%	%9	83%	%0	77	377	20	1848	97
Pradesh S	Uttar Pradesh Nagar	1726680	1647	1558	%26	%28	13%	%98	14%	20%	20%	%8	%96	2%	95	344	20	1991	115
Pradesh S	Uttar Pradesh Shahjahanpur	3329287	3779	3356	%68	%16	%6	%68	11%	74%	79%	2%	%99	%0	114	2136	64	5915	178
Uttar Pradesh Shamli	shamli	1468195	1482	1431	%26	%62	21%	%28	13%	74%	26%	%8	61%	%0	101	339	23	1821	124
Uttar Pradesh Shravasti	Shravasti	1240728	1173	666	85%	%16	%6	%68	11%	%28	13%	%9	39%	%0	95	47	4	1220	98
Pradesh S	Uttar Pradesh Siddharthnagar	2832995	921	581	%89	%86	2%	%76	%8	%99	34%	2%	2%	%0	33	496	18	1417	50
Uttar Pradesh Sitapur	Sitapur	4962912	7031	2908	84%	%76	%8	84%	16%	28%	42%	2%	85%	%0	142	785	16	7816	157
Pradesh 5	Uttar Pradesh Sonbhadra	2067880	2037	1842	%06	%96	4%	84%	16%	84%	16%	2%	95%	%0	66	394	19	2431	118
Uttar Pradesh Sultanpur	Jultanpur	2636547	2209	1901	%98	%76	%8	%88	12%	%29	33%	2%	26%	1%	84	419	16	2628	100
Uttar Pradesh Unnao	Jnnao	3453359	5389	1699	71%	%98	14%	84%	16%	%95	44%	2%	37%	1%	69	612	18	3001	87
Uttar Pradesh Varanasi	/aranasi	4084063	4395	3801	%98	82%	18%	%88	12%	20%	20%	%6	54%	3%	108	1766	43	6161	151

	_																													
Annual Total Notifi- cation Rate	73	66	48	29	225	102	213	170	87	129	75	144	105	237	134	124	94	94	119	154	174	140	92	101	150	87	123	291	262	51
Total Notifi- cation	498	283	208	191	4211	022	4506	98/1	463	336	510	2617	381	813	641	4742	7753	555	4437	2728	2688	2612	424	5935	6173	2611	5240	1339	1371	2759
Private Sector Notifi- cation Rate	0	0	0	0	84	0	62	38	1	7	1	23	0	137	53	18	2	53	7	10	31	41	09	17	8	11	7	155	107	6
Private Sector Notifi- cation	0	0	0	0	1578	0	1321	401	7	19	4	418	0	472	254	9/9	180	313	271	176	611	2099	274	1022	129	323	282	713	558	502
Notifi- cation Rate (Public)	73	66	48	29	141	102	150	132	85	122	75	121	105	66	81	106	92	41	112	144	142	66	33	84	147	92	117	136	156	42
HIV Status Positive % (of Known)	4%	%0	%0	%0	%0	1%	%0	%0	1%	7%	%0	1%	%0	1%	3%	%0	1%	7%	1%	1%	3%	2%	3%	1%	1%	2%	%0	2%	4%	1%
HIV Status Known %	2%	%44	2%	22%	%89	46%	45%	46%	72%	%28	%98	19%	7%	%29	%08	39%	%99	23%	52%	41%	38%	22%	%02	%02	84%	%2%	17%	74%	26%	29%
Paedi- atric TB %	3%	3%	3%	4%	%2	4%	%9	%9	3%	3%	3%	%2	4%	%2	%9	3%	4%	4%	3%	3%	2%	%9	10%	3%	4%	3%	2%	11%	10%	2%
Clin- ically Diag- nosed	%98	35%	51%	41%	22%	38%	40%	36%	20%	45%	34%	49%	45%	36%	32%	30%	35%	41%	79%	30%	39%	36%	44%	38%	31%	37%	30%	43%	44%	32%
Microbiolog- biolog- ically Con- firmed %	64%	%29	46%	26%	43%	%29	%09	61%	%08	25%	%99	51%	25%	64%	%89	%02	%29	26%	74%	20%	61%	61%	%99	%79	%69	%89	%02	22%	%95	%89
Previ- ously Treat- ed %	21%	25%	19%	12%	20%	20%	21%	26%	27%	20%	28%	21%	25%	10%	18%	3%	13%	16%	12%	%8	15%	14%	12%	13%	13%	10%	12%	18%	15%	12%
% New TB Patients	%62	75%	81%	%88	%08	%08	%62	74%	73%	%08	72%	%62	75%	%06	82%	%26	%28	84%	%88	92%	85%	%98	%88	%28	%28	%06	%88	82%	85%	88%
Extra Pul- mo- nary TB %	21%	24%	19%	14%	27%	19%	17%	22%	12%	24%	17%	12%	25%	32%	25%	10%	17%	27%	14%	18%	30%	79%	38%	23%	21%	27%	19%	35%	29%	21%
Pul- mo- nary TB %	%62	%92	81%	%98	73%	81%	83%	%82	%88	%92	83%	%88	75%	%89	75%	%06	83%	73%	%98	82%	%02	74%	%29	22%	%62	73%	81%	%29	71%	%62
Treat- ment Initiat- ed %	%86	%86	%96	%26	%68	%76	%86	85%	%66	%96	95%	51%	%86	94%	%96	%86	91%	%06	%26	95%	%76	%06	%68	94%	91%	%86	%96	%96	%96	86%
Treat- ment Initiat- ed	488	278	199	181	2346	208	3124	1172	453	305	468	1114	373	322	371	3995	6912	218	4038	2413	2561	4610	133	4613	5475	2245	4738	604	784	1940
Public Sector Notifi- cation	498	283	208	191	2633	220	3185	1385	456	317	206	2199	381	341	387	4066	7573	242	4166	2552	2786	9609	150	4913	6044	2288	4958	979	813	2257
Total Pop- ulation	28689	285769	430142	285191	1868054	755034	2119322	1050438	534489	260492	677919	1812853	362584	343370	478796	3820920	8206092	592016	3721150	1775299	1957089	5144052	812624	5865199	4111379	2999094	4247688	460812	522660	5412430
District Name	Almora	Bageshwar	Chamoli	Champawat	Dehradun	Garhwal	Hardwar	Nainital	Pithoragarh	Rudraprayag	Tehri Garhwal	Udhamsingh Nagar	Uttarkashi	Alipore	Bagbazar	Bankura	Barddhaman	Behala	Birbhum	Dakshin Dina- jpur	Darjiling	Haora	Hazi	Hugli	Jalpaiguri	Koch Bihar	Maldah	Maniktala	Manshatala	Medinipur East
State Name	Uttarakhand	Uttarakhand	Uttarakhand	West bengal	West bengal	West bengal	West bengal	West bengal	West bengal	West bengal	West bengal	West bengal	West bengal	West bengal																

State Name	District Name	Total Pop- ulation	Public Sector Notifi- cation	Treat- ment Initiat- ed	Treat- ment Initiat- ed %	Pul- mo- nary TB %	Extra Pul- mo- nary TB %	% New TB Patients	Previ- ously Treat- ed %	Micro- biolog- ically Con- firmed %	Clin- ically Diag- nosed	Paedi- atric TB %	HIV Status Known %	HIV Status Positive % (of Known)	Notifi- cation Rate (Public)	Private Sector Notifi- cation	Private Sector Notifi- cation Rate	Total Notifi- cation	Annual Total Notifi- cation Rate
West bengal	West bengal   Medinipur West	6314525	5485	5190	%26	83%	17%	%16	%6	%02	30%	2%	%95	1%	87	28	0	5513	87
West bengal MTMTB	MTMTB	509160	150	133	%68	%62	21%	%26	2%	%26	3%	3%	4%	%0	59	810	159	096	189
West bengal	Murshidabad	7546056	9809	4582	75%	%62	21%	%68	11%	%02	30%	4%	31%	%0	81	1024	14	7110	94
West bengal	Nadia	5491317	3919	3719	%26	75%	25%	%88	12%	%29	35%	3%	82%	1%	71	546	10	4465	81
West bengal	North 24 Par- ganas	10712638	6462	5762	%68	%22	23%	%28	15%	71%	762	4%	%62	2%	09	1848	17	8310	78
West bengal	Puruliya	3110849	2156	2034	94%	%88	12%	%28	13%	%59	35%	3%	%29	%0	69	121	4	2277	73
West bengal	South 24 Par- ganas	8662432	5102	4278	84%	%92	24%	%68	11%	%89	32%	4%	25%	1%	59	647	7	5749	99
West bengal	Strand Bank	375685	147	120	82%	74%	%97	%18	19%	%82	23%	2%	%89	%6	39	297	62	444	118
West bengal	Tangra	532018	847	922	%26	%69	31%	%62	21%	61%	39%	11%	%82	2%	159	516	26	1363	256
West bengal	Tollygunge	492687	365	363	%66	72%	28%	%98	14%	%29	35%	4%	%89	3%	74	231	47	296	121
West bengal	Uttar Dinajpur	3188286	2232	2176	%26	82%	18%	%28	13%	71%	76%	2%	25%	2%	70	165	5	2397	75
INDIA		1321476476 1444	1444175	175 1147855	%62	82%	18%	%28	15%	61%	39%	%9	%29	3%	109	383784	29	1827959	138

# Annexure 2(a i): Treatment Outcome of Microbiologically Confirmed New TB patients notified in 2016 from public sector

State	Registered		Cured	Treatment	Died	Failure	Lost to	Treatment	Not
		Completed		Success			Follow-	Regimen	Reported
A 11 D 1 1	40407	<b>5</b> 0/	0.40/	000/	40/	10/	up	Changed	20/
Andhra Pradesh	48136	5%	84%	89%	4%	1%	3%	1%	2%
Andman and Nicobar	168	2%	82%	84%	5%	2%	2%	4%	4%
Arunachal Pradesh	853	4%	61%	65%	1%	1%	4%	5%	25%
Assam	14925	8%	70%	78%	4%	1%	5%	0%	11%
Bihar	31386	14%	58%	72%	2%	1%	5%	0%	20%
Chandigarh	1134	4%	83%	87%	3%	2%	4%	1%	2%
Chhattisgarh	13131	7%	82%	89%	5%	1%	4%	0%	0%
Dadra and Nagar Haveli	193	5%	84%	90%	3%	2%	1%	3%	3%
Daman and Diu	122	17%	75%	93%	4%	1%	0%	2%	1%
Delhi	14526	2%	83%	85%	3%	3%	6%	2%	2%
Goa	616	6%	80%	85%	3%	3%	5%	1%	2%
Gujarat	41144	2%	86%	88%	5%	2%	4%	1%	1%
Haryana	14797	8%	71%	79%	4%	2%	4%	1%	11%
Himachal Pradesh	5301	8%	81%	89%	4%	2%	3%	1%	1%
Jammu and Kashmir	3480	8%	77%	85%	4%	2%	3%	0%	7%
Jharkhand	16811	7%	84%	92%	3%	1%	4%	0%	0%
Karnataka	27397	3%	77%	80%	6%	2%	5%	1%	7%
Kerala	9948	5%	79%	84%	5%	4%	4%	1%	3%
Lakshadweep	16	38%	56%	94%	6%	0%	0%	0%	0%
Madhya Pradesh	46935	6%	76%	83%	4%	1%	4%	0%	9%
Maharashtra	46167	4%	76%	79%	5%	1%	5%	2%	8%
Manipur	678	7%	73%	79%	3%	3%	6%	1%	7%
Meghalaya	1369	5%	75%	80%	4%	1%	4%	3%	9%
Mizoram	570	6%	67%	74%	4%	2%	3%	1%	18%
Nagaland	1023	4%	63%	68%	1%	3%	2%	0%	26%
Odisha	20888	4%	68%	72%	4%	1%	3%	0%	19%
Puducherry	652	4%	85%	89%	4%	3%	4%	0%	0%
Punjab	14753	9%	77%	86%	5%	2%	5%	0%	1%
Rajasthan	33961	4%	86%	90%	4%	1%	4%	1%	1%
Sikkim	424	2%	64%	66%	2%	3%	1%	19%	8%
Tamil Nadu	37967	4%	72%	76%	5%	1%	5%	0%	12%
Tripura	1265	4%	67%	71%	4%	2%	4%	0%	19%
Uttar Pradesh	118649	6%	58%	64%	3%	1%	4%	1%	27%
Uttarakhand	5096	6%	71%	78%	4%	1%	6%	1%	10%
West bengal	41677	3%	83%	86%	5%	2%	6%	1%	1%
INDIA	616201	5%	<b>74%</b>	79%	<b>4</b> %	1%	4%	1%	10%

Note: For 2016, Telangana state outcome data is included along with Andhra Pradesh state.

# Annexure 2(a ii):Treatment Outcome of Microbiologically Confirmed Previously treated TB patients notified in 2016 from public sector

State	Registered	Cure	Treatment Completed	Treatment Success	Died	Failure	Lost to Followup	Treatment Regimen Changed	Not Reported
Andhra Pradesh	13904	69%	7%	76%	8%	3%	7%	4%	3%
Andman and Nicobar	56	75%	4%	79%	4%	4%	7%	4%	4%
Arunachal Pradesh	282	46%	4%	50%	2%	1%	7%	16%	24%
Assam	3385	49%	12%	60%	8%	3%	12%	4%	13%
Bihar	5729	50%	17%	67%	4%	1%	8%	3%	16%
Chandigarh	322	76%	4%	80%	6%	2%	6%	3%	3%
Chhattisgarh	1910	61%	11%	72%	10%	3%	12%	3%	0%
Dadra and Nagar Haveli	69	68%	3%	71%	4%	1%	10%	7%	6%
Daman and Diu	47	66%	15%	81%	6%	2%	0%	11%	0%
Delhi	6582	69%	2%	71%	6%	4%	10%	6%	3%
Goa	154	71%	6%	77%	5%	4%	10%	3%	1%
Gujarat	16439	71%	4%	75%	10%	4%	9%	2%	1%
Haryana	6581	60%	10%	70%	7%	3%	6%	3%	11%
Himachal Pradesh	2187	70%	11%	81%	6%	3%	6%	4%	1%
Jammu and Kashmir	1261	63%	10%	74%	6%	4%	6%	3%	8%
Jharkhand	2478	68%	11%	79%	5%	2%	9%	3%	1%
Karnataka	8436	54%	5%	58%	10%	4%	15%	4%	9%
Kerala	1850	62%	7%	69%	7%	6%	10%	3%	5%
Lakshadweep	1	100%	0%	100%	0%	0%	0%	0%	0%
Madhya Pradesh	10450	58%	10%	68%	7%	3%	9%	4%	9%
Maharashtra	13797	54%	6%	60%	9%	4%	13%	5%	9%
Manipur	184	59%	7%	66%	3%	3%	11%	5%	11%
Meghalaya	312	54%	6%	61%	5%	5%	9%	13%	7%
Mizoram	132	56%	9%	65%	5%	3%	6%	4%	17%
Nagaland	352	55%	9%	64%	4%	3%	5%	1%	22%
Odisha	4036	52%	8%	60%	8%	2%	10%	2%	19%
Puducherry	187	63%	6%	69%	12%	10%	8%	1%	0%
Punjab	5274	63%	12%	76%	8%	3%	8%	3%	2%
Rajasthan	14510	72%	7%	78%	8%	2%	7%	3%	1%
Sikkim	160	68%	1%	69%	3%	4%	2%	14%	9%
Tamil Nadu	10869	53%	5%	59%	8%	4%	12%	3%	14%
Tripura	253	52%	4%	57%	5%	2%	10%	1%	26%
Uttar Pradesh	27941	46%	8%	54%	6%	1%	7%	5%	26%
Uttarakhand	1993	57%	7%	64%	5%	3%	9%	4%	14%
West bengal	9480	65%	4%	69%	8%	4%	12%	5%	2%
INDIA	171615	59%	7%	67%	8%	3%	9%	4%	10%

 $Note: For \ 2016, Telangana \ state \ outcome \ data \ is \ included \ along \ with \ Andhra \ Pradesh \ state.$ 

## Annexure 2(b i):Treatment Outcome of Clinically diagnosed New TB patients notified in 2016 from public sector

State	Registered	Treatment Success	Died	Failure	Lost to Fol- lowup	Treatment Regimen Changed	Not Reported
Andhra Pradesh	34940	92%	3%	0%	2%	0%	3%
Andman and Nicobar	247	89%	3%	0%	4%	0%	3%
Arunachal Pradesh	1329	73%	1%	1%	3%	1%	22%
Assam	15104	79%	3%	0%	6%	0%	12%
Bihar	20919	74%	2%	0%	5%	0%	19%
Chandigarh	1399	95%	1%	0%	1%	0%	2%
Chhattisgarh	14404	92%	4%	0%	3%	0%	0%
Dadra and Nagar Haveli	219	95%	2%	0%	0%	0%	2%
Daman and Diu	158	94%	3%	1%	0%	1%	2%
Delhi	30825	94%	1%	0%	3%	0%	2%
Goa	712	93%	3%	0%	1%	0%	2%
Gujarat	23246	93%	4%	0%	2%	0%	1%
Haryana	17237	85%	2%	0%	2%	0%	11%
Himachal Pradesh	5924	94%	3%	0%	2%	0%	1%
Jammu and Kashmir	4310	88%	3%	1%	3%	0%	6%
Jharkhand	14088	92%	2%	0%	5%	0%	1%
Karnataka	21491	84%	6%	0%	4%	0%	7%
Kerala	8944	89%	3%	0%	3%	0%	4%
Lakshadweep	22	95%	0%	0%	0%	0%	5%
Madhya Pradesh	51897	86%	2%	0%	3%	0%	9%
Maharashtra	50717	84%	4%	0%	4%	1%	8%
Manipur	780	86%	3%	0%	5%	0%	6%
Meghalaya	2016	82%	4%	0%	4%	1%	9%
Mizoram	1283	80%	2%	0%	2%	0%	16%
Nagaland	1176	65%	2%	0%	2%	0%	31%
Odisha	18746	75%	4%	0%	3%	0%	18%
Puducherry	545	97%	3%	0%	1%	0%	0%
Punjab	16448	93%	3%	0%	3%	0%	1%
Rajasthan	37191	93%	3%	0%	3%	0%	1%
Sikkim	724	88%	4%	1%	1%	3%	5%
Tamil Nadu	29927	80%	4%	0%	2%	0%	14%
Tripura	788	72%	5%	0%	5%	0%	18%
Uttar Pradesh	98754	67%	2%	0%	3%	0%	27%
Uttarakhand	5599	85%	2%	0%	4%	0%	8%
West bengal	30508	90%	5%	0%	4%	0%	2%
INDIA	562661	80%	3%	83%	3%	0%	3%

Note: For 2016, Telangana state outcome data is inclluded along with Andhra Pradesh state.

# Annexure 2(b ii): Treatment Outcome of Clinically diagnosed Previously treated TB patients notified in 2016 from public sector

State	Grand Total	Treaetment Success	Died	Failure	Lost to Followup	Treatment Regimen Changed	Not Reported
Andhra Pradesh	6375	86%	6%	0%	4%	1%	3%
Andman and Nicobar	30	77%	13%	0%	0%	0%	10%
Arunachal Pradesh	325	65%	3%	0%	6%	2%	24%
Assam	3482	70%	5%	0%	10%	1%	14%
Bihar	4214	73%	3%	0%	7%	0%	17%
Chandigarh	128	93%	2%	0%	3%	0%	2%
Chhattisgarh	1532	86%	5%	1%	8%	0%	0%
Dadra and Nagar Haveli	33	88%	6%	3%	0%	3%	0%
Daman and Diu	43	95%	2%	2%	0%	0%	0%
Delhi	5758	88%	3%	0%	6%	1%	2%
Goa	75	93%	0%	1%	1%	4%	0%
Gujarat	8674	88%	6%	0%	4%	0%	1%
Haryana	2880	77%	5%	0%	4%	1%	14%
Himachal Pradesh	663	85%	7%	0%	5%	1%	2%
Jammu and Kashmir	410	82%	5%	1%	3%	0%	9%
Jharkhand	2947	88%	3%	0%	6%	0%	1%
Karnataka	3727	74%	9%	0%	8%	1%	8%
Kerala	690	82%	5%	1%	7%	1%	4%
Lakshadweep	0	0%	0%	0%	0%	0%	0%
Madhya Pradesh	6468	79%	4%	0%	5%	1%	11%
Maharashtra	12192	73%	7%	1%	8%	2%	10%
Manipur	126	83%	4%	0%	6%	0%	8%
Meghalaya	317	68%	7%	1%	7%	5%	12%
Mizoram	179	80%	2%	0%	7%	0%	12%
Nagaland	187	68%	1%	2%	3%	1%	26%
Odisha	2130	70%	6%	0%	6%	0%	17%
Puducherry	33	94%	6%	0%	0%	0%	0%
Punjab	2027	87%	5%	1%	5%	1%	1%
Rajasthan	5783	86%	6%	1%	6%	1%	1%
Sikkim	126	86%	4%	0%	2%	4%	4%
Tamil Nadu	3502	74%	6%	0%	5%	0%	14%
Tripura	106	61%	8%	0%	7%	0%	25%
Uttar Pradesh	16168	63%	3%	0%	5%	1%	28%
Uttarakhand	833	76%	4%	0%	8%	1%	11%
West bengal	4325	82%	7%	0%	7%	1%	2%
INDIA	96490	3%	74%	77%	5%	0%	6%

Note: For 2016, Telangana state outcome data is inclluded along with Andhra Pradesh state.

### Annexure 2(c i): Treatment Outcome of HIV infected New TB cases notified from Public Sector in 2016

State	PLHIV-TB Registered	Treatment Outcome	Report- ing %	Cure %	Treat- ment	Treat- ment	Death %	Failure %	Lost to follow-	Treatment Regimen
	for Treat- ment	reported			Complet- ed %	Success %			up %	Changed
Andhra Pradesh	4954	4359	88%	37%	47%	84%	11%	1%	4%	1%
Andman and Nicobar	1	1	100%	0%	0%	0%	100%	0%	0%	0%
Arunachal Pradesh	4	2	50%	0%	100%	100%	0%	0%	0%	0%
Assam	121	59	49%	10%	69%	80%	12%	2%	3%	0%
Bihar	710	306	43%	21%	63%	84%	9%	0%	6%	0%
Chandigarh	19	19	100%	40%	40%	80%	5%	0%	10%	0%
Chhattisgarh	362	269	74%	24%	51%	75%	17%	1%	4%	1%
Dadra and Nagar Haveli	9	7	78%	29%	71%	100%	0%	0%	0%	0%
Daman and Diu	6	0	0%							
Delhi	579	238	41%	16%	67%	83%	6%	0%	7%	1%
Goa	62	40	65%	28%	55%	83%	10%	3%	5%	0%
Gujarat	1986	1674	84%	21%	58%	79%	15%	0%	4%	0%
Haryana	369	247	67%	21%	58%	79%	13%	0%	5%	0%
Himachal Pradesh	73	59	81%	22%	58%	80%	15%	2%	2%	2%
Jammu and Kashmir	20	4	20%	50%	0%	50%	25%	0%	0%	0%
Jharkhand	131	62	47%	24%	60%	84%	8%	2%	3%	0%
Karnataka	4988	4207	84%	25%	51%	76%	16%	1%	6%	0%
Kerala	191	108	57%	28%	52%	80%	7%	2%	7%	2%
Lakshadweep	0									
Madhya Pradesh	675	370	55%	22%	61%	83%	9%	1%	5%	0%
Maharashtra	5785	4016	69%	25%	51%	76%	13%	0%	6%	1%
Manipur	65	57	88%	21%	63%	84%	0%	4%	12%	0%
Meghalaya	57	14	25%	14%	57%	71%	14%	0%	14%	0%
Mizoram	156	107	69%	21%	68%	89%	5%	0%	6%	0%
Nagaland	117	93	79%	25%	47%	72%	13%	5%	8%	0%
Odisha	550	215	39%	24%	52%	76%	20%	0%	2%	0%
Puducherry	17	17	100%	32%	53%	84%	5%	5%	5%	0%
Punjab	372	191	51%	22%	55%	77%	14%	1%	5%	1%
Rajasthan	533	444	83%	20%	57%	78%	16%	1%	5%	0%
Sikkim	12	2	17%	50%	50%	100%	0%	0%	0%	0%
Tamil Nadu	3284	2181	66%	26%	52%	78%	15%	1%	5%	1%
Telangana	1905	1447	76%	38%	42%	81%	13%	1%	4%	0%
Tripura	34	18	53%	39%	56%	94%	0%	0%	6%	0%
Uttar Pradesh	1278	430	34%	20%	51%	71%	17%	0%	9%	1%
Uttarakhand	61	29	48%	17%	62%	79%	14%	0%	0%	3%
West bengal	884	567	64%	22%	58%	80%	12%	2%	4%	1%
INDIA	30440	21865	<b>72%</b>	28%	51%	79%	13%	1%	5%	1%

India TB Report 2018

## Annexure 2(c ii): Treatment Outcome of HIV infected Previously Treated TB cases notified from Public Sector in 2016

State	PLHIV-TB Registered for Treat- ment	Treatment Outcome reported	Report- ing %	Cure %	Treat- ment Com- pleted	Treat- ment Success %	Death %	Failure %	Lost to follow- up %	Treatment Regimen Changed %
Andhra Pradesh	1255	1100	88%	39%	37%	77%	15%	1%	5%	2%
Andman and Nicobar	0									
Arunachal Pradesh	0									
Assam	26	14	54%	0%	57%	57%	29%	0%	14%	0%
Bihar	187	78	42%	29%	54%	83%	10%	0%	4%	0%
Chandigarh	4	4	100%	25%	50%	75%	0%	25%	0%	0%
Chhattisgarh	60	45	75%	18%	42%	60%	22%	2%	16%	0%
Dadra and Nagar Haveli	1	1	100%	0%	100%	100%	0%	0%	0%	0%
Daman and Diu	1	0	0%							
Delhi	278	113	41%	21%	52%	73%	10%	1%	10%	4%
Goa	20	13	65%	23%	46%	69%	23%	0%	8%	0%
Gujarat	981	825	84%	19%	56%	74%	15%	2%	8%	1%
Haryana	112	73	65%	32%	30%	62%	25%	1%	8%	3%
Himachal Pradesh	34	28	82%	32%	43%	75%	21%	0%	4%	0%
Jammu and Kashmir	0									
Jharkhand	51	24	47%	25%	50%	75%	0%	0%	21%	4%
Karnataka	1233	1052	85%	22%	43%	65%	18%	2%	11%	2%
Kerala	56	32	57%	25%	41%	66%	6%	0%	16%	3%
Lakshadweep	0									
Madhya Pradesh	203	112	55%	20%	55%	75%	12%	2%	12%	0%
Maharashtra	2081	1463	70%	20%	48%	68%	15%	2%	9%	3%
Manipur	24	21	88%	29%	52%	81%	5%	0%	10%	5%
Meghalaya	16	3	19%	33%	67%	100%	0%	0%	0%	0%
Mizoram	48	36	75%	14%	75%	89%	3%	0%	6%	3%
Nagaland	32	26	81%	42%	46%	88%	4%	4%	4%	0%
Odisha	135	52	39%	25%	40%	65%	23%	0%	8%	4%
Puducherry	6	6	100%	43%	0%	43%	29%	29%	0%	0%
Punjab	120	62	52%	31%	42%	73%	15%	3%	5%	3%
Rajasthan	208	174	84%	33%	34%	67%	18%	1%	9%	4%
Sikkim	0									
Tamil Nadu	985	646	66%	30%	44%	74%	13%	2%	10%	1%
Telangana	442	336	76%	38%	33%	71%	18%	3%	5%	1%
Tripura	0									
Uttar Pradesh	437	146	33%	15%	49%	64%	22%	1%	8%	3%
Uttarakhand	23	10	43%	10%	60%	70%	10%	0%	10%	0%
West bengal	273	175	64%	23%	39%	63%	23%	2%	9%	2%
INDIA	9262	6672	<b>72</b> %	26%	45%	71%	16%	2%	8%	2%

## Annexure (3a): Intensified TB case finding activities at ICTC

State	ICTC attendees (excl.	Clients referred for	Clients diagnosed	Clients initiate on TB
	pregnant women)	TB testing N (%)	with TB N (%)	treatment N (%)
Andaman and	17099	429 (3%)	2 (0%)	0 (0%)
Nicobar				
Andhra Pradesh	846549	77122 (9% )	4896 (6%)	4754 (97%)
Arunachal Pradesh	4654	272 (6% )	112 (41%)	4 (4%)
Assam	128847	9061 (7% )	1030 (11%)	314 (30%)
Bihar	373456	27676 (7% )	5362 (19%)	450 (8%)
Chandigarh	80996	611 (1% )	13 (2% )	3 (23%)
Chhattisgarh	238060	16350 (7%)	1484 (9%)	971 (65% )
Dadar and Nagar Haveli	15066	139 (1% )	18 (13% )	18 (100%)
Daman and Diu	11905	139 (1%)	43 (31%)	23 (53% )
Delhi	355989	11967 (3% )	436 (4%)	339 (78% )
Goa	32748	779 (2% )	18 (2% )	15 (83%)
Gujarat	955968	105350 (11%)	4950 (5% )	4223 (85%)
Haryana	328884	19207 (6% )	1722 (9% )	234 (14% )
Himachal Pradesh	101052	5528 (5% )	606 (11% )	69 (11% )
Jammu and Kashmir	39158	843 (2% )	75 (9% )	4 (5% )
Jharkhand	150442	10921 (7% )	1391 (13% )	275 (20% )
Karnataka	1675878	125023 (7%)	5907 (5% )	5210 (88%)
Kerala	415669	13096 (3%)	188 (1% )	79 (42%)
Lakshadweep		0 (0%)	0 (0%)	0 (0%)
Madhya Pradesh	586290	37061 (6%)	2262 (6% )	1102 (49%)
Maharashtra	2157175	211303 (10% )	13058 (6%)	11272 (86%)
Manipur	62660	3689 (6%)	22 (1%)	11 (50%)
Meghalaya	19461	193 (1%)	32 (17%)	19 (59%)
Mizoram	20180	981 (5% )	58 (6%)	31 (53%)
Nagaland	66003	2910 (4%)	198 (7%)	115 (58%)
Odisha	446589	30879 (7%)	1777 (6%)	1143 (64% )
Pondicherry	43372	1901 (4%)	153 (8%)	31 (20%)
Punjab	342478	13433 (4%)	1186 (9% )	252 (21%)
Rajasthan	585702	43772 (7%)	2051 (5% )	1339 (65% )
Sikkim	9014	107 (1%)	49 (46%)	9 (18%)
Tamil Nadu	2953119	246439 (8%)	6824 (3% )	5545 (81%)
Telangana	498582	42422 (9% )	3423 (8%)	2694 (79%)
Tripura	42265	1129 (3% )	125 (11%)	4 (3%)
Uttar Pradesh	1031708	57963 (6% )	8895 (15%)	3457 (39%)
Uttarakhand	94019	4629 (5% )	304 (7% )	126 (41%)
West Bengal	684012	28798 (4%)	1244 (4%)	599 (48% )
Grand Total	15415049	1152122 (7%)	69914 (6%)	44734 (64% )
			,	

**India TB Report 2018** 

## Annexure (3b): Intensified case finding activities in ART centre

State	PLHIV attending ART centre	PLHIV screened for TB N (%)	PLHIV with presumptive TB N (%)	PLHIV referred for TB diagnosis test N (%)	PLHIV tested for TB N (%)	PLHIV diagnosed with TB N (%)	PLHIV micro- biologically confirmed N (%)
Andaman & Nicobar	159	147 (92%)	19 (13%)	19 (100%)	19 (100%)	1 (5%)	1 (100%)
Andhra Pradesh	1551382	1405803 (91%)	63907 (5%)	50603 (79%)	44948 (89%)	5243 (12%)	3591 (68%)
Arunachal Pradesh	346	345 (100%)	22 (6%)	22 (100%)	22 (100%)	0 (0%)	#DIV/0!
Assam	42693	37370 (88%)	1495 (4%)	1230 (82%)	443 (36%)	144 (33%)	42 (29%)
Bihar	366722	259267 (71%)	19010 (7%)	11471 (60%)	6678 (58%)	1407 (21%)	812 (58%)
Chandigarh	34760	32253 (93%)	624 (2%)	461 (74%)	332 (72%)	91 (27%)	28 (31%)
Chhattisgarh	95806	72448 (76%)	5073 (7%)	4859 (96%)	4560 (94%)	318 (7%)	254 (80%)
Delhi	241253	197878 (82%)	9221 (5%)	5374 (58%)	4219 (79%)	1046 (25%)	476 (46%)
Goa	23632	23560 (100%)	1162 (5%)	431 (37%)	153 (35%)	24 (16%)	23 (96%)
Gujarat	580260	548172 (94%)	16426 (3%)	15263 (93%)	14038 (92%)	3116 (22%)	1283 (41%)
Haryana	54362	47999 (88%)	988 (2%)	988 (100%)	700 (71%)	278 (40%)	147 (53%)
Himachal Pradesh	38694	31998 (83%)	657 (2%)	588 (89%)	579 (98%)	76 (13%)	60 (79%)
Jammu & Kashmir	24772	24765 (100%)	537 (2%)	473 (88%)	273 (58%)	82 (30%)	38 (46%)
Jharkhand	89380	74811 (84%)	1897 (3%)	1815 (96%)	1539 (85%)	253 (16%)	156 (62%)
Karnataka	1449138	1291801 (89%)	78119 (6%)	65016 (83%)	58373 (90%)	5156 (9%)	3146 (61%)
Kerala	122475	109532 (89%)	6118 (6%)	2497 (41%)	1966 (79%)	299 (15%)	172 (58%)
Madhya Pradesh	209134	164324 (79%)	13951 (8%)	8824 (63%)	5421 (61%)	1012 (19%)	631 (62%)
Maharashtra	1808177	1639850 (91%)	107244 (7%)	63846 (60%)	54442 (85%)	7838 (14%)	3686 (47%)
Manipur	134611	78065 (58%)	992 (1%)	807 (81%)	760 (94%)	186 (24%)	125 (67%)
Meghalaya	15459	11628 (75%)	611 (5%)	472 (77%)	195 (41%)	138 (71%)	75 (54%)
Mizoram	42409	35243 (83%)	2447 (7%)	1035 (42%)	781 (75%)	230 (29%)	222 (97%)
Nagaland	57160	22701 (40%)	1039 (5%)	639 (62%)	515 (81%)	314 (61%)	225 (72%)
Odisha	148217	117290 (79%)	4968 (4%)	4879 (98%)	4378 (90%)	438 (10%)	340 (78%)
Pondicherry	13258	10673 (81%)	377 (4%)	332 (88%)	332 (100%)	38 (11%)	27 (71%)
Punjab	253208	232989 (92%)	7393 (3%)	3107 (42%)	2791 (90%)	498 (18%)	367 (74%)
Rajasthan	307128	260152 (85%)	13861 (5%)	13269 (96%)	11830 (89%)	1497 (13%)	968 (65%)
Sikkim	1529	1084 (71%)	37 (3%)	31 (84%)	18 (58%)	18 (100%)	18 (100%)
Tamil Nadu	1113586	995295 (89%)	54778 (6%)	47210 (86%)	43032 (91%)	4138 (10%)	2609 (63%)
Telangana	622834	384214 (62%)	73919 (19%)	11766 (16%)	9827 (84%)	2280 (23%)	1796 (79%)
Tripura	9378	9237 (98%)	365 (4%)	357 (98%)	263 (74%)	23 (9%)	17 (74%)
Uttar Pradesh	613053	550736 (90%)	17906 (3%)	11765 (66%)	9431 (80%)	2226 (24%)	1008 (45%)
Uttarakhand	27228	6807 (25%)	1115 (16%)	771 (69%)	379 (49%)	160 (42%)	116 (73%)
West Bengal	295189	234477 (79%)	8324 (4%)	5526 (66%)	3518 (64%)	517 (15%)	356 (69%)
INDIA	10762163	8912914 (83%)	514602 (6%)	335746 (65%)	286755 (85%)	39085 (14%)	22815 (58%)

#### Annexure (4 a) State wise Notification of DRTB cases in 2017

State	No. of districts implementing Universal DST	Number of DR-TB Centres (Nodal + District) functional	Number of Presumptive DR-TB patient subjected to DST/DRT	Number of MDR/RR- TB patients notified in 2017	Number of MDR/RR- TB patients initiated on treatment in 2017#	Number of XDR TB patients initiated on treatment in 2017#
Andaman & Nicobar	3	1	1326	54	49	0
Andhra Pradesh	0	9	20313	892	738	34
Arunachal Pradesh	14	2	3198	197	196	0
Assam	0	4	7004	410	415	11
Bihar	0	6	35850	1848	1660	165
Chandigarh	1	1	2062	59	48	1
Chhattisgarh	0	4	19334	328	272	0
Dadra & Nagar Haveli	1	1	1401	19	6	4
Daman & Diu	2	0	281	8	2	0
Delhi	0	25	13161	1074	1653	163
Goa	2	1	545	54	40	5
Gujarat*	0	34	42340	2266	1982	179
Haryana	0	2	25944	856	755	9
Himachal Pradesh	10	2	3159	222	239	7
Jammu & Kashmir	14	3	7192	155	127	0
Jharkhand	15	4	17182	595	495	9
Karnataka	0	7	18495	1182	973	17
Kerala*	14	14	8158	236	249	13
Lakshadweep	1	0	14	0	0	0
Madhya Pradesh	0	9	35633	1870	1583	62
Maharashtra	79	17	86560	8465	8396	879
Manipur	9	1	2686	54	46	1
Meghalaya	6	2	3955	200	226	13
Mizoram	8	1	2281	62	57	0
Nagaland	11	2	1761	66	81	0
Odisha	31	3	15472	328	329	17
Puducherry	0	1	457	15	14	0
Punjab	10	3	12279	554	506	21
Rajasthan	0	7	36687	2402	2547	196
Sikkim	5	1	3085	233	262	8
Tamil Nadu	0	6	114708	1492	1139	36
Telangana	0	11	39398	961	854	10
Tripura	8	1	503	30	35	0
Uttar Pradesh	0	16	121842	9138	7837	619
Uttarakhand	13	2	5936	448	306	12
West Bengal	0	19	24045	1832	1833	175
Grand Total	257	222	734247	38605	35950	2666

Notes: \* Data from Daman-Diu & Dadra Nagar Haveli is included in Gujarat: Lakshdweep is included in Kerala for 6/12 months interim and treatment outcome report.

<sup>#</sup> These numbers are NOT from the same cohort of patients from which MDR/RR-TB diagnosed are reported, but rather from treatment initiation registers only. The current PMDT information system does not allow for cohort-based reporting of MDR TB patients, hence this should not yet be taken as proportion of MDR/RR-TB diagnosed and used as an indicator for efficiency of initiation on treatment.

<sup>\$</sup> This also excludes extra pulmonary patients put on treatment

Annexure (4b): State wise 12-month Culture conversion of DRTB cases notified between 4Q15 to 3Q16

	Mush of MIDP/PP	(/o) VIV 4 JU 11.0	(/0/	Out of L. N.	(/0)	Out of Is	(/0)	, JO 11.0	N.O.	Jo the O	
	Number of Michael		(0/) ::	Out 01 b, 180. ( /o)	(%) :o	Out of 10, 100. (%)	(0/) :0N:	Out of by INO.	D, INO.	Out of b, INO.	D, INO.
State	TB patients initiated	who are alive,	ılive,	who are alive,	live,	who are alive,	alive,	(%) who died	o died	(%) who lost to	lost to
	on treatment during	on treatment and	nt and	on treatment and	nt and	on treatment and	ent and			dn wolloj	dn A
Andaman & Nicohar		21 21	38%	1 2%	2% 2%	19	35%	11	20%	2	4%
Andhra Pradesh	290	436	55%	45	<b>%9</b>	31	4%	150	19%	104	13%
Arunachal Pradesh	183	73	40%	1	1%	63	34%	14	%8	34	19%
Assam	380	205	54%	11	3%	38	10%	42	11%	55	14%
Bihar	1501	570	38%	74	2%	463	31%	170	11%	174	12%
Chandigarh	46	33	72%	0	%0	0	%0	3	2%	4	%6
Chhattisgarh	181	88	46%	1	1%	23	13%	30	17%	34	19%
Dadra & Nagar Haveli											
Delhi	1138	529	46%	23	%6	144	13%	106	%6	192	17%
Goa	44	23	52%	4	%6	Ω.	11%	3	2%	4	%6
Gujarat*	2191	938	43%	127	%9	179	%8	314	14%	334	15%
Haryana	717	416	28%	2	%0	26	%8	111	15%	100	14%
Himachal Pradesh	232	137	26%	8	3%	43	19%	18	%8	13	%9
Jammu & Kashmir	109	75	%69	2	2%	12	11%	14	13%	7	%9
Jharkhand	322	124	39%	5	2%	101	31%	32	10%	44	14%
Karnataka	808	360	45%	38	2%	81	10%	162	70%	119	15%
Kerala*	191	106	25%	7	4%	25	13%	31	16%	15	%8
Lakshadweep											
Madhya Pradesh	1347	641	48%	06	2%	151	11%	229	17%	185	14%
Maharashtra	7205	2651	37%	233	3%	1148	16%	822	12%	970	13%
Manipur	55	19	35%	0	%0	2	4%	9	11%	8	15%
Meghalaya	249	112	45%	18	2%	48	19%	31	12%	26	10%
Mizoram	35	23	%99	1	3%	3	%6	9	17%	2	%9
Nagaland	43	11	76%	0	%0	18	45%	4	%6	10	23%
Odisha	239	121	51%	15	%9	44	18%	28	12%	17	2%
Puducherry	17	8	47%	0	%0	1	%9	1	%9	9	35%
Punjab	540	305	26%	36	2%	38	2%	98	16%	56	10%
Rajasthan	1991	797	40%	109	2%	340	17%	351	18%	249	13%
Sikkim	250	165	%99	4	2%	9	2%	27	11%	25	10%
Tamil Nadu	1052	513	49%	59	%9	62	%9	162	15%	211	20%
Telangana	647	402	62%	19	3%	36	%9	111	17%	59	%6
Tripura	16	6	26%	1	%9	1	%9	2	13%	3	19%
Uttar Pradesh	5936	2986	20%	375	%9	579	10%	857	14%	752	13%
Uttarakhand	305	147	48%	7	2%	89	22%	59	10%	46	15%
West Bengal	1856	1013	25%	83	4%	137	2%	274	15%	235	13%
Grand Total	30671	14057	46%	1399	2%	3962	13%	4270	14%	4095	13%

Notes: \* Data from Daman-Diu & Dadra Nagar Haveli is included in Gujarat: Lakshdweep is included in Kerala for 6/12 months interim and treatment outcome

current PMDT information system does not allow for cohort-based reporting of MDR TB patients, hence this should not yet be taken as proportion of MDR/RR-TB \$ This also excludes extra pulmonary # These numbers are NOT from the same cohort of patients from which MDR/RR-TB diagnosed are reported, but rather from treatment initiation registers only. The diagnosed and used as an indicator for efficiency of initiation on treatment. patients put on treatment

Annexure (4c): State wise Treatment Outcomes of DRTB cases notified between 3Q14 to 2Q15

	NI.	J-1-0	7-1-0	-		į	d	,		77	0) [M - ] - 1	1
	MDR/RR-TB	c, No.	c, No.	of c,	No. (%)	(%)	S. So	No. (%)	(%) who failed	c, ivo. e failed	were declared with	o, with
State	patients initiated	reported	reported as	Success	who died	died	who	who lost to	treatment	nent	outcome like Switch	switch
	on Cat IV during	as Cured	Treatment	Rate			follo	dn wolloj			to XDR regimen,	nen,
	3Q14 to 2Q15 (c)		Completed								stopped due to ADR,	ADR,
Andaman & Nicobar	25	12	3	%09	7	28%	1	4%	1	4%		4%
Andhra Pradesh	573	238	39	48%	139	24%	110	19%	14	2%	33	%9
Arunachal Pradesh	135	52	30	%19	14	10%	34	25%	0	%0	Ŋ	4%
Assam	352	122	63	23%	61	17%	73	21%	3	1%	08	%6
Bihar	780	281	156	26%	142	18%	125	16%	56	3%	20	%9
Chandigarh	62	29	17	47%	8	%8	27	28%	2	2%	14	14%
Chhattisgarh	164	48	42	25%	38	23%	26	16%	3	2%	7	4%
Dadra & Nagar Haveli												
Daman & Diu												
Delhi	1302	553	158	25%	178	14%	225	17%	18	1%	170	13%
Goa	44	13	3	36%	12	27%	9	14%	0	%0	10	23%
Gujarat*	1838	557	206	42%	373	20%	382	21%	62	3%	258	14%
Haryana	629	253	06	25%	141	22%	110	17%	3	%0	32	2%
Himachal Pradesh	223	78	33	20%	28	13%	20	%6	5	2%	59	26%
Jammu & Kashmir	227	78	36	20%	48	21%	45	20%	3	1%	17	2%
Jharkhand	209	62	42	50%	38	18%	47	22%	9	3%	14	2%
Karnataka	618	213	80	47%	143	23%	131	21%	7	1%	44	2%
Kerala*	200	83	38	61%	27	14%	21	11%	13	2%	18	%6
Lakshadweep												
Madhya Pradesh	1010	413	93	20%	213	21%	203	20%	36	4%	52	2%
Maharashtra	5116	1171	752	38%	844	16%	1021	20%	104	2%	1224	24%
Manipur	28	10	7	61%	4	14%	9	21%	0	%0	1	4%
Meghalaya	120	50	22	%09	20	17%	18	15%	3	3%	7	%9
Mizoram	86	27	29	22%	17	17%	13	13%	1	1%	11	11%
Nagaland	73	20	15	48%	8	11%	17	23%	0	%0	13	18%
Odisha	291	115	30	20%	26	76%	49	17%	1	%0	20	%/
Puducherry	22	11	0	20%	3	14%	9	27%	1	2%	1	2%
Punjab	458	172	47	48%	88	19%	107	23%	^	2%	37	%8
Rajasthan	1669	560	203	46%	390	23%	371	22%	41	2%	104	%9
Sikkim	198	131	3	%89	59	15%	13	2%	2	1%	20	10%
Tamil Nadu	1153	358	26	36%	289	72%	325	28%	20	2%	64	%9
Telangana	673	296	37	46%	170	25%	126	19%	16	2%	28	4%
Tripura	94	43	9	25%	18	19%	17	18%	2	2%	&	%6
Uttar Pradesh	4107	1139	868	20%	991	24%	699	16%	77	2%	333	%8
Uttarakhand	199	48	49	46%	43	22%	38	19%	1	1%	20	10%
West Bengal	1629	560	239	49%	273	17%	315	19%	84	2%	158	10%
Grand Total	24354	9622	3563	47%	4873	20%	4697	19%	562	2%	2863	12%

Notes: \* Data from Daman-Diu & Dadra Nagar Haveli is included in Gujarat. Lakshdweep is included in Kerala for 6/12 months interim and treatment outcome report.

# These numbers are NOT from the same cohort of patients from which MDR/RR-TB diagnosed are reported, but rather from treatment initiation registers only. The current PMDT information system does not allow for cohort-based reporting of MDR TB patients, hence this should not yet be taken as proportion of MDR/RR-TB diagnosed and used as an indicator for efficiency of initiation on treatment.

\$ This also excludes extra pulmonary patients put on treatment

Annexure (5a): Human Resources (Part -I)

State         Firledminologist (AVD)         MO-STC         TH-HIV Conclinator         Firl Condition         Th Conclination         Intercept (Principal Intercept)         Th Conclination         Intercept (Principal Intercept)							State Level	evel					
Sanctioned In Place Sanctioned In Sanctioned Place   P	State	Epidemiolog	ist (APO)	MO – S	rc	TB-HIV Coo	rdinator	PPM Coordi	nator	DR TB Coord	linator	State IEC Officer	fficer
A billion of the Nicobarr (a) (a) (b) (b) (b) (c) (c) (c) (c) (c) (c) (c) (c) (c) (c		Sanctioned	In Place	Sanctioned	In Place	Sanctioned	In Place	Sanctioned	In Place	Sanctioned	In Place	Sanctioned	In Place
Pack Nicobar         0         0         1         1         1         0         0         0         0         0         0         0         0         0         1         1         Peacesh         1         1         1         1         Peacesh         1         1         0 <td>1</td> <td>2</td> <td>3</td> <td>4</td> <td>5</td> <td>9</td> <td>7</td> <td>8</td> <td>6</td> <td>10</td> <td>11</td> <td>12</td> <td>13</td>	1	2	3	4	5	9	7	8	6	10	11	12	13
Prodesh   1   1   1   1   1   1   1   1   1	Andaman & Nicobar	0	0	1	1	1	0	0	0	0	0	1	1
latified by the state of the st	Andhra Pradesh	1	1	1	0	1	1	1	1	1	1	1	1
arth 0 0 0 1 1 1 1 1 1 0 0 0 1 1 1 1 1 1 1	Arunachal	1	0	1	0	0	0	0	0	0	0	1	1
anth-to-to-to-to-to-to-to-to-to-to-to-to-to-	Assam	0	0	1	1	1	1	0	0	1	0	1	1
garth         0         0         1         1         1         0 <td>Bihar</td> <td>1</td> <td>0</td> <td>1</td> <td>0</td> <td>1</td> <td>0</td> <td>1</td> <td>0</td> <td>1</td> <td>0</td> <td>1</td> <td>1</td>	Bihar	1	0	1	0	1	0	1	0	1	0	1	1
garth         1         1         1         1         1         1         0         1         1         0         1         0         1         0         1         0         1         0         1         0         1         0 <td>Chandigarh</td> <td>0</td> <td>0</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>1</td> <td>1</td>	Chandigarh	0	0	1	1	1	1	0	0	0	0	1	1
Havelia         1         0         1         1         0 </td <td>Chhattisgarh</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>0</td> <td>1</td> <td>1</td> <td>0</td> <td>0</td> <td>1</td> <td>1</td>	Chhattisgarh	1	1	1	1	1	0	1	1	0	0	1	1
k Diu         1         1         1         1         0 <td>Dadra &amp; Haveli</td> <td>1</td> <td>0</td> <td>1</td> <td>1</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>1</td> <td>1</td>	Dadra & Haveli	1	0	1	1	0	0	0	0	0	0	1	1
Heraceck 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Daman & Diu	1	1	1	1	0	0	0	0	0	0	0	0
Herekey 1 1 0 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1	Delhi	1	1	1	1	1	0	1	0	1	0	1	1
Heracesh 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Goa	1	0	1	0	1	0	0	0	1	0	1	1
Herdesh 1 1 0 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 0 0 0 1 0	Gujarat	1	1	1	1	1	1	1	1	1	1	1	1
Interestry (a) (a) (b) (b) (c) (c) (c) (c) (c) (c) (c) (c) (c) (c	Haryana	1	1	0	0	1	0	1	0	1	0	1	1
r         1	Himachal Pradesh	1	0	1	0	1	0	1	0	1	0	1	1
r         1         1         1         1         0         0         0         0         0         0         nd         n <th< td=""><td>Jammu</td><td>1</td><td>1</td><td>1</td><td>0</td><td>1</td><td>1</td><td>1</td><td>0</td><td>1</td><td>0</td><td>1</td><td>1</td></th<>	Jammu	1	1	1	0	1	1	1	0	1	0	1	1
hd         1         0         1         0         1         0         1         0         1         1         1         hand         1         hand         1<	Kashmir	1	1	1	1	1	0	0	0	0	0	1	1
ka         1         1         1         0         1	Jharkhand	1	0	1	0	1	0	1	0	1	0	1	1
tweep         1         0         1         1         1         1         0         0         1           shtra         0	Karnataka	1	1	1	0	1	0	1	1	1	0	1	1
threep         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         0         1         the         whta         shtra         2         0         1	Kerala	1	0	1	1	1	1	0	0	1	0	1	Т
shtra         2         0         1         0         1 <td>Lakshadweep</td> <td>0</td> <td>1</td> <td>1</td>	Lakshadweep	0	0	0	0	0	0	0	0	0	0	1	1
aya         1	Maharashtra	2	0	1	0	1	1	1	0	1	0	1	1
aya         1	Manipur	1	1	1	1	1	0	1	1	1	1	1	1
nn         1         0         1	Meghalaya	1	1	1	1	1	1	1	1	1	1	1	0
nd         1         1         1         1         1         0         1         0         1         0         1	Mizoram	1	0	1	1	1	1	1	1	1	0	1	1
nd         1	MP	1	1	1	0	1	0	1	0	1	0	1	0
nerry         1         1         1         1         1         0         1         0         1         0         1         1         1         0         1         0         1         0         1         0 <td>Nagaland</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>0</td> <td>1</td> <td>1</td>	Nagaland	1	1	1	1	1	1	1	1	1	0	1	1
erry         0         0         1         1         1         0         0         0         0           an         1         0         1         0         1         0 <td>Odisha</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>0</td> <td>1</td> <td>0</td> <td>1</td> <td>1</td> <td>1</td> <td>0</td>	Odisha	1	1	1	1	1	0	1	0	1	1	1	0
an         1         0         1         0         1         0	Pondicherry	0	0	1	1	1	1	0	0	0	0	1	1
an         1         0         1         0         1         0         1         0         1	Punjab	1	0	1	0	1	1	0	0	0	0	1	0
na         1         0         1         1         1         0         1         0         1         0         1         0         1         0         1         0         1	Rajasthan	1	0	1	0	1	0	1	1	1	0	1	1
1         0         1         0         1         0         1         2	Sikkim	1	0	1	1	1	0	1	0	1	1	1	0
1         1	Telangana	1	0	1	0	1	1	0	0	1	0	1	1
1         0         0         1         1         0	TN	1	1	1	1	1	1	1	1	1	1	1	1
1         2         2         0         2         1         2         2         2         2           1         0         0         0         0         0         0         0         0         0           2         1         1         1         1         2         1         2         2         2	Tripura	1	0	0	1	1	0	0	0	0	0	1	1
1         0         0         1         1         0         0         0         0         0           2         1         1         1         1         2         1         2         2         2         2	UP	2	2	2	0	2	1	2	2	2	0	2	2
2 1 1 1 1 2 1 2 2 2	Uttarakhand	0	0	1	1	0	0	0	0	0	0	1	1
	West Bengal	2	1	1	1	2	-	2	2	2	1	2	2

Annexure (5a): Human Resources (Part-II)

						State	State Level					
	State Accountant	ıntant	Technical Officer-	fficer-	DEO-STC		Pharmacist - SDS	SDS-	Store Assistant -	tant -	Director (STDC	(DC)
State			Proc. and Logistics	gistics					SDS			
	Sanctioned	ln.	Sanctioned	In	Sanctioned	In	Sanctioned	ln.	Sanctioned	In	Sanctioned	ln
		Place		Place		Place		Place		Place		Place
1	14	15	16	17	18	19	20	21	22	23	24	25
Andaman & Nicobar	1	1	0	0	1	1	1	0	1	1	0	0
Andhra Pradesh	1	1	1	1	1	1	1	0	1	0	0	0
Arunachal	1	1	1	0	1	1	1	0	1	1	0	0
Assam	1	1	1	1	1	1	1	1	1	1	0	0
Bihar	1	0	1	0	1	1	1	1	1	1	2	2
Chandigarh	1	1	0	0	1	1	1	1	1	1	0	0
Chhattisgarh	1	0	0	0	1	1	1	1	1	1	0	0
Dadra & Haveli	1	1	0	0	1	1	1	1	1	0	0	0
Daman & Diu	1	1	0	0	1	1	1	1	0	0	0	0
Delhi	1	1	1	0	1	1	2	1	2	0	1	1
Goa	1	1	0	0	1	1	1	1	1	1	0	0
Gujarat	1	1	1	0	1	1	1	1	1	1	1	1
Haryana	1	1	1	0	1	1	0	1	1	1	1	0
Himachal Pradesh	1	1	1	0	1	1	1	0	1	1	1	1
Jammu	1	1	1	0	1	1	1	1	1	1	0	0
Kashmir	1	1	1	1	1	1	1	1	1	1	0	1
Jharkhand	2	1	1	0	1	1	1	1	1	1	1	1
Karnataka	2	7	1	1	2	2	2	2	2	1	1	1
Kerala	2	1	1	1	1	1	1	1	1	0	1	1
Lakshdweep	1	0	0	0	1	1	0	0	0	0	0	0
Maharashtra	3	8	1	0	2	2	9	4	6	4	2	2
Manipur	1	1	1	0	1	1	1	1	1	1	1	1
Meghalaya	1	0	1	0	1	1	1	1	1	1	0	0
Mizoram	1	1	0	0	1	1	1	1	1	1	0	0
MP	1	1	1	1	2	1	1	1	1	1	1	1
Nagaland	1	1	1	1	1	1	1	1	1	1	0	0
Odisha	1	1	0	0	1	1	1	0	1	0	1	1
Pondicherry	1	1	0	0	1	1	1	1	1	1	1	1
Punjab	1	1	0	0	1	1	0	0	0	0	1	1
Rajasthan	1	1	1	1	1	1	2	1	3	1	1	1
Sikkim	1	1	1	0	1	1	1	1	1	1	1	1
Telangana	1	0	1	0	1	0	1	1	1	1	1	1
ZL	2	2	1	1	2	2	2	2	3	3	1	1
Tripura	1	1	1	0	0	0	1	1	1	1	0	0
UP	2	2	2	0	2	1	4	4	8	2	1	1
Uttarakhand	1	1	0	0	1	1	2	2	2	2	1	1
West Bengal	2	2	1	1	1	1	2	2	4	2	1	1

Annexure (5a): Human Resources (Part-III)

	TRT				87	C&DST				
State	opio	logist (IRL)	Microbiologist (C-DST)		Technical Officer	Officer	Senior Lab. Tech.	o. Tech.	Lab technicians	icians
	Sanctioned	In Place	Sanctioned	In Place	Sanctioned	In Place	Sanctioned	In Place	Sanctioned	In Place
1	26	27	28	29	30	31	32	33	34	35
Andaman & Nicobar	1	0	0	0	0	0	0	0	0	0
Andhra Pradesh	1	1	0	0	0	0	1	0	0	0
Arunachal	1	1	1	1	0	0	1	1	0	0
Assam	1	1	0	0	0	0	0	0	0	0
Bihar	2	2	4	3	2	1	2	0	8	9
Chandigarh	0	0	1	1	1	1	0	0	2	2
Chhattisgarh	1	1	1	0	0	0	0	0	2	0
Dadra & Haveli	0	0	0	0	0	0	0	0	0	0
Daman & Diu	0	0	0	0	0	0	0	0	0	0
Delhi	3	3	4	3	2	0	4	4	4	4
Goa	1	1	0	0	0	0	0	0	0	0
Gujarat	1	1	2	2	1	1	1	1	6	8
Haryana	1	1	0	0	0	0	0	0	0	0
Himachal Pradesh	1	1	2	1	0	0	0	0	4	0
Jammu	1	1	0	0	0	0	0	0	0	0
Kashmir	1	1	0	0	0	0	0	0	0	0
Jharkhand	1	1	1	0	0	0	1	0	0	0
Karnataka	1	1	3	3	0	0	1	1	9	1
Kerala	1	1	0	0	0	0	0	0	0	0
Lakshdweep	0	0	0	0	0	0	0	0	0	0
Maharashtra	8	5	7	5	2	1	2	1	4	4
Manipur	1	1	0	0	0	0	0	0	0	0
Meghalaya	0	0	0	0	0	0	0	0	0	0
Mizoram	0	0	0	0	0	0	0	0	0	0
MP	1	1	2	1	0	0	0	0	2	1
Nagaland	0	0	0	0	0	0	0	0	0	0
Odisha	1	1	1	1	1	1	4	0	2	1
Pondicherry	1	1	1	1	0	0	0	0	4	4
Punjab	1	0	0	0	0	0	0	0	0	0
Rajasthan	1	1	3	2	2	2	1	0	15	15
Sikkim	1	1	1	1	0	0	0	0	0	0
Telangana	1	0	1	0	0	0	0	0	0	0
NI	0	0	1	1	0	0	1	1	9	9
Tripura	0	0	1	1	0	0	1	1	0	0
UP	4	4	7	2	2	2	5	0	4	2
Uttarakhand	1	1	0	0	0	0	0	0	0	0
West Bengal	2	2	2	2	1	0	1	0	9	2

Annexure (5a): Human Resources (Part-IV)

						Dist	District level					
State	Senior MO – 1	- DR	Counsellor – DR	- DR	SA – DR TB Centre	Centre	MO-DTC	TC	MO-TC	C	Senior DR TB –	R TB –
State	I b cent		I D Cent		1000	7.		1	,	<u>د</u> ر	ins virial	pervisor
	Sanctioned	ın Place	Sanctioned	III Place	Sanctioned	ın Place	Sanctioned	ın Place	Sanchoned	ın Place	Sanctioned	ın Place
1	36	37	38	39	40	41	42	43	44	45	46	47
Andaman & Nicobar	1	0	1	0	1	1	8	0	8	0	8	3
Andhra Pradesh	6	4	6	4	6	7	rc	4	225	225	13	11
Arunachal	2	0	0	0	2	2	14	14	9	9	14	14
Assam	5	3	r.	2	5	3	10	0	154	73	27	27
Bihar	9	5	0	0	9	9	38	34	534	208	38	28
Chandigarh	1	1	0	0	1	1	0	0	4	4	1	1
Chhattisgarh	4	3	4	4	4	4	6	4	155	155	27	25
Dadra & Haveli	0	0	0	0	0	0	0	0	0	0	1	1
Daman & Diu	0	0	0	0	0	0	0	0	0	0	2	1
Delhi	4	2	4	0	4	4	25	25	38	14	26	23
Goa	1	0	1	1	1	1	0	0	9	5	2	2
Gujarat	5	5	r.	5	5	5	21	20	306	298	38	38
Haryana	0	0	3	1	3	1	0	0	64	64	21	19
Himachal Pradesh	4	1	4	0	4	2	5	1	74	74	12	11
Jammu	1	1	1	0	1	0	7	5	14	14	9	9
Kashmir	2	1	0	0	2	2	2	0	25	25	8	8
Jharkhand	5	0	5	1	2	2	8	1	146	128	24	21
Karnataka	9	3	9	3	9	2	10	2	196	196	33	32
Kerala	2	1	0	0	2	2	14	14	73	73	14	14
Lakshdweep	0	0	0	0	0	0	0	0	0	0	0	0
Maharashtra	19	15	18	4	22	13	138	132	401	383	84	72
Manipur	1	0	2	2	2	2	3	I	11	11	16	7
Meghalaya	2	2	2	2	2	2	1	0	19	18	7	7
Mizoram	1	1	1	1	1	1	12	12	12	7	8	8
MP	6	3	6	3	6	0	22	11	228	183	51	40
Nagaland	2	2	2	7	2	2	2	1	13	13	11	11
Odisha	3	2	3	0	3	3	6	5	269	260	31	59
Pondicherry	1	1	0	0	1	1	3	3	7	9	1	1
Punjab	2	1	0	0	2	1	3	2	134	134	22	19
Rajasthan	7	2	7	5	7	9	36	32	283	263	34	28
Sikkim	1	0	1	0	1	1	0	0	5	2	5	5
Telangana	7	1	7	0	7	3	5	7	171	171	11	11
IN	8	8	13	13	8	8	20	20	137	137	36	98
Tripura	1	1	1	0	1	1	3	1	0	9	8	7
UP	23	19	23	17	23	17	14	2	993	661	68	83
Uttarakhand	2	1	2	2	2	2	16	^	95	95	13	12
West Bengal	6	Ŋ	6	9	6	7	^	3	461	414	48	38

# Annexure (5a): Human Resources (Part-V)

						Distric	District Level					
	District P	PM	Accountant	ant	Senior Treatment	tment	Senior TB Lab	Lab	Lab. Techs. (LT)	(LT) –	TBHV	
State	Coordinator	tor			Supervisor (STS)	(STS)	Supervisor (STLS)	(STLS)	RNTCP Contractual	tractual		
	Sanctioned	In	Sanctioned	In	Sanctioned	In	Sanctioned	In	Sanctioned	In	Sanctioned	In
		Place		Place		Place		Place		Place		Place
1	48	46	20	51	52	23	54	22	99	25	58	26
Andaman & Nicobar	0	0	3	2	6	6	4	4	3	3	4	3
Andhra Pradesh	13	2	13	10	225	188	109	104	242	181	147	118
Arunachal	0	0	14	14	20	20	17	17	10	10	0	0
Assam	27	25	27	25	153	146	78	92	95	85	34	32
Bihar	38	0	0	0	534	158	223	145	558	381	95	15
Chandigarh	0	0	0	0	4	4	5	5	13	13	14	14
Chhattisgarh	27	56	27	24	155	146	69	09	140	117	48	46
Dadra & Haveli	0	0	0	0	2	7	1	0	1	1	1	1
Daman & Diu	0	0	0	0	2	1	2	2	2	2	2	2
Delhi	25	0	25	0	72	32	38	32	186	169	240	228
Goa	2	2	0	0	9	5	4	4	5	4	6	7
Gujarat	35	33	98	33	306	667	150	143	189	149	243	236
Haryana	21	0	21	0	119	75	52	49	77	22	86	70
Himachal Pradesh	10	0	12	0	74	89	52	43	101	74	20	0
Jammu	9	0	9	2	49	32	18	18	0	0	7	7
Kashmir	8	0	8	7	34	24	25	25	20	20	21	18
Jharkhand	24	6	24	11	206	29	101	64	169	112	74	46
Karnataka	33	26	31	23	273	194	136	132	181	164	217	192
Kerala	0	0	14	14	73	73	73	73	117	117	45	45
Lakshdweep	0	0	0	0	1	1	1	1	3	3	0	0
Maharashtra	26	46	26	55	460	409	318	287	336	319	527	508
Manipur	6	8	6	8	27	21	19	16	23	20	8	2
Meghalaya	7	0	7	7	19	16	13	13	2	2	12	12
Mizoram	8	8	8	8	12	11	6	6	7	7	4	4
MP	51	0	51	16	253	201	166	141	246	202	205	167
Nagaland	111	1	11	11	48	18	13	13	12	12	7	4
Odisha	31	59	31	15	314	246	109	68	156	90	54	44
Pondicherry	0	0	1	0	7	9	5	5	4	4	6	6
Punjab	0	0	0	0	134	103	59	43	142	106	102	80
Rajasthan	34	56	34	26	283	797	152	65	29	23	06	33
Sikkim	5	4	5	5	5	5	5	5	4	1	1	1
Telangana	31	0	11	0	171	138	96	81	150	135	100	26
TN	37	37	36	36	461	461	143	143	359	359	371	371
Tripura	0	0	8	7	20	17	13	8	13	11	3	3
UP	68	28	75	89	866	830	412	388	826	910	498	450
Uttarakhand	0	0	13	10	95	74	31	30	70	20	28	26
West Bengal	28	19	28	14	462	388	193	162	380	337	373	183

Table (5a): Human Resources (Part-VI)

			Medical	Colleges		
State	TBHV-Medical	MO – Medical	LT – Medical			
Otato	College	College	College			
	Sanctioned	In Place	Sanctioned	In Place	Sanctioned	In Place
1	09	61	62	63	64	65
Andaman & Nicobar	1	0	0	0	0	0
Andhra Pradesh	22	20	22	11	22	18
Arunachal	0	0	0	0	0	0
Assam	9	9	9	5	9	9
Bihar	11	2	11	9	11	9
Chandigarh	2	2	2	2	2	2
Chhattisgarh	6	9	6	8	6	ιΩ
Dadra & Haveli	0	0	0	0	0	0
Daman & Diu	0	0	0	0	0	0
Delhi	14	7	14	7	14	9
Goa	1	1	1	0	1	1
Gujarat	19	18	17	13	26	24
Haryana	6	3	6	0	0	0
Himachal Pradesh	1	1	3	2	4	3
Jammu	2	2	2	2	2	2
Kashmir	3	3	3	2	3	3
Jharkhand	3	3	3	1	3	3
Karnataka	46	44	44	26	44	44
Kerala	24	24	17	12	25	25
Lakshdweep	0	0	0	0	0	0
Maharashtra	0	0	45	23	45	42
Manipur	2	2	2	1	2	2
Meghalaya	1	1	1	1	1	1
Mizoram	0	0	0	0	0	0
MP	13	12	13	8	13	10
Nagaland	0	0	0	0	0	0
Odisha	9	9	9	1	7	IJ
Pondicherry	10	6	4	3	6	6
Punjab	6	8	3	2	6	8
Rajasthan	8	8	9	2	8	5
Sikkim	1	1	1	0	1	1
Telangana	22	12	22	12	22	14
NT	53	53	41	41	49	49
Tripura	2	2	2	1	2	2
UP	36	27	36	17	40	29
Uttarakhand	4	2	ω	0	4	3
West Bengal	15	13	15	6	15	9

#### Annexure (5b): CBNAAT laboratories

S1. No	State/UT	Existing CBNAAT Machines	Additional CBNAAT Machines Deployed	Total CBNAT Machines
1	Andaman & Nicobar	4	0	4
2	Andhra Pradesh	15	28	43
3	Arunachal Pradesh	8	3	11
4	Assam	16	14	30
5	Bihar	37	32	69
6	Chandigarh	1	1	2
7	Chhattisgarh	9	19	28
8	Dadar & Nagar Haveli	1	0	1
9	Daman & Diu	2	0	2
10	Delhi	16	15	31
11	Goa	2	0	2
12	Gujarat	25	35	60
13	Haryana	14	12	26
14	Himachal Pradesh	9	6	15
15	Jammu & Kashmir	12	2	14
16	Jharkhand	21	15	36
17	Karnataka	36	28	64
18	Kerala	14	6	20
19	Lakshadweep	1	0	1
20	Madhya Pradesh	35	36	71
21	Maharashtra	71	42	113
22	Manipur	9	0	9
23	Meghalaya	6	1	7
24	Mizoram	7	1	8
25	Nagaland	6	3	9
26	Orissa	27	13	40
27	Pondicherry	1	0	1
28	Punjab	14	15	29
29	Rajasthan	30	28	58
30	Sikkim	4	3	7
31	Tamil Nadu	31	27	58
32	Telangana	14	15	29
33	Tripura	6	0	6
34	Uttar Pradesh	77	65	142
35	Uttarakhand	9	4	13
36	West Bengal	38	38	76
	INDIA	628	507	1135

#### Annexure (5c): Certified C&DST Laboratories

S.	State	IRL / C-DST Laboratory	NRL/IRL/C&DST/NGO/	LC	LC	FL LPA	SL LPA
No	Suite	11127 6 201 242 014101	MC and PVT labs	FLDST	SLDST	12 2112	02 2111
1	Andaman & Nicobar	RMRC, Port Blair	ICMR TB CDST	-	-	-	-
			Laboratory				
2	Andhra Pradesh	DFIT, Nellore	NGO TB CDST Laboratory	-	-	С	С
3	Andhra Pradesh	SVIMS, Tirupati	Medical College	-	-	-	-
4	Andhra Pradesh	IRL, Visakhapatnam	IRL	С	С	С	С
5	Arunachal Pradesh	IRL-Naharlagun	IRL	-	-	-	-
6	Assam	RMRC, Dibrugarh	ICMR TB CDST	-	-	-	-
			Laboratory				
7	Assam	IRL, Guwahati	IRL	С	С	С	С
8	Bihar	IRL, Patna	IRL	С	-	С	С
9	Bihar	JLNMCH, Bhagalpur	Medical College	С	-	С	С
10	Bihar	DFIT, Darbhanga	NGO TB CDST Laboratory	-	-	С	С
11	Chandigarh	PGIMER Chandigarh	Medical College	С	С	С	С
12	Chhattisgarh	IRL Raipur	IRL	С	С	С	С
13	Delhi	NRL NITRD	NRL	С	С	С	С
14	Delhi	IRL NDTB Delhi	IRL	С	С	С	С
15	Delhi	AIIMS - Medicine	IRL	С	С	С	С
16	Delhi	AIIMS - Laboratory	Medical College	-	-	С	-
		Medicine					
17	Goa	IRL Goa	IRL	-	-	-	-
18	Gujarat	IRL Ahmadabad	IRL	С	С	С	С
19	Gujarat	MPSMS, Jamnagar	Medical COllege	С	С	С	С
20	Gujarat	Microcare, Surat	Pvt TB CDST Laboratory	-	-	-	-
21	Haryana	IRL Karnal	IRL	-	-	С	С
22	Himachal Pradesh	IRL Dharampur	IRL	-	-	С	С
23	Himachal Pradesh	TB C-DST Laboratory,	Medical College	-	-	-	-
		Tanda					
24	Jammu &Kashmir	IRL Jammu	IRL	-	-	-	-
25	Jammu & Kashmir	IRL Srinagar	IRL	-	-	С	С
26	Jharkhand	IRL Ranchi	IRL	С	-	С	С
27	Karnataka	NRL NTI	NRL	С	С	С	С
28	Karnataka	IRL, Bangalore	IRL	С	С	С	С
29	Karnataka	KIMS, Hubli	Medical College	С	С	С	С
30	Karnataka	GMC, Raichur	Medical College	С	-	С	С
31	Kerala	IRL Thiruvananthapuram	IRL	С	С	С	С
32	Madhya Pradesh	NRL BMHRC	NRL	С	С	С	С
33	Madhya Pradesh	IRL Indore	IRL	С	С	С	С
34	Madhya Pradesh	Choitram Hospital, Indore	Pvt TB CDST Laboratory	-	-	-	-
35	Madhya Pradesh	NIRTH, Jabalpur	ICMR TB CDST	-	-	С	-
	261	TD7 3.7	Laboratory			_	
36	Maharashtra	IRL Nagpur	IRL	С	С	С	С
37	Maharashtra	IRL Pune	IRL	С	С	С	С

India TB Report 2018

S.	State	IRL / C-DST Laboratory	NRL/IRL/C&DST/NGO/	LC	LC	FL LPA	SL LPA
No			MC and PVT labs	FLDST	SLDST		
38	Maharashtra	JJ Hospital, Mumbai	Medical College	С	С	С	С
39	Maharashtra	MGIMS, Wardha	Medical College	-	-	-	-
40	Maharashtra	Metropolis, Mumbai	Pvt TB CDST Laboratory	С	-	С	NA
41	Maharashtra	SRL, Mumbai	Pvt TB CDST Laboratory	С	С	-	-
42	Maharashtra	Infexn, Thane	Pvt TB CDST Laboratory	С	С	-	-
43	Maharashtra	PD. Hinduja, Mumbai	Pvt TB CDST Laboratory	С	С	С	С
44	Maharashtra	GTB, Sewree, Mumbai	Govt sector Lab	С	С	С	С
45	Maharashtra	Aurangabad	Meidcal College	-	-	С	С
46	Maharashtra	K. J. Somaiah Hospital, Mumbai	Pvt TB CDST Laboratory	-	-	-	-
47	Maharashtra	BJMC, Pune	Medical Colege	-	-	-	-
48	Meghalaya	Nazerath, Shillong	Pvt TB CDST Laboratory	-	-	С	-
49	Odisha	NRL RMRC	NRL	С	С	С	С
50	Odisha	IRL Cuttack	IRL	С	С	С	С
51	Puducherry	IRL Puducherry	IRL	С	С	С	С
52	Punjab	IRL Patiala	IRL	С	С	С	С
53	Rajasthan	IRL Ajmer	IRL	С	С	С	С
54	Rajasthan	SMS Jaipur	Medical COllege	С	С	С	С
55	Rajasthan	DMRC, Jodhpur	ICMR TB CDST Laboratory	-	-	-	-
56	Rajasthan	IRL, Jodhpur	IRL	-	-	С	С
57	Sikkim	IRL Gangtok	IRL	-	-	-	-
58	Tamilnadu	NRL NIRT	NRL	С	С	С	С
59	Tamilnadu	IRL Chennai	IRL	С	С	С	С
60	Tamilnadu	CMC , Vellore	Pvt TB CDST Laboratory	-	-	-	-
61	Tamilnadu	Shankar Nethralaya, Chennai	Pvt TB CDST Laboratory	С	-	-	-
62	Tamilnadu	GMC, Madurai	Medical College	С	С	С	С
63	Telangana	IRL Hyderabad	IRL	С	С	С	С
64	Telangana	BPHRC, Hyderabad	NGO TB CDST Laboratory	С	С	С	-
65	Uttar Pradesh	NRL JALMA	NRL	С	С	С	С
66	Uttar Pradesh	IRL Lucknow	IRL	С	С	С	С
67	Uttar Pradesh	BHU, Varanasi	Medical COllege	С	С	С	С
68	Uttar Pradesh	IRL, Agra	IRL	С	С	С	С
69	Uttar Pradesh	AMU, Aligarh	Medical COllege	-	-	С	С
70	Uttar Pradesh	Subharti Medical College,	Pvt TB CDST Laboratory	-	-	С	-
		Meerut					
71	Uttarakhand	IRL Dehradun	IRL	-	-	С	-
72	West Bengal	IRL Kolkata	IRL	С	С	С	С
73	West Bengal	SRL,Kolkata	Pvt TB C-DST Laboratory	С	-	-	-
74	West Bengal	NBMC Siliguri	Medical college	-	-	С	C

<sup>&</sup>quot;C" - Certified